CN111670034A - 用于治疗自身免疫性疾病的吡喃并吡唑类和吡唑并吡啶类免疫调节剂 - Google Patents
用于治疗自身免疫性疾病的吡喃并吡唑类和吡唑并吡啶类免疫调节剂 Download PDFInfo
- Publication number
- CN111670034A CN111670034A CN201880087852.5A CN201880087852A CN111670034A CN 111670034 A CN111670034 A CN 111670034A CN 201880087852 A CN201880087852 A CN 201880087852A CN 111670034 A CN111670034 A CN 111670034A
- Authority
- CN
- China
- Prior art keywords
- amino
- pyridin
- methyl
- equiv
- methanone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract description 4
- DKAHKEKMRSHQLY-UHFFFAOYSA-N pyrano[3,2-c]pyrazole Chemical class C1=COC2=CN=NC2=C1 DKAHKEKMRSHQLY-UHFFFAOYSA-N 0.000 title abstract description 3
- 150000005229 pyrazolopyridines Chemical class 0.000 title abstract description 3
- 238000011282 treatment Methods 0.000 title description 7
- 239000002955 immunomodulating agent Substances 0.000 title description 2
- 229940121354 immunomodulator Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 95
- 108010071241 Factor XIIa Proteins 0.000 claims abstract description 13
- 108090000190 Thrombin Proteins 0.000 claims abstract description 8
- 229960004072 thrombin Drugs 0.000 claims abstract description 7
- -1 hydroxy, amino Chemical group 0.000 claims description 103
- 239000001257 hydrogen Substances 0.000 claims description 55
- 229910052739 hydrogen Inorganic materials 0.000 claims description 55
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 41
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 150000002431 hydrogen Chemical class 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 125000003368 amide group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000004043 oxo group Chemical group O=* 0.000 claims description 7
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical class C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 6
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical class C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims description 6
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 150000003254 radicals Chemical class 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical compound C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 claims description 5
- 125000002837 carbocyclic group Chemical group 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 4
- FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical class C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 claims description 4
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 230000024883 vasodilation Effects 0.000 claims description 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 2
- WGSMVIHKBMAWRN-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1-benzofuran Chemical compound C1C=CC=C2OCCC21 WGSMVIHKBMAWRN-UHFFFAOYSA-N 0.000 claims description 2
- KELIOZMTDOSCMM-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1-benzothiophene Chemical compound C1C=CC=C2SCCC21 KELIOZMTDOSCMM-UHFFFAOYSA-N 0.000 claims description 2
- CSDFHCDNAZPVKH-UHFFFAOYSA-N 2,3,3a,7a-tetrahydro-1h-indazole Chemical compound C1=CC=CC2CNNC21 CSDFHCDNAZPVKH-UHFFFAOYSA-N 0.000 claims description 2
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical class C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 108060005987 Kallikrein Proteins 0.000 claims description 2
- 102000001399 Kallikrein Human genes 0.000 claims description 2
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Chemical class C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims description 2
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical class C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 150000003530 tetrahydroquinolines Chemical class 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 150000002475 indoles Chemical class 0.000 claims 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract description 3
- 239000003114 blood coagulation factor Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 308
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 275
- 239000007787 solid Substances 0.000 description 236
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 232
- 239000000203 mixture Substances 0.000 description 158
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 158
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 157
- 239000012071 phase Substances 0.000 description 100
- 235000019439 ethyl acetate Nutrition 0.000 description 92
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 88
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 64
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 63
- 238000006243 chemical reaction Methods 0.000 description 60
- 239000012044 organic layer Substances 0.000 description 58
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 57
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 49
- 239000000741 silica gel Substances 0.000 description 49
- 229910002027 silica gel Inorganic materials 0.000 description 49
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- 239000012043 crude product Substances 0.000 description 47
- 239000003921 oil Substances 0.000 description 47
- 238000002953 preparative HPLC Methods 0.000 description 44
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 40
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 39
- 239000012298 atmosphere Substances 0.000 description 34
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 32
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 32
- 229910052757 nitrogen Inorganic materials 0.000 description 32
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 238000010791 quenching Methods 0.000 description 25
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 24
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 24
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 23
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 23
- 238000003756 stirring Methods 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- 239000012267 brine Substances 0.000 description 22
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- 239000000706 filtrate Substances 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 18
- 239000003208 petroleum Substances 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 238000001816 cooling Methods 0.000 description 17
- 238000001914 filtration Methods 0.000 description 17
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- KSSZTAUSXHHILI-UHFFFAOYSA-N 6-methylsulfonyl-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-3-amine Chemical compound CS(=O)(=O)N1CCc2c(N)n[nH]c2C1 KSSZTAUSXHHILI-UHFFFAOYSA-N 0.000 description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- 239000012131 assay buffer Substances 0.000 description 12
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 11
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 9
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 9
- 102100035792 Kininogen-1 Human genes 0.000 description 9
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 9
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 9
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 208000009386 Experimental Arthritis Diseases 0.000 description 8
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 238000004296 chiral HPLC Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 8
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 239000007832 Na2SO4 Substances 0.000 description 7
- 230000035605 chemotaxis Effects 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000011261 inert gas Substances 0.000 description 7
- 238000012746 preparative thin layer chromatography Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- HOWHRPFUMVOEQQ-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-(8-ethyl-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound CCC1=CC=CC2=C1NCCC2C(=O)N1N=C(N)C2=C1CN(CC2)S(C)(=O)=O HOWHRPFUMVOEQQ-UHFFFAOYSA-N 0.000 description 6
- WPRRIZXPHGBQTD-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-[8-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-yl]methanone Chemical compound CS(=O)(=O)N1CCC2=C(C1)N(N=C2N)C(=O)C1CCNC2=C1C=CC=C2C(F)(F)F WPRRIZXPHGBQTD-UHFFFAOYSA-N 0.000 description 6
- HTPQUXPACGFSBF-UHFFFAOYSA-N (3-amino-7-methyl-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-(8-methyl-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound CC1N(CCC2=C(N)N(N=C12)C(=O)C1CCNC2=C1C=CC=C2C)S(C)(=O)=O HTPQUXPACGFSBF-UHFFFAOYSA-N 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- KZDJJMGVMVOJHC-UHFFFAOYSA-N 6-fluoro-8-methyl-1,2,3,4-tetrahydroquinoline-4-carbaldehyde Chemical compound CC1=CC(=CC2=C1NCCC2C=O)F KZDJJMGVMVOJHC-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- RKOTXQYWCBGZLP-UHFFFAOYSA-N N-[(2,4-difluorophenyl)methyl]-2-ethyl-9-hydroxy-3-methoxy-1,8-dioxospiro[3H-pyrido[1,2-a]pyrazine-4,3'-oxolane]-7-carboxamide Chemical compound CCN1C(OC)C2(CCOC2)N2C=C(C(=O)NCC3=C(F)C=C(F)C=C3)C(=O)C(O)=C2C1=O RKOTXQYWCBGZLP-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- LBVHJXXHNBALMR-UHFFFAOYSA-N 6-fluoro-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound C1=C(F)C=C2C(C(=O)O)CCNC2=C1 LBVHJXXHNBALMR-UHFFFAOYSA-N 0.000 description 5
- DEVHVEPUKFVUMH-UHFFFAOYSA-N 6-fluoro-8-methyl-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound CC1=CC(F)=CC2=C1NCCC2C(O)=O DEVHVEPUKFVUMH-UHFFFAOYSA-N 0.000 description 5
- KLGHCJZGRCOJOZ-UHFFFAOYSA-N 8-chloro-1,2,3,4-tetrahydroquinoline-4-carbaldehyde Chemical compound ClC1=CC=CC2=C1NCCC2C=O KLGHCJZGRCOJOZ-UHFFFAOYSA-N 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- OHMDLPSPZVSXFF-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-(6-ethyl-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound CCC1=CC2=C(NCCC2C(=O)N2N=C3CN(CCC3=C2N)S(C)(=O)=O)C=C1 OHMDLPSPZVSXFF-UHFFFAOYSA-N 0.000 description 4
- XWCADRXAUCPOOB-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-(6-fluoro-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound CS(=O)(=O)N1CCC2=C(N)N(N=C2C1)C(=O)C1CCNC2=C1C=C(F)C=C2 XWCADRXAUCPOOB-UHFFFAOYSA-N 0.000 description 4
- NXICIJPRONLUNA-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-(6-methyl-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound CC1=CC2=C(NCCC2C(=O)N2N=C3CN(CCC3=C2N)S(C)(=O)=O)C=C1 NXICIJPRONLUNA-UHFFFAOYSA-N 0.000 description 4
- HTCSUCDYUISMCG-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-(8-methyl-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound NC=1N(N=C2CN(CCC2=1)S(=O)(=O)C)C(=O)C1CCNC2=C(C=CC=C12)C HTCSUCDYUISMCG-UHFFFAOYSA-N 0.000 description 4
- XWCADRXAUCPOOB-LLVKDONJSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-[(4R)-6-fluoro-1,2,3,4-tetrahydroquinolin-4-yl]methanone Chemical compound C=12CCN(CC2=NN(C=1N)C(=O)[C@@H]1CCNC2=CC=C(F)C=C12)S(=O)(=O)C XWCADRXAUCPOOB-LLVKDONJSA-N 0.000 description 4
- KBXMKQKGUGKZRA-UHFFFAOYSA-N 6-benzyl-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-3-amine Chemical compound C1CC=2C(N)=NNC=2CN1CC1=CC=CC=C1 KBXMKQKGUGKZRA-UHFFFAOYSA-N 0.000 description 4
- DOGYXMMDLLLFJF-UHFFFAOYSA-N 6-methyl-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound N1CCC(C(O)=O)C2=CC(C)=CC=C21 DOGYXMMDLLLFJF-UHFFFAOYSA-N 0.000 description 4
- SWOANRNXSUXXLB-UHFFFAOYSA-N 8-chloro-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)CCNC2=C1Cl SWOANRNXSUXXLB-UHFFFAOYSA-N 0.000 description 4
- LJQYQWOPXLPHDV-UHFFFAOYSA-N 8-fluoroquinoline-4-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=NC2=C1F LJQYQWOPXLPHDV-UHFFFAOYSA-N 0.000 description 4
- HSPNNHDKBJINIT-UHFFFAOYSA-N 8-methyl-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound OC(=O)C1CCNC2=C1C=CC=C2C HSPNNHDKBJINIT-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 4
- TYDZTFFITPOAIC-UHFFFAOYSA-N CC1=CC(F)=CC2=C1NCCC2C(=O)N1N=C2CN(CCC2=C1N)S(C)(=O)=O Chemical compound CC1=CC(F)=CC2=C1NCCC2C(=O)N1N=C2CN(CCC2=C1N)S(C)(=O)=O TYDZTFFITPOAIC-UHFFFAOYSA-N 0.000 description 4
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 4
- XAYZIWJLBMFDPT-UHFFFAOYSA-N (3-amino-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-2-yl)-(1-tert-butyl-6-fluoro-8-methyl-3,4-dihydro-2H-quinolin-4-yl)methanone Chemical compound C(C)(C)(C)N1CCC(C2=CC(=CC(=C12)C)F)C(=O)N1N=C2C(CNCC2)=C1N XAYZIWJLBMFDPT-UHFFFAOYSA-N 0.000 description 3
- DISHGFUUSLGEPG-UHFFFAOYSA-N (3-amino-6,7-dihydro-4H-pyrano[4,3-c]pyrazol-1-yl)-(6-fluoro-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound NC1=NN(C(=O)C2CCNC3=C2C=C(F)C=C3)C2=C1COCC2 DISHGFUUSLGEPG-UHFFFAOYSA-N 0.000 description 3
- QJMKVOPDZNNLBK-UHFFFAOYSA-N (3-amino-6-benzyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-(2-methyl-1H-indol-4-yl)methanone Chemical compound C(C1=CC=CC=C1)N1CC=2C(CC1)=C(N(N=2)C(=O)C1=C2C=C(NC2=CC=C1)C)N QJMKVOPDZNNLBK-UHFFFAOYSA-N 0.000 description 3
- MLDUUCQJKVIFTD-UHFFFAOYSA-N (3-amino-6-ethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-(1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound NC1=NN(C=2CN(CCC=21)CC)C(=O)C1CCNC2=CC=CC=C12 MLDUUCQJKVIFTD-UHFFFAOYSA-N 0.000 description 3
- USCOJXXCHWFEDM-UHFFFAOYSA-N (3-amino-6-ethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-(1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound NC=1N(N=C2CN(CCC2=1)CC)C(=O)C1CCNC2=CC=CC=C12 USCOJXXCHWFEDM-UHFFFAOYSA-N 0.000 description 3
- NXTQWSMOLFJZFG-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-(2,2-dimethyl-3,4-dihydro-1H-quinolin-4-yl)methanone Chemical compound NC1=NN(C=2CN(CCC=21)S(=O)(=O)C)C(=O)C1CC(NC2=CC=CC=C12)(C)C NXTQWSMOLFJZFG-UHFFFAOYSA-N 0.000 description 3
- LBSDTNGERQTEKR-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-(6-ethyl-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound CCC1=CC2=C(NCCC2C(=O)N2N=C(N)C3=C2CN(CC3)S(C)(=O)=O)C=C1 LBSDTNGERQTEKR-UHFFFAOYSA-N 0.000 description 3
- PWHZAKJDYDYBCR-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-(6-ethyl-8-methyl-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound CCC1=CC2=C(NCCC2C(=O)N2N=C(N)C3=C2CN(CC3)S(C)(=O)=O)C(C)=C1 PWHZAKJDYDYBCR-UHFFFAOYSA-N 0.000 description 3
- JTNXKAHPYMQEFM-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-(6-methoxy-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound COC1=CC2=C(NCCC2C(=O)N2N=C(N)C3=C2CN(CC3)S(C)(=O)=O)C=C1 JTNXKAHPYMQEFM-UHFFFAOYSA-N 0.000 description 3
- XWMVYVKWXLCPDT-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-(8-chloro-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound CS(=O)(=O)N1CCC2=C(C1)N(N=C2N)C(=O)C1CCNC2=C1C=CC=C2Cl XWMVYVKWXLCPDT-UHFFFAOYSA-N 0.000 description 3
- FXJFKLXRZXZDQA-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-(8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound CS(=O)(=O)N1CCC2=C(C1)N(N=C2N)C(=O)C1CCNC2=C1C=CC=C2F FXJFKLXRZXZDQA-UHFFFAOYSA-N 0.000 description 3
- HOYWIOSQHZBGGV-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-[6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-yl]methanone Chemical compound CS(=O)(=O)N1CCC2=C(C1)N(N=C2N)C(=O)C1CCNC2=C1C=C(C=C2)C(F)(F)F HOYWIOSQHZBGGV-UHFFFAOYSA-N 0.000 description 3
- IAOQELCVOJALMZ-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-(1,2,3,4-tetrahydro-1,8-naphthyridin-4-yl)methanone Chemical compound CS(=O)(=O)N1CCC2=C(N)N(N=C2C1)C(=O)C1CCNC2=NC=CC=C12 IAOQELCVOJALMZ-UHFFFAOYSA-N 0.000 description 3
- CJEORVWTYOHIEJ-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-(2-methyl-4,5,6,7-tetrahydroisoindol-4-yl)methanone Chemical compound NC=1N(N=C2CN(CCC2=1)S(=O)(=O)C)C(=O)C1C2=CN(C=C2CCC1)C CJEORVWTYOHIEJ-UHFFFAOYSA-N 0.000 description 3
- SYBODYDXBHCADD-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-(6-propan-2-yl-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound CC(C)C1=CC2=C(NCCC2C(=O)N2N=C3CN(CCC3=C2N)S(C)(=O)=O)C=C1 SYBODYDXBHCADD-UHFFFAOYSA-N 0.000 description 3
- FXDAGAYQHYWILW-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-(8-chloro-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound CS(=O)(=O)N1CCC2=C(N)N(N=C2C1)C(=O)C1CCNC2=C1C=CC=C2Cl FXDAGAYQHYWILW-UHFFFAOYSA-N 0.000 description 3
- XWCADRXAUCPOOB-NSHDSACASA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-[(4S)-6-fluoro-1,2,3,4-tetrahydroquinolin-4-yl]methanone Chemical compound C=12CCN(CC2=NN(C=1N)C(=O)[C@@H]1C2=C(NCC1)C=CC(F)=C2)S(=O)(=O)C XWCADRXAUCPOOB-NSHDSACASA-N 0.000 description 3
- SPINKZDEDXOEMX-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-[6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-yl]methanone Chemical compound CS(=O)(=O)N1CCC2=C(N)N(N=C2C1)C(=O)C1CCNC2=C1C=C(C=C2)C(F)(F)F SPINKZDEDXOEMX-UHFFFAOYSA-N 0.000 description 3
- DVGBUGLPBBIKQB-UHFFFAOYSA-N (3-amino-6-phenyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-(6-fluoro-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound NC1=NN(C(=O)C2CCNC3=C2C=C(F)C=C3)C2=C1CCN(C2)C1=CC=CC=C1 DVGBUGLPBBIKQB-UHFFFAOYSA-N 0.000 description 3
- WLMQBEJVLAIDSV-UHFFFAOYSA-N (3-amino-6-phenyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-(6-fluoro-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound NC1=C2CCN(CC2=NN1C(=O)C1CCNC2=C1C=C(F)C=C2)C1=CC=CC=C1 WLMQBEJVLAIDSV-UHFFFAOYSA-N 0.000 description 3
- QHALSCLQHASOFO-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine-4-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)CCNC2=N1 QHALSCLQHASOFO-UHFFFAOYSA-N 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- NIAYZQLKUNOGRH-UHFFFAOYSA-N 2,2-dimethyl-3,4-dihydro-1h-quinoline-4-carboxylic acid Chemical compound C1=CC=C2NC(C)(C)CC(C(O)=O)C2=C1 NIAYZQLKUNOGRH-UHFFFAOYSA-N 0.000 description 3
- UHBIMVXSOCBHIC-UHFFFAOYSA-N 2,2-dimethyl-4-trimethylsilyloxy-1,3-dihydroquinoline-4-carbonitrile Chemical compound CC1(C)CC(O[Si](C)(C)C)(C#N)C2=C(N1)C=CC=C2 UHBIMVXSOCBHIC-UHFFFAOYSA-N 0.000 description 3
- QTVBCDXLQJHLCJ-UHFFFAOYSA-N 2-chloro-4,5,6,7-tetrahydro-1H-indole-4-carboxylic acid Chemical compound ClC=1NC=2CCCC(C=2C=1)C(=O)O QTVBCDXLQJHLCJ-UHFFFAOYSA-N 0.000 description 3
- ZBKQYVJEXGFEPV-UHFFFAOYSA-N 2-ethyl-4,5,6,7-tetrahydro-1H-indole-4-carboxylic acid Chemical compound C(C)C=1NC=2CCCC(C=2C=1)C(=O)O ZBKQYVJEXGFEPV-UHFFFAOYSA-N 0.000 description 3
- NUBJHNKCWFUFKW-UHFFFAOYSA-N 2-methyl-1h-indole-4-carboxylic acid Chemical compound C1=CC=C2NC(C)=CC2=C1C(O)=O NUBJHNKCWFUFKW-UHFFFAOYSA-N 0.000 description 3
- XJFLYIJIXQQVQJ-UHFFFAOYSA-N 2-methyl-4,5,6,7-tetrahydroisoindole-4-carboxylic acid Chemical compound C1CCC(C(O)=O)C2=CN(C)C=C21 XJFLYIJIXQQVQJ-UHFFFAOYSA-N 0.000 description 3
- ALKAATBPDHYIFW-UHFFFAOYSA-N 2-methyl-6,7-dihydro-5h-isoindol-4-one Chemical compound C1CCC(=O)C2=CN(C)C=C21 ALKAATBPDHYIFW-UHFFFAOYSA-N 0.000 description 3
- IDWUSJOEYZAKSW-UHFFFAOYSA-N 3-(pyridin-1-ium-2-ylamino)propanoate Chemical class OC(=O)CCNC1=CC=CC=N1 IDWUSJOEYZAKSW-UHFFFAOYSA-N 0.000 description 3
- QALFVTXZNIAVFC-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indole-4-carboxylic acid Chemical compound OC(=O)C1CCCC2=C1C=CN2 QALFVTXZNIAVFC-UHFFFAOYSA-N 0.000 description 3
- JPBCMOIWNWVAKZ-UHFFFAOYSA-N 4-bromo-6-ethenyl-8-methylquinoline Chemical compound BrC1=CC=NC2=C(C=C(C=C12)C=C)C JPBCMOIWNWVAKZ-UHFFFAOYSA-N 0.000 description 3
- WDVHQDJBYWFIPC-UHFFFAOYSA-N 4-bromo-6-fluoro-8-methylquinoline Chemical compound Cc1cc(F)cc2c(Br)ccnc12 WDVHQDJBYWFIPC-UHFFFAOYSA-N 0.000 description 3
- ZLLWNTMVQORUCR-UHFFFAOYSA-N 4-bromo-8-(trifluoromethyl)quinoline Chemical compound C1=CN=C2C(C(F)(F)F)=CC=CC2=C1Br ZLLWNTMVQORUCR-UHFFFAOYSA-N 0.000 description 3
- KEZCZGIXNBDAAB-UHFFFAOYSA-N 4-bromo-8-ethylquinoline Chemical compound C1=CN=C2C(CC)=CC=CC2=C1Br KEZCZGIXNBDAAB-UHFFFAOYSA-N 0.000 description 3
- ZTCUNVSNCQDTQR-UHFFFAOYSA-N 4-bromo-8-methoxyquinoline Chemical compound C1=CN=C2C(OC)=CC=CC2=C1Br ZTCUNVSNCQDTQR-UHFFFAOYSA-N 0.000 description 3
- IDGLXERCZWXTCV-UHFFFAOYSA-N 4-bromo-8-methylquinoline Chemical compound C1=CN=C2C(C)=CC=CC2=C1Br IDGLXERCZWXTCV-UHFFFAOYSA-N 0.000 description 3
- JZPPOOWVXUZBIU-UHFFFAOYSA-N 6-acetamido-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound CC(=O)NC1=CC2=C(NCCC2C(O)=O)C=C1 JZPPOOWVXUZBIU-UHFFFAOYSA-N 0.000 description 3
- QKZZTVSKZXPJAC-UHFFFAOYSA-N 6-bromoquinoline-4-carboxylic acid Chemical compound C1=C(Br)C=C2C(C(=O)O)=CC=NC2=C1 QKZZTVSKZXPJAC-UHFFFAOYSA-N 0.000 description 3
- VSXYSSIGYAXJNT-UHFFFAOYSA-N 6-ethenyl-8-methyl-1H-quinolin-4-one Chemical compound CC=1C=C(C=C2C(C=CNC=12)=O)C=C VSXYSSIGYAXJNT-UHFFFAOYSA-N 0.000 description 3
- DELCTCNPEUBCCG-UHFFFAOYSA-N 6-ethenylquinoline-4-carboxylic acid Chemical compound C1=C(C=C)C=C2C(C(=O)O)=CC=NC2=C1 DELCTCNPEUBCCG-UHFFFAOYSA-N 0.000 description 3
- JLLPEAYBZGDKQH-UHFFFAOYSA-N 6-ethyl-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound N1CCC(C(O)=O)C2=CC(CC)=CC=C21 JLLPEAYBZGDKQH-UHFFFAOYSA-N 0.000 description 3
- IKFWBIFODMIJCH-UHFFFAOYSA-N 6-ethyl-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-3-amine Chemical compound C1N(CC)CCC2=C1NN=C2N IKFWBIFODMIJCH-UHFFFAOYSA-N 0.000 description 3
- APTLHGMXAYJXDI-UHFFFAOYSA-N 6-fluoro-8-methyl-1h-quinolin-4-one Chemical compound N1C=CC(=O)C2=C1C(C)=CC(F)=C2 APTLHGMXAYJXDI-UHFFFAOYSA-N 0.000 description 3
- PBYPMVLCXWJEQV-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound N1CCC(C(O)=O)C2=CC(OC)=CC=C21 PBYPMVLCXWJEQV-UHFFFAOYSA-N 0.000 description 3
- URMBLJWNBITPCV-UHFFFAOYSA-N 6-methylquinoline-4-carboxylic acid Chemical compound N1=CC=C(C(O)=O)C2=CC(C)=CC=C21 URMBLJWNBITPCV-UHFFFAOYSA-N 0.000 description 3
- OFARLFYWLVLNIE-UHFFFAOYSA-N 6-phenyl-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound OC(=O)C1CCNC2=C1C=C(C=C2)C1=CC=CC=C1 OFARLFYWLVLNIE-UHFFFAOYSA-N 0.000 description 3
- BAHAQHNXBOUTIA-UHFFFAOYSA-N 6-phenylquinoline-4-carboxylic acid Chemical compound C1=C2C(C(=O)O)=CC=NC2=CC=C1C1=CC=CC=C1 BAHAQHNXBOUTIA-UHFFFAOYSA-N 0.000 description 3
- AXPJFVUUSZEBBQ-UHFFFAOYSA-N 6-prop-1-en-2-ylquinoline-4-carboxylic acid Chemical compound C=C(C)C=1C=C2C(=CC=NC2=CC=1)C(=O)O AXPJFVUUSZEBBQ-UHFFFAOYSA-N 0.000 description 3
- IVBFVBURYFRZTI-UHFFFAOYSA-N 6-propan-2-yl-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound N1CCC(C(O)=O)C2=CC(C(C)C)=CC=C21 IVBFVBURYFRZTI-UHFFFAOYSA-N 0.000 description 3
- KQQXRXPCNNXCRH-UHFFFAOYSA-N 7-methyl-4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridin-3-amine Chemical compound CC1NCCC2=C1NN=C2N KQQXRXPCNNXCRH-UHFFFAOYSA-N 0.000 description 3
- OIMOVIQGZFCFLR-UHFFFAOYSA-N 8-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound C1=CC=C(C(F)(F)F)C2=C1C(C(=O)O)CCN2 OIMOVIQGZFCFLR-UHFFFAOYSA-N 0.000 description 3
- YBQQVKSIRLQGQW-UHFFFAOYSA-N 8-ethyl-1h-quinolin-4-one Chemical compound N1C=CC(=O)C2=C1C(CC)=CC=C2 YBQQVKSIRLQGQW-UHFFFAOYSA-N 0.000 description 3
- ALXSOYUGMZCKRV-UHFFFAOYSA-N 8-methoxy-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound OC(=O)C1CCNC2=C1C=CC=C2OC ALXSOYUGMZCKRV-UHFFFAOYSA-N 0.000 description 3
- QHMYOJAIEQCUQX-UHFFFAOYSA-N 8-methylquinoline-4-carboxylic acid Chemical compound C1=CN=C2C(C)=CC=CC2=C1C(O)=O QHMYOJAIEQCUQX-UHFFFAOYSA-N 0.000 description 3
- XEZLHMANWBLNME-JTQLQIEISA-N C1CNC2=C([C@H]1C(=O)N3C(=C4CCNCC4=N3)N)C=CC=C2Cl Chemical compound C1CNC2=C([C@H]1C(=O)N3C(=C4CCNCC4=N3)N)C=CC=C2Cl XEZLHMANWBLNME-JTQLQIEISA-N 0.000 description 3
- SHZCWYZJVONKFR-UHFFFAOYSA-N CC1(C)CC(C(=O)N2N=C3CN(CCC3=C2N)S(C)(=O)=O)C2=C(N1)C=CC=C2 Chemical compound CC1(C)CC(C(=O)N2N=C3CN(CCC3=C2N)S(C)(=O)=O)C2=C(N1)C=CC=C2 SHZCWYZJVONKFR-UHFFFAOYSA-N 0.000 description 3
- HTCSUCDYUISMCG-CYBMUJFWSA-N CC1=C2C(=CC=C1)[C@@H](CCN2)C(=O)N3C(=C4CCN(CC4=N3)S(=O)(=O)C)N Chemical class CC1=C2C(=CC=C1)[C@@H](CCN2)C(=O)N3C(=C4CCN(CC4=N3)S(=O)(=O)C)N HTCSUCDYUISMCG-CYBMUJFWSA-N 0.000 description 3
- TYDZTFFITPOAIC-GFCCVEGCSA-N CC1=CC(=CC2=C1NCC[C@H]2C(=O)N3C(=C4CCN(CC4=N3)S(=O)(=O)C)N)F Chemical compound CC1=CC(=CC2=C1NCC[C@H]2C(=O)N3C(=C4CCN(CC4=N3)S(=O)(=O)C)N)F TYDZTFFITPOAIC-GFCCVEGCSA-N 0.000 description 3
- VWXBJACPADKYAM-LLVKDONJSA-N CC1=CC(=CC2=C1NCC[C@H]2C(=O)N3C(=C4CCOCC4=N3)N)F Chemical compound CC1=CC(=CC2=C1NCC[C@H]2C(=O)N3C(=C4CCOCC4=N3)N)F VWXBJACPADKYAM-LLVKDONJSA-N 0.000 description 3
- JVZOUCHVUHTXQB-UHFFFAOYSA-N CC1=CC(F)=CC2=C1NCCC2C(=O)N1N=C(N)C2=C1CN(CC2)S(C)(=O)=O Chemical compound CC1=CC(F)=CC2=C1NCCC2C(=O)N1N=C(N)C2=C1CN(CC2)S(C)(=O)=O JVZOUCHVUHTXQB-UHFFFAOYSA-N 0.000 description 3
- VWXBJACPADKYAM-NSHDSACASA-N CC1=CC(F)=CC2=C1NCC[C@@H]2C(=O)N1N=C2COCCC2=C1N Chemical compound CC1=CC(F)=CC2=C1NCC[C@@H]2C(=O)N1N=C2COCCC2=C1N VWXBJACPADKYAM-NSHDSACASA-N 0.000 description 3
- HTCSUCDYUISMCG-ZDUSSCGKSA-N CC1=CC=CC2=C1NCC[C@@H]2C(=O)N1N=C2CN(CCC2=C1N)S(C)(=O)=O Chemical compound CC1=CC=CC2=C1NCC[C@@H]2C(=O)N1N=C2CN(CCC2=C1N)S(C)(=O)=O HTCSUCDYUISMCG-ZDUSSCGKSA-N 0.000 description 3
- AFIIEHQATRGIHT-UHFFFAOYSA-N CC1N(CCC=2C1=NNC=2N)S(=O)(=O)C Chemical compound CC1N(CCC=2C1=NNC=2N)S(=O)(=O)C AFIIEHQATRGIHT-UHFFFAOYSA-N 0.000 description 3
- OHMDLPSPZVSXFF-CYBMUJFWSA-N CCC1=CC2=C(C=C1)NCC[C@H]2C(=O)N3C(=C4CCN(CC4=N3)S(=O)(=O)C)N Chemical compound CCC1=CC2=C(C=C1)NCC[C@H]2C(=O)N3C(=C4CCN(CC4=N3)S(=O)(=O)C)N OHMDLPSPZVSXFF-CYBMUJFWSA-N 0.000 description 3
- PONHZIIANACDEL-UHFFFAOYSA-N CCC1=CC2=C(NCCC2C(=O)N2N=C3CN(CCC3=C2N)S(C)(=O)=O)C(C)=C1 Chemical compound CCC1=CC2=C(NCCC2C(=O)N2N=C3CN(CCC3=C2N)S(C)(=O)=O)C(C)=C1 PONHZIIANACDEL-UHFFFAOYSA-N 0.000 description 3
- RXWNGDFRBSERNG-UHFFFAOYSA-N COC1=CC2=C(NCCC2C(=O)N2N=C3CN(CCC3=C2N)S(C)(=O)=O)C=C1 Chemical compound COC1=CC2=C(NCCC2C(=O)N2N=C3CN(CCC3=C2N)S(C)(=O)=O)C=C1 RXWNGDFRBSERNG-UHFFFAOYSA-N 0.000 description 3
- KHADBRGQACDTPI-UHFFFAOYSA-N COC1=CC=CC2=C1NCCC2C(=O)N1N=C(N)C2=C1CN(CC2)S(C)(=O)=O Chemical compound COC1=CC=CC2=C1NCCC2C(=O)N1N=C(N)C2=C1CN(CC2)S(C)(=O)=O KHADBRGQACDTPI-UHFFFAOYSA-N 0.000 description 3
- VENDHXBGIRNKHA-UHFFFAOYSA-N COC1=CC=CC2=C1NCCC2C(=O)N1N=C2CN(CCC2=C1N)S(C)(=O)=O Chemical compound COC1=CC=CC2=C1NCCC2C(=O)N1N=C2CN(CCC2=C1N)S(C)(=O)=O VENDHXBGIRNKHA-UHFFFAOYSA-N 0.000 description 3
- QQARPEDNHHBOQS-UHFFFAOYSA-N CS(=O)(=O)N1CCC2=C(C1)N(N=C2N)C(=O)C1CCNC2=C1C=C(C=C2)C1=CC=CC=C1 Chemical compound CS(=O)(=O)N1CCC2=C(C1)N(N=C2N)C(=O)C1CCNC2=C1C=C(C=C2)C1=CC=CC=C1 QQARPEDNHHBOQS-UHFFFAOYSA-N 0.000 description 3
- SBILBIOMRLWHSA-UHFFFAOYSA-N CS(=O)(=O)N1CCC2=C(C1)N(N=C2N)C(=O)C1CCNC2=C1C=C(F)C=C2 Chemical compound CS(=O)(=O)N1CCC2=C(C1)N(N=C2N)C(=O)C1CCNC2=C1C=C(F)C=C2 SBILBIOMRLWHSA-UHFFFAOYSA-N 0.000 description 3
- FXDAGAYQHYWILW-NSHDSACASA-N CS(=O)(=O)N1CCC2=C(N(N=C2C1)C(=O)[C@H]3CCNC4=C3C=CC=C4Cl)N Chemical compound CS(=O)(=O)N1CCC2=C(N(N=C2C1)C(=O)[C@H]3CCNC4=C3C=CC=C4Cl)N FXDAGAYQHYWILW-NSHDSACASA-N 0.000 description 3
- TVILCJBOXIYLSK-UHFFFAOYSA-N CS(=O)(=O)N1CCC2=C(N)N(N=C2C1)C(=O)C1CCNC2=C1C=C(C=C2)C1=CC=CC=C1 Chemical compound CS(=O)(=O)N1CCC2=C(N)N(N=C2C1)C(=O)C1CCNC2=C1C=C(C=C2)C1=CC=CC=C1 TVILCJBOXIYLSK-UHFFFAOYSA-N 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- ZFPCXRUTZKRIJC-UHFFFAOYSA-N FC(S(=O)(=O)OC=1C2=CN(C=C2CCC=1)C)(F)F Chemical compound FC(S(=O)(=O)OC=1C2=CN(C=C2CCC=1)C)(F)F ZFPCXRUTZKRIJC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- RCGTZUXOELYXAD-UHFFFAOYSA-N NC1=C2COCCC2=NN1C(=O)C1CCNC2=C1C=C(F)C=C2 Chemical compound NC1=C2COCCC2=NN1C(=O)C1CCNC2=C1C=C(F)C=C2 RCGTZUXOELYXAD-UHFFFAOYSA-N 0.000 description 3
- RYVWGZCUNOBKDC-UHFFFAOYSA-N NC1=NN(C=2CN(CCC=21)S(=O)(=O)C)C(=O)C1CCNC2=NC=CC=C12 Chemical compound NC1=NN(C=2CN(CCC=21)S(=O)(=O)C)C(=O)C1CCNC2=NC=CC=C12 RYVWGZCUNOBKDC-UHFFFAOYSA-N 0.000 description 3
- BNXJBZUYVVXPBG-UHFFFAOYSA-N NC=1N(N=C2CNCCC2=1)C(=O)OC(C)(C)C Chemical compound NC=1N(N=C2CNCCC2=1)C(=O)OC(C)(C)C BNXJBZUYVVXPBG-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- IIXHYDNIIKLYAK-UHFFFAOYSA-M [Na+].CCC1=CC2=C(NCCC2C([O-])=O)C(C)=C1 Chemical compound [Na+].CCC1=CC2=C(NCCC2C([O-])=O)C(C)=C1 IIXHYDNIIKLYAK-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- SKMSTCUKRXSUFW-UHFFFAOYSA-N ethyl 2-(3-bromopropoxy)acetate Chemical compound CCOC(=O)COCCCBr SKMSTCUKRXSUFW-UHFFFAOYSA-N 0.000 description 3
- FSXUELPDMWMWDV-UHFFFAOYSA-N ethyl 2-(3-cyanopropoxy)acetate Chemical compound C(#N)CCCOCC(=O)OCC FSXUELPDMWMWDV-UHFFFAOYSA-N 0.000 description 3
- VBTCKWCAJKCYRR-UHFFFAOYSA-N ethyl 2-(3-hydroxypropoxy)acetate Chemical compound CCOC(=O)COCCCO VBTCKWCAJKCYRR-UHFFFAOYSA-N 0.000 description 3
- BOPOMQCSQFWHNU-UHFFFAOYSA-N ethyl 6-fluoro-8-methyl-4-oxo-1h-quinoline-3-carboxylate Chemical compound C1=C(F)C=C2C(=O)C(C(=O)OCC)=CNC2=C1C BOPOMQCSQFWHNU-UHFFFAOYSA-N 0.000 description 3
- IXXFUMUBUIACJY-UHFFFAOYSA-N ethyl 8-ethyl-4-oxo-1h-quinoline-3-carboxylate Chemical compound C1=CC=C2C(=O)C(C(=O)OCC)=CNC2=C1CC IXXFUMUBUIACJY-UHFFFAOYSA-N 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- BWAOECJSYDPAFS-UHFFFAOYSA-N methyl 2-ethyl-4,5,6,7-tetrahydro-1H-indole-4-carboxylate Chemical compound C(C)C=1NC=2CCCC(C=2C=1)C(=O)OC BWAOECJSYDPAFS-UHFFFAOYSA-N 0.000 description 3
- BAKNQGTWFZYQJE-UHFFFAOYSA-N methyl 2-methyl-4,5,6,7-tetrahydroisoindole-4-carboxylate Chemical compound CN1C=C2CCCC(C2=C1)C(=O)OC BAKNQGTWFZYQJE-UHFFFAOYSA-N 0.000 description 3
- QVWBKHXJYRAUGW-UHFFFAOYSA-N methyl 2-methyl-6,7-dihydroisoindole-4-carboxylate Chemical compound CN1C=C2CCC=C(C2=C1)C(=O)OC QVWBKHXJYRAUGW-UHFFFAOYSA-N 0.000 description 3
- PAVDVXXCLOTNMI-UHFFFAOYSA-N methyl 6-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-4-carboxylate Chemical compound COC(=O)C1CCNc2ccc(cc12)C(F)(F)F PAVDVXXCLOTNMI-UHFFFAOYSA-N 0.000 description 3
- OIZXWABQZYNTGA-UHFFFAOYSA-N methyl 6-(trifluoromethyl)quinoline-4-carboxylate Chemical compound FC(C=1C=C2C(=CC=NC2=CC=1)C(=O)OC)(F)F OIZXWABQZYNTGA-UHFFFAOYSA-N 0.000 description 3
- FYSLZQXLZANSKV-UHFFFAOYSA-N methyl 6-acetamido-1,2,3,4-tetrahydroquinoline-4-carboxylate Chemical compound COC(=O)C1CCNC2=C1C=C(NC(C)=O)C=C2 FYSLZQXLZANSKV-UHFFFAOYSA-N 0.000 description 3
- NTHFCGGCCIJMDJ-UHFFFAOYSA-N methyl 6-acetamidoquinoline-4-carboxylate Chemical compound C(C)(=O)NC=1C=C2C(=CC=NC2=CC=1)C(=O)OC NTHFCGGCCIJMDJ-UHFFFAOYSA-N 0.000 description 3
- ALGCBFKUODRNDC-UHFFFAOYSA-N methyl 6-aminoquinoline-4-carboxylate Chemical compound COC(=O)c1ccnc2ccc(N)cc12 ALGCBFKUODRNDC-UHFFFAOYSA-N 0.000 description 3
- FUAUZGGNGMNBHQ-UHFFFAOYSA-N methyl 6-ethenyl-8-methylquinoline-4-carboxylate Chemical compound CC=1C=C(C=C2C(=CC=NC=12)C(=O)OC)C=C FUAUZGGNGMNBHQ-UHFFFAOYSA-N 0.000 description 3
- WZSJOILWRVPSSJ-UHFFFAOYSA-N methyl 6-ethyl-8-methyl-1,2,3,4-tetrahydroquinoline-4-carboxylate Chemical compound CCC1=CC2=C(NCCC2C(=O)OC)C(C)=C1 WZSJOILWRVPSSJ-UHFFFAOYSA-N 0.000 description 3
- YQTPKQFOVKWUIA-UHFFFAOYSA-N methyl 6-fluoro-1,2,3,4-tetrahydroquinoline-4-carboxylate Chemical compound C1=C(F)C=C2C(C(=O)OC)CCNC2=C1 YQTPKQFOVKWUIA-UHFFFAOYSA-N 0.000 description 3
- XKSMYQMGBKHPQX-UHFFFAOYSA-N methyl 6-fluoro-8-methyl-1,2,3,4-tetrahydroquinoline-4-carboxylate Chemical compound COC(=O)C1CCNC2=C1C=C(F)C=C2C XKSMYQMGBKHPQX-UHFFFAOYSA-N 0.000 description 3
- CQILDYUYFMYVCC-UHFFFAOYSA-N methyl 6-fluoro-8-methylquinoline-4-carboxylate Chemical compound COC(=O)c1ccnc2c(C)cc(F)cc12 CQILDYUYFMYVCC-UHFFFAOYSA-N 0.000 description 3
- VLXVKGYFNNGRBF-UHFFFAOYSA-N methyl 6-fluoroquinoline-4-carboxylate Chemical compound COC(=O)c1ccnc2ccc(F)cc12 VLXVKGYFNNGRBF-UHFFFAOYSA-N 0.000 description 3
- SOJFMSIOJOEQPO-UHFFFAOYSA-N methyl 6-methoxy-1,2,3,4-tetrahydroquinoline-4-carboxylate Chemical compound C1=C(OC)C=C2C(C(=O)OC)CCNC2=C1 SOJFMSIOJOEQPO-UHFFFAOYSA-N 0.000 description 3
- UXVFOFFVXPRWBZ-UHFFFAOYSA-N methyl 6-methoxyquinoline-4-carboxylate Chemical compound C1=C(OC)C=C2C(C(=O)OC)=CC=NC2=C1 UXVFOFFVXPRWBZ-UHFFFAOYSA-N 0.000 description 3
- LDZREOFREHJKBL-UHFFFAOYSA-N methyl 6-methylquinoline-4-carboxylate Chemical compound COC(=O)c1ccnc2ccc(C)cc12 LDZREOFREHJKBL-UHFFFAOYSA-N 0.000 description 3
- ONHAGAMYJXWHOP-UHFFFAOYSA-N methyl 8-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-4-carboxylate Chemical compound COC(=O)C1CCNc2c1cccc2C(F)(F)F ONHAGAMYJXWHOP-UHFFFAOYSA-N 0.000 description 3
- KEUVJFPIVIMOOK-UHFFFAOYSA-N methyl 8-(trifluoromethyl)quinoline-4-carboxylate Chemical compound FC(C=1C=CC=C2C(=CC=NC=12)C(=O)OC)(F)F KEUVJFPIVIMOOK-UHFFFAOYSA-N 0.000 description 3
- VUNYNKAYPAROAX-UHFFFAOYSA-N methyl 8-chloro-1,2,3,4-tetrahydroquinoline-4-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)CCNC2=C1Cl VUNYNKAYPAROAX-UHFFFAOYSA-N 0.000 description 3
- RPSIOFOYAQOQFN-UHFFFAOYSA-N methyl 8-chloroquinoline-4-carboxylate Chemical compound ClC=1C=CC=C2C(=CC=NC=12)C(=O)OC RPSIOFOYAQOQFN-UHFFFAOYSA-N 0.000 description 3
- WFFJRCCWRIBOLR-UHFFFAOYSA-N methyl 8-ethyl-1,2,3,4-tetrahydroquinoline-4-carboxylate Chemical compound COC(=O)C1CCNC2=C1C=CC=C2CC WFFJRCCWRIBOLR-UHFFFAOYSA-N 0.000 description 3
- KVJFILRBJOBDAH-UHFFFAOYSA-N methyl 8-ethylquinoline-4-carboxylate Chemical compound CCc1cccc2c(ccnc12)C(=O)OC KVJFILRBJOBDAH-UHFFFAOYSA-N 0.000 description 3
- KUKNCZIZMQFVSH-UHFFFAOYSA-N methyl 8-fluoroquinoline-4-carboxylate Chemical compound COC(=O)c1ccnc2c(F)cccc12 KUKNCZIZMQFVSH-UHFFFAOYSA-N 0.000 description 3
- PDUWYZDPCTVTHE-UHFFFAOYSA-N methyl 8-methoxy-1,2,3,4-tetrahydroquinoline-4-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)CCNC2=C1OC PDUWYZDPCTVTHE-UHFFFAOYSA-N 0.000 description 3
- QSFHFIGETKEACP-UHFFFAOYSA-N methyl 8-methoxyquinoline-4-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CC=NC2=C1OC QSFHFIGETKEACP-UHFFFAOYSA-N 0.000 description 3
- OQSSKGSCBLWROY-UHFFFAOYSA-N methyl 8-methylquinoline-4-carboxylate Chemical compound CC=1C=CC=C2C(=CC=NC=12)C(=O)OC OQSSKGSCBLWROY-UHFFFAOYSA-N 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- BFXHOSDYAZWOOY-UHFFFAOYSA-N tert-butyl 2-ethenyl-5-ethylpyrrole-1-carboxylate Chemical compound C(C)C=1N(C(=CC=1)C=C)C(=O)OC(C)(C)C BFXHOSDYAZWOOY-UHFFFAOYSA-N 0.000 description 3
- YGTLCGNVJZRZIK-UHFFFAOYSA-N tert-butyl 2-ethyl-5-formylpyrrole-1-carboxylate Chemical compound C(C)C=1N(C(=CC=1)C=O)C(=O)OC(C)(C)C YGTLCGNVJZRZIK-UHFFFAOYSA-N 0.000 description 3
- AHGNLFYXPZBDMS-UHFFFAOYSA-N tert-butyl 3-amino-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC2=C1C(N)=NN2 AHGNLFYXPZBDMS-UHFFFAOYSA-N 0.000 description 3
- COBQQHXCPHGBLL-UHFFFAOYSA-N tert-butyl 3-amino-6-benzyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-2-carboxylate Chemical compound NC=1N(N=C2CN(CCC2=1)CC1=CC=CC=C1)C(=O)OC(C)(C)C COBQQHXCPHGBLL-UHFFFAOYSA-N 0.000 description 3
- ZQLXNSYGEUCMLS-UHFFFAOYSA-N tert-butyl 3-amino-6-ethyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-2-carboxylate Chemical compound NC=1N(N=C2CN(CCC2=1)CC)C(=O)OC(C)(C)C ZQLXNSYGEUCMLS-UHFFFAOYSA-N 0.000 description 3
- VVWQMOJSCRZLMV-UHFFFAOYSA-N tert-butyl 3-amino-6-phenyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-2-carboxylate Chemical compound NC=1N(N=C2CN(CCC2=1)C1=CC=CC=C1)C(=O)OC(C)(C)C VVWQMOJSCRZLMV-UHFFFAOYSA-N 0.000 description 3
- PXBXVTVZSHSDHR-UHFFFAOYSA-N (3-amino-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-1-yl)-(8-chloro-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound NC1=NN(C(=O)C2CCNC3=C2C=CC=C3Cl)C2=C1CCNC2 PXBXVTVZSHSDHR-UHFFFAOYSA-N 0.000 description 2
- NSCOOHIWYIDUSU-UHFFFAOYSA-N (3-amino-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-2-yl)-(2-methyl-1H-indol-4-yl)methanone Chemical compound NC=1N(N=C2CNCCC2=1)C(=O)C1=C2C=C(NC2=CC=C1)C NSCOOHIWYIDUSU-UHFFFAOYSA-N 0.000 description 2
- XEZLHMANWBLNME-UHFFFAOYSA-N (3-amino-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-2-yl)-(8-chloro-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound NC1=C2CCNCC2=NN1C(=O)C1CCNC2=C1C=CC=C2Cl XEZLHMANWBLNME-UHFFFAOYSA-N 0.000 description 2
- JWIHNGAVKKLSJU-UHFFFAOYSA-N (3-amino-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)-(6-fluoro-8-methyl-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical class CC1=CC(F)=CC2=C1NCCC2C(=O)N1N=C(N)C2=C1CCNC2 JWIHNGAVKKLSJU-UHFFFAOYSA-N 0.000 description 2
- FRESKFJHYUCMED-UHFFFAOYSA-N (3-amino-5-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-2-yl)-(2-chloro-4,5,6,7-tetrahydro-1H-indol-4-yl)methanone Chemical compound NC=1N(N=C2C=1CN(CC2)C)C(=O)C1C=2C=C(NC=2CCC1)Cl FRESKFJHYUCMED-UHFFFAOYSA-N 0.000 description 2
- WCMHZPZUKVQJDB-UHFFFAOYSA-N (3-amino-6-benzyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-(8-chloro-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound NC1=NN(C=2CN(CCC=21)CC1=CC=CC=C1)C(=O)C1CCNC2=C(C=CC=C12)Cl WCMHZPZUKVQJDB-UHFFFAOYSA-N 0.000 description 2
- NRZFWRSOPGTXMN-UHFFFAOYSA-N (3-amino-6-benzyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-(8-chloro-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound NC1=C2CCN(CC3=CC=CC=C3)CC2=NN1C(=O)C1CCNC2=C1C=CC=C2Cl NRZFWRSOPGTXMN-UHFFFAOYSA-N 0.000 description 2
- PIDNAJBQGDTWBR-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-(2-methyl-4,5,6,7-tetrahydroisoindol-4-yl)methanone Chemical compound NC1=NN(C=2CN(CCC=21)S(=O)(=O)C)C(=O)C1C2=CN(C=C2CCC1)C PIDNAJBQGDTWBR-UHFFFAOYSA-N 0.000 description 2
- PBGBNTJUCYSZTO-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-2-yl)-(8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound CS(=O)(=O)N1CCC2=C(N)N(N=C2C1)C(=O)C1CCNC2=C1C=CC=C2F PBGBNTJUCYSZTO-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- RWVLKDAXCNBLPV-UHFFFAOYSA-N 2,2-dimethyl-1,3-dihydroquinolin-4-one Chemical compound C1=CC=C2NC(C)(C)CC(=O)C2=C1 RWVLKDAXCNBLPV-UHFFFAOYSA-N 0.000 description 2
- GLGXFIOPGKDBIF-UHFFFAOYSA-N 2,3-dihydro-1h-1,8-naphthyridin-4-one Chemical compound C1=CC=C2C(=O)CCNC2=N1 GLGXFIOPGKDBIF-UHFFFAOYSA-N 0.000 description 2
- KFLNDCIGSSBKBA-UHFFFAOYSA-N 2,5,6,7-tetrahydroisoindol-4-one Chemical compound O=C1CCCC2=CNC=C12 KFLNDCIGSSBKBA-UHFFFAOYSA-N 0.000 description 2
- MLPVBIWIRCKMJV-UHFFFAOYSA-N 2-ethylaniline Chemical compound CCC1=CC=CC=C1N MLPVBIWIRCKMJV-UHFFFAOYSA-N 0.000 description 2
- OZOGDBPFACPLTR-UHFFFAOYSA-N 4-(2-aminophenyl)-2-methylbut-3-yn-2-ol Chemical compound CC(C)(O)C#CC1=CC=CC=C1N OZOGDBPFACPLTR-UHFFFAOYSA-N 0.000 description 2
- VDSIOWUVAUJOLX-UHFFFAOYSA-N 4-(3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-1-carbonyl)-6-fluoro-3,4-dihydro-1H-quinolin-2-one Chemical compound NC1=NN(C=2CN(CCC=21)S(=O)(=O)C)C(=O)C1CC(NC2=CC=C(C=C12)F)=O VDSIOWUVAUJOLX-UHFFFAOYSA-N 0.000 description 2
- JLMGKQDKNCHMBB-UHFFFAOYSA-N 4-(3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-2-carbonyl)-6-fluoro-3,4-dihydro-1H-quinolin-2-one Chemical compound NC=1N(N=C2CN(CCC2=1)S(=O)(=O)C)C(=O)C1CC(NC2=CC=C(C=C12)F)=O JLMGKQDKNCHMBB-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- XWZPEOLKMRCJFO-UHFFFAOYSA-N 4-bromo-8-fluoroquinoline Chemical class C1=CN=C2C(F)=CC=CC2=C1Br XWZPEOLKMRCJFO-UHFFFAOYSA-N 0.000 description 2
- CQPGDDAKTTWVDD-UHFFFAOYSA-N 4-bromobutanenitrile Chemical compound BrCCCC#N CQPGDDAKTTWVDD-UHFFFAOYSA-N 0.000 description 2
- PEBCEYLPABLCLR-UHFFFAOYSA-N 4-trimethylsilyloxy-2,3-dihydro-1H-1,8-naphthyridine-4-carbonitrile Chemical compound C[Si](C)(C)OC1(CCNC2=NC=CC=C12)C#N PEBCEYLPABLCLR-UHFFFAOYSA-N 0.000 description 2
- BKJUUCHAWNTSCF-UHFFFAOYSA-N 5-methyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-3-amine Chemical compound C1N(C)CCC2=C1C(N)=NN2 BKJUUCHAWNTSCF-UHFFFAOYSA-N 0.000 description 2
- XYGFKHOPKDJAOX-UHFFFAOYSA-N 6-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound C1=C(C(F)(F)F)C=C2C(C(=O)O)CCNC2=C1 XYGFKHOPKDJAOX-UHFFFAOYSA-N 0.000 description 2
- KZVGINRYKFTCDC-UHFFFAOYSA-N 6-benzyl-7-methyl-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-3-amine Chemical compound C(C1=CC=CC=C1)N1C(C=2C(CC1)=C(NN=2)N)C KZVGINRYKFTCDC-UHFFFAOYSA-N 0.000 description 2
- SZVGRVWNQYKHAS-UHFFFAOYSA-N 6-propan-2-ylquinoline-4-carboxylic acid Chemical compound N1=CC=C(C(O)=O)C2=CC(C(C)C)=CC=C21 SZVGRVWNQYKHAS-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- MMSJWCZEAICBAA-UHFFFAOYSA-N 8-ethyl-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound OC(=O)C1CCNC2=C1C=CC=C2CC MMSJWCZEAICBAA-UHFFFAOYSA-N 0.000 description 2
- GPYRLYNZXSKSGD-UHFFFAOYSA-N 8-fluoro-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)CCNC2=C1F GPYRLYNZXSKSGD-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- SDPPHXXJFDNRSQ-UHFFFAOYSA-N CC(C)C1=CC2=C(NCCC2C(=O)N2N=C(N)C3=C2CN(CC3)S(C)(=O)=O)C=C1 Chemical compound CC(C)C1=CC2=C(NCCC2C(=O)N2N=C(N)C3=C2CN(CC3)S(C)(=O)=O)C=C1 SDPPHXXJFDNRSQ-UHFFFAOYSA-N 0.000 description 2
- PLWNMYAAKIFQOT-NSHDSACASA-N CC1=CC(F)=CC2=C1NCC[C@@H]2C(=O)N1N=C2CCNCC2=C1N Chemical compound CC1=CC(F)=CC2=C1NCC[C@@H]2C(=O)N1N=C2CCNCC2=C1N PLWNMYAAKIFQOT-NSHDSACASA-N 0.000 description 2
- OHMDLPSPZVSXFF-ZDUSSCGKSA-N CCC1=CC2=C(NCC[C@@H]2C(=O)N2N=C3CN(CCC3=C2N)S(C)(=O)=O)C=C1 Chemical compound CCC1=CC2=C(NCC[C@@H]2C(=O)N2N=C3CN(CCC3=C2N)S(C)(=O)=O)C=C1 OHMDLPSPZVSXFF-ZDUSSCGKSA-N 0.000 description 2
- VENDHXBGIRNKHA-LBPRGKRZSA-N COC1=CC=CC2=C1NCC[C@@H]2C(=O)N1N=C2CN(CCC2=C1N)S(C)(=O)=O Chemical compound COC1=CC=CC2=C1NCC[C@@H]2C(=O)N1N=C2CN(CCC2=C1N)S(C)(=O)=O VENDHXBGIRNKHA-LBPRGKRZSA-N 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- HJHZJABTQVMFSW-UHFFFAOYSA-N N-[4-(3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-1-carbonyl)-1,2,3,4-tetrahydroquinolin-6-yl]acetamide Chemical compound CC(=O)NC1=CC2=C(NCCC2C(=O)N2N=C(N)C3=C2CN(CC3)S(C)(=O)=O)C=C1 HJHZJABTQVMFSW-UHFFFAOYSA-N 0.000 description 2
- YXADALZFVYDMRE-UHFFFAOYSA-N N-[4-(3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-2-carbonyl)-1,2,3,4-tetrahydroquinolin-6-yl]acetamide Chemical compound CC(=O)NC1=CC2=C(NCCC2C(=O)N2N=C3CN(CCC3=C2N)S(C)(=O)=O)C=C1 YXADALZFVYDMRE-UHFFFAOYSA-N 0.000 description 2
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- GVFPRHVKUVRFCT-UHFFFAOYSA-N NC1=NN(C=2CN(CCC=21)C(=O)OC(C)(C)C)C(=O)C=1C=2C=C(NC=2C=CC=1)C Chemical compound NC1=NN(C=2CN(CCC=21)C(=O)OC(C)(C)C)C(=O)C=1C=2C=C(NC=2C=CC=1)C GVFPRHVKUVRFCT-UHFFFAOYSA-N 0.000 description 2
- PQGJGPTVJVXJLS-UHFFFAOYSA-N NC1=NNC=2CCC(NC=21)C Chemical compound NC1=NNC=2CCC(NC=21)C PQGJGPTVJVXJLS-UHFFFAOYSA-N 0.000 description 2
- OPSJJYMMFBCQID-UHFFFAOYSA-N NC=1N(N=C2C=1CN(CC2)C(=O)OCC1=CC=CC=C1)C(=O)C1C=2C=C(NC=2CCC1)CC Chemical compound NC=1N(N=C2C=1CN(CC2)C(=O)OCC1=CC=CC=C1)C(=O)C1C=2C=C(NC=2CCC1)CC OPSJJYMMFBCQID-UHFFFAOYSA-N 0.000 description 2
- IHLKLCIDIHLQJB-UHFFFAOYSA-N NC=1N(N=C2CN(CCC2=1)C(=O)OC(C)(C)C)C(=O)C=1C=2C=C(NC=2C=CC=1)C Chemical compound NC=1N(N=C2CN(CCC2=1)C(=O)OC(C)(C)C)C(=O)C=1C=2C=C(NC=2C=CC=1)C IHLKLCIDIHLQJB-UHFFFAOYSA-N 0.000 description 2
- 229910017909 NH2NH2H2O Inorganic materials 0.000 description 2
- 229910020667 PBr3 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229910019020 PtO2 Inorganic materials 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical compound O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical group C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- YAHKFZGMKQRTKA-UHFFFAOYSA-N tert-butyl 3-amino-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC2=C1NN=C2N YAHKFZGMKQRTKA-UHFFFAOYSA-N 0.000 description 2
- LPYKGROAZMIMAN-UHFFFAOYSA-N tert-butyl 3-amino-2-(2-methyl-1H-indole-4-carbonyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate Chemical compound NC=1N(N=C2C=1CN(CC2)C(=O)OC(C)(C)C)C(=O)C1=C2C=C(NC2=CC=C1)C LPYKGROAZMIMAN-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000004724 ultra fast liquid chromatography Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XHGIWCXAACQYGK-OALUTQOASA-N (2s)-5-(diaminomethylideneazaniumyl)-2-[[(2s)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]pentanoate Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(O)=O)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 XHGIWCXAACQYGK-OALUTQOASA-N 0.000 description 1
- XJMNZAJKSXWNJE-UHFFFAOYSA-N (3-amino-2,3,4,5,6,7-hexahydropyrazolo[4,3-c]pyridin-1-yl)-(1-tert-butyl-6-fluoro-8-methyl-3,4-dihydro-2H-quinolin-4-yl)methanone Chemical compound C(C)(C)(C)N1CCC(C2=CC(=CC(=C12)C)F)C(=O)N1NC(C=2CNCCC=21)N XJMNZAJKSXWNJE-UHFFFAOYSA-N 0.000 description 1
- WTXHTBCOHNKKPX-UHFFFAOYSA-N (3-amino-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-2-yl)-(2-ethyl-4,5,6,7-tetrahydro-1H-indol-4-yl)methanone Chemical compound NC=1N(N=C2C=1CNCC2)C(=O)C1C=2C=C(NC=2CCC1)CC WTXHTBCOHNKKPX-UHFFFAOYSA-N 0.000 description 1
- FKMZPOAJKKGJSV-UHFFFAOYSA-N (3-amino-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-2-yl)-(2-methyl-1H-indol-4-yl)methanone Chemical compound NC=1N(N=C2C=1CNCC2)C(=O)C1=C2C=C(NC2=CC=C1)C FKMZPOAJKKGJSV-UHFFFAOYSA-N 0.000 description 1
- FFJIDQSVJZVRCR-UHFFFAOYSA-N (3-amino-6-benzyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-(2-methyl-1H-indol-4-yl)methanone Chemical compound NC1=NN(C=2CN(CCC=21)CC1=CC=CC=C1)C(=O)C1=C2C=C(NC2=CC=C1)C FFJIDQSVJZVRCR-UHFFFAOYSA-N 0.000 description 1
- KTKPBZCERKVHEX-UHFFFAOYSA-N (3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-(6-methyl-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound NC1=NN(C=2CN(CCC=21)S(=O)(=O)C)C(=O)C1CCNC2=CC=C(C=C12)C KTKPBZCERKVHEX-UHFFFAOYSA-N 0.000 description 1
- KWFWSHDPGVJBCR-UHFFFAOYSA-N (3-amino-7-methyl-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-(8-methyl-1,2,3,4-tetrahydroquinolin-4-yl)methanone Chemical compound N1=C(C2=C(N1C(=O)C1CCNC3=C1C=CC=C3C)C(C)N(CC2)S(=O)(=O)C)N KWFWSHDPGVJBCR-UHFFFAOYSA-N 0.000 description 1
- 125000006659 (C1-C20) hydrocarbyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- ARCSZHIPWBDSGJ-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,6-naphthyridine Chemical compound C1=NC=C2CCCNC2=C1 ARCSZHIPWBDSGJ-UHFFFAOYSA-N 0.000 description 1
- LHJKXHUFXRHBBQ-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)CCNC2=C1 LHJKXHUFXRHBBQ-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- PFKMGWBJECRDFB-UHFFFAOYSA-N 1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-3-amine Chemical class C1OCCC2=C1NN=C2N PFKMGWBJECRDFB-UHFFFAOYSA-N 0.000 description 1
- DVNGOOLQHQHDIA-UHFFFAOYSA-N 1,4,6,7-tetrahydropyrano[4,3-c]pyrazol-3-amine Chemical class C1COCC2=C1NN=C2N DVNGOOLQHQHDIA-UHFFFAOYSA-N 0.000 description 1
- LMNMEBVATDFLKD-UHFFFAOYSA-N 1,4-dihydropyrazolo[4,3-c]pyridine-5-carboxylic acid Chemical compound C1=CN(C(=O)O)CC2=C1NN=C2 LMNMEBVATDFLKD-UHFFFAOYSA-N 0.000 description 1
- KASJZXHXXNEULX-UHFFFAOYSA-N 1,5,6,7-tetrahydroindol-4-one Chemical compound O=C1CCCC2=C1C=CN2 KASJZXHXXNEULX-UHFFFAOYSA-N 0.000 description 1
- FAYQULXQEJNZNE-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-4,5,6,7-tetrahydroindole-4-carbonitrile Chemical compound CC1=CC=C(C=C1)S(=O)(=O)N1C=CC2=C1CCCC2C#N FAYQULXQEJNZNE-UHFFFAOYSA-N 0.000 description 1
- WIQSEKHYJHDERY-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-4-trimethylsilyloxy-6,7-dihydro-5h-indole-4-carbonitrile Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(CCCC2(O[Si](C)(C)C)C#N)=C2C=C1 WIQSEKHYJHDERY-UHFFFAOYSA-N 0.000 description 1
- YODKWYHJKWMTAO-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-6,7-dihydro-5h-indol-4-one Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(CCCC2=O)=C2C=C1 YODKWYHJKWMTAO-UHFFFAOYSA-N 0.000 description 1
- KVQSNPJBEMCDIX-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-6,7-dihydroindole-4-carbonitrile Chemical compound CC1=CC=C(C=C1)S(=O)(=O)N1C=CC2=C1CCC=C2C#N KVQSNPJBEMCDIX-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- SLKHVISWZNCHIF-UHFFFAOYSA-N 1-O-tert-butyl 4-O-methyl 2-ethyl-4,5,6,7-tetrahydroindole-1,4-dicarboxylate Chemical compound CCC1=CC2=C(CCCC2C(=O)OC)N1C(=O)OC(C)(C)C SLKHVISWZNCHIF-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- BTAZYPDSTNYFCY-UHFFFAOYSA-N 2-chloro-4,5,6,7-tetrahydro-1H-indole-4-carbaldehyde Chemical compound ClC=1NC=2CCCC(C=2C=1)C=O BTAZYPDSTNYFCY-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- UBPDKIDWEADHPP-UHFFFAOYSA-N 2-iodoaniline Chemical compound NC1=CC=CC=C1I UBPDKIDWEADHPP-UHFFFAOYSA-N 0.000 description 1
- YOBJYKJAYMZIJN-UHFFFAOYSA-N 2-methyl-1h-indole-4-carbaldehyde Chemical compound C1=CC=C2NC(C)=CC2=C1C=O YOBJYKJAYMZIJN-UHFFFAOYSA-N 0.000 description 1
- CEBKHWWANWSNTI-UHFFFAOYSA-N 2-methylbut-3-yn-2-ol Chemical compound CC(C)(O)C#C CEBKHWWANWSNTI-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WMZKLNXGSMVQSD-UHFFFAOYSA-N 3-(3-amino-6-methylsulfonyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridin-1-yl)-2-methyl-4,5,6,7-tetrahydroisoindole-4-carbaldehyde Chemical compound NC1=NN(C=2CN(CCC=21)S(=O)(=O)C)C=1N(C=C2CCCC(C=12)C=O)C WMZKLNXGSMVQSD-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- FUCYABRIJPUVAT-UHFFFAOYSA-N 3-phenylmethoxypropan-1-ol Chemical compound OCCCOCC1=CC=CC=C1 FUCYABRIJPUVAT-UHFFFAOYSA-N 0.000 description 1
- AKJPYSFHVDOBSG-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridin-3-amine Chemical compound C1NCCC2=C1NN=C2N AKJPYSFHVDOBSG-UHFFFAOYSA-N 0.000 description 1
- NHSOJKZKPNWXIO-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridin-3-amine Chemical compound C1CNCC2=C1NN=C2N NHSOJKZKPNWXIO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HIWPTYUKGHNQCU-UHFFFAOYSA-N 4-bromo-6-fluoroquinoline Chemical compound N1=CC=C(Br)C2=CC(F)=CC=C21 HIWPTYUKGHNQCU-UHFFFAOYSA-N 0.000 description 1
- HRFFYKLVLCFCQG-UHFFFAOYSA-N 4-bromo-6-methoxyquinoline Chemical compound N1=CC=C(Br)C2=CC(OC)=CC=C21 HRFFYKLVLCFCQG-UHFFFAOYSA-N 0.000 description 1
- UMYVTXZXVRDOMW-UHFFFAOYSA-N 4-bromo-6-methylquinoline Chemical compound N1=CC=C(Br)C2=CC(C)=CC=C21 UMYVTXZXVRDOMW-UHFFFAOYSA-N 0.000 description 1
- PQEQWWQAYPZCRU-UHFFFAOYSA-N 4-bromo-6-nitroquinoline Chemical compound N1=CC=C(Br)C2=CC([N+](=O)[O-])=CC=C21 PQEQWWQAYPZCRU-UHFFFAOYSA-N 0.000 description 1
- IDHOUYADRURUHC-UHFFFAOYSA-N 4-bromo-8-chloroquinoline Chemical compound C1=CN=C2C(Cl)=CC=CC2=C1Br IDHOUYADRURUHC-UHFFFAOYSA-N 0.000 description 1
- KMHLGVTVACLEJE-UHFFFAOYSA-N 4-fluoro-2-methylaniline Chemical compound CC1=CC(F)=CC=C1N KMHLGVTVACLEJE-UHFFFAOYSA-N 0.000 description 1
- QFDMETKURRPUKW-UHFFFAOYSA-N 4-oxooxane-3-carbonitrile Chemical compound O=C1CCOCC1C#N QFDMETKURRPUKW-UHFFFAOYSA-N 0.000 description 1
- DGWZGZSZVXVVPK-UHFFFAOYSA-N 5-ethyl-1h-pyrrole-2-carbaldehyde Chemical compound CCC1=CC=C(C=O)N1 DGWZGZSZVXVVPK-UHFFFAOYSA-N 0.000 description 1
- CEIVPELVRVTMJW-UHFFFAOYSA-N 6-(trifluoromethyl)-1h-quinolin-4-one Chemical compound N1C=CC(=O)C2=CC(C(F)(F)F)=CC=C21 CEIVPELVRVTMJW-UHFFFAOYSA-N 0.000 description 1
- OLUYDTPGXGNMEB-UHFFFAOYSA-N 6-bromo-8-methyl-1h-quinolin-4-one Chemical compound N1C=CC(=O)C2=C1C(C)=CC(Br)=C2 OLUYDTPGXGNMEB-UHFFFAOYSA-N 0.000 description 1
- VEXBQKRANOCCQI-UHFFFAOYSA-N 6-chloro-1,2,3,4-tetrahydroquinoline-4-carboxylic acid Chemical compound C1=C(Cl)C=C2C(C(=O)O)CCNC2=C1 VEXBQKRANOCCQI-UHFFFAOYSA-N 0.000 description 1
- ZRYMLJGLNAOPNK-UHFFFAOYSA-N 6-chloroquinoline-4-carboxylic acid Chemical compound C1=C(Cl)C=C2C(C(=O)O)=CC=NC2=C1 ZRYMLJGLNAOPNK-UHFFFAOYSA-N 0.000 description 1
- XDMOJKNIUKPXMF-UHFFFAOYSA-N 6-fluoro-1,2,3,4-tetrahydroquinoline-4-carbaldehyde Chemical compound FC1=CC2=C(NCCC2C=O)C=C1 XDMOJKNIUKPXMF-UHFFFAOYSA-N 0.000 description 1
- PXJPYWRFHOWZQA-UHFFFAOYSA-N 6-fluoro-2-oxo-3,4-dihydro-1h-quinoline-4-carboxylic acid Chemical compound C1=C(F)C=C2C(C(=O)O)CC(=O)NC2=C1 PXJPYWRFHOWZQA-UHFFFAOYSA-N 0.000 description 1
- FKGISXGCGZCPFM-UHFFFAOYSA-N 6-methyl-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-3-amine Chemical compound C1N(C)CCC2=C1NN=C2N FKGISXGCGZCPFM-UHFFFAOYSA-N 0.000 description 1
- MHPAEJXMONRAOY-UHFFFAOYSA-N 6-phenyl-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-3-amine Chemical compound C1(=CC=CC=C1)N1CC=2C(CC1)=C(NN=2)N MHPAEJXMONRAOY-UHFFFAOYSA-N 0.000 description 1
- UDRWADJLLWWJOE-UHFFFAOYSA-N 8-(trifluoromethyl)-1H-quinolin-4-one Chemical compound C1=CC=C2C(O)=CC=NC2=C1C(F)(F)F UDRWADJLLWWJOE-UHFFFAOYSA-N 0.000 description 1
- OITOTRKRSUTPAM-UHFFFAOYSA-N 8-ethylquinoline-4-carboxylic acid Chemical compound C1=CN=C2C(CC)=CC=CC2=C1C(O)=O OITOTRKRSUTPAM-UHFFFAOYSA-N 0.000 description 1
- MLCOGYBXLCRWHP-UHFFFAOYSA-N 8-fluoro-1,2,3,4-tetrahydroquinoline-4-carbaldehyde Chemical compound C1CNC2=C(C1C=O)C=CC=C2F MLCOGYBXLCRWHP-UHFFFAOYSA-N 0.000 description 1
- HTELWJVKZKSAQI-UHFFFAOYSA-N 8-fluoro-1h-quinolin-4-one Chemical compound N1C=CC(=O)C2=C1C(F)=CC=C2 HTELWJVKZKSAQI-UHFFFAOYSA-N 0.000 description 1
- DJVLMLGPDKKYJW-UHFFFAOYSA-N 8-methoxy-1h-quinolin-4-one Chemical compound N1C=CC(=O)C2=C1C(OC)=CC=C2 DJVLMLGPDKKYJW-UHFFFAOYSA-N 0.000 description 1
- HTISUYZVEWQIMP-UHFFFAOYSA-N 8-methyl-1h-quinolin-4-one Chemical compound C1=CN=C2C(C)=CC=CC2=C1O HTISUYZVEWQIMP-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000017917 Atypical chemokine receptor Human genes 0.000 description 1
- 108060003357 Atypical chemokine receptor Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- ZTXJWFHANXXVMY-UHFFFAOYSA-N C(C)C=1NC=2CCCC(C=2C=1)C=O Chemical compound C(C)C=1NC=2CCCC(C=2C=1)C=O ZTXJWFHANXXVMY-UHFFFAOYSA-N 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- TYDZTFFITPOAIC-LBPRGKRZSA-N CC1=CC(F)=CC2=C1NCC[C@@H]2C(=O)N1N=C2CN(CCC2=C1N)S(C)(=O)=O Chemical compound CC1=CC(F)=CC2=C1NCC[C@@H]2C(=O)N1N=C2CN(CCC2=C1N)S(C)(=O)=O TYDZTFFITPOAIC-LBPRGKRZSA-N 0.000 description 1
- PONHZIIANACDEL-CQSZACIVSA-N CCC1=CC2=C(C(=C1)C)NCC[C@H]2C(=O)N3C(=C4CCN(CC4=N3)S(=O)(=O)C)N Chemical compound CCC1=CC2=C(C(=C1)C)NCC[C@H]2C(=O)N3C(=C4CCN(CC4=N3)S(=O)(=O)C)N PONHZIIANACDEL-CQSZACIVSA-N 0.000 description 1
- XZHSBQFUPQPDAV-UHFFFAOYSA-N CCC1=CC2=C(NCCC2C(O)=O)C(C)=C1 Chemical compound CCC1=CC2=C(NCCC2C(O)=O)C(C)=C1 XZHSBQFUPQPDAV-UHFFFAOYSA-N 0.000 description 1
- PONHZIIANACDEL-AWEZNQCLSA-N CCC1=CC2=C(NCC[C@@H]2C(=O)N2N=C3CN(CCC3=C2N)S(C)(=O)=O)C(C)=C1 Chemical compound CCC1=CC2=C(NCC[C@@H]2C(=O)N2N=C3CN(CCC3=C2N)S(C)(=O)=O)C(C)=C1 PONHZIIANACDEL-AWEZNQCLSA-N 0.000 description 1
- HXNUBQDXBDOCCP-UHFFFAOYSA-N CCC1=CC=C2NCCC(C=O)C2=C1 Chemical compound CCC1=CC=C2NCCC(C=O)C2=C1 HXNUBQDXBDOCCP-UHFFFAOYSA-N 0.000 description 1
- CEYDOWKTVNAPHT-UHFFFAOYSA-N COC1=CC=CC2=C1NCCC2C=O Chemical compound COC1=CC=CC2=C1NCCC2C=O CEYDOWKTVNAPHT-UHFFFAOYSA-N 0.000 description 1
- TUEJXRXRVQERAG-UHFFFAOYSA-N CS(=O)(=O)N1CCC2=C(N)N(N=C2C1)C(=O)C1CCNC2=C1C=C(Cl)C=C2 Chemical compound CS(=O)(=O)N1CCC2=C(N)N(N=C2C1)C(=O)C1CCNC2=C1C=C(Cl)C=C2 TUEJXRXRVQERAG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010080805 Factor XIa Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100031787 Myosin regulatory light polypeptide 9 Human genes 0.000 description 1
- 101710107065 Myosin regulatory light polypeptide 9 Proteins 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- CPUXJCBFTJAZLO-UHFFFAOYSA-N NC1NN(C2=C1CNCC2)C(=O)C1CCNC2=C(C=C(C=C12)F)C Chemical compound NC1NN(C2=C1CNCC2)C(=O)C1CCNC2=C(C=C(C=C12)F)C CPUXJCBFTJAZLO-UHFFFAOYSA-N 0.000 description 1
- ZJAVKLPSMDYMPG-UHFFFAOYSA-N NC=1NN=C2C=1CN(CC2)C(=O)OCC1=CC=CC=C1 Chemical compound NC=1NN=C2C=1CN(CC2)C(=O)OCC1=CC=CC=C1 ZJAVKLPSMDYMPG-UHFFFAOYSA-N 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- WOMYOSWWSXSBNA-UHFFFAOYSA-N OC(=O)C1=CCNC2=C1C=C(C=C2)C(F)(F)F Chemical compound OC(=O)C1=CCNC2=C1C=C(C=C2)C(F)(F)F WOMYOSWWSXSBNA-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000003827 Plasma Kallikrein Human genes 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000009809 T cell chemotaxis Effects 0.000 description 1
- 230000006043 T cell recruitment Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000004945 acylaminoalkyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000000676 alkoxyimino group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N beta-hydroxyethanesulfonic acid Natural products OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- WBAWRRKHTWWMRW-UHFFFAOYSA-N diethyl 2-[(2-ethylanilino)methylidene]propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)=CNC1=CC=CC=C1CC WBAWRRKHTWWMRW-UHFFFAOYSA-N 0.000 description 1
- PWSTVBKOEBXNBE-UHFFFAOYSA-N diethyl 2-[(4-fluoro-2-methylanilino)methylidene]propanedioate Chemical compound FC1=CC(=C(C=C1)NC=C(C(=O)OCC)C(=O)OCC)C PWSTVBKOEBXNBE-UHFFFAOYSA-N 0.000 description 1
- 230000026058 directional locomotion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- GMGUSXWDHVXICB-UHFFFAOYSA-N ethyl 1-(4-methylphenyl)sulfonyl-4,5,6,7-tetrahydroindole-4-carboxylate Chemical compound CCOC(=O)C1CCCc2c1ccn2S(=O)(=O)c1ccc(C)cc1 GMGUSXWDHVXICB-UHFFFAOYSA-N 0.000 description 1
- SRDUUGCHJFNOGW-UHFFFAOYSA-N ethyl 2-(3-cyanopropylamino)propanoate Chemical compound CCOC(=O)C(C)NCCCC#N SRDUUGCHJFNOGW-UHFFFAOYSA-N 0.000 description 1
- VGYZLVOIKKQBKB-UHFFFAOYSA-N ethyl 2-(3-phenylmethoxypropoxy)acetate Chemical compound CCOC(=O)COCCCOCC1=CC=CC=C1 VGYZLVOIKKQBKB-UHFFFAOYSA-N 0.000 description 1
- ULOLIZHBYWAICY-UHFFFAOYSA-N ethyl 2-(benzylamino)acetate Chemical compound CCOC(=O)CNCC1=CC=CC=C1 ULOLIZHBYWAICY-UHFFFAOYSA-N 0.000 description 1
- VICVAODCXHLLTI-UHFFFAOYSA-N ethyl 2-[benzyl(3-cyanopropyl)amino]acetate Chemical compound CCOC(=O)CN(CCCC#N)CC1=CC=CC=C1 VICVAODCXHLLTI-UHFFFAOYSA-N 0.000 description 1
- YGUFGWCHDUMDDH-UHFFFAOYSA-N ethyl 2-[benzyl(3-cyanopropyl)amino]propanoate Chemical compound C(C1=CC=CC=C1)N(C(C(=O)OCC)C)CCCC#N YGUFGWCHDUMDDH-UHFFFAOYSA-N 0.000 description 1
- JCXLZWMDXJFOOI-UHFFFAOYSA-N ethyl 2-aminopropanoate;hydron;chloride Chemical compound [Cl-].CCOC(=O)C(C)[NH3+] JCXLZWMDXJFOOI-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000022288 lymphocyte chemotaxis Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000004373 methylthiopropyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000005054 naphthyridines Chemical class 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 125000005592 polycycloalkyl group Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- XNYFAJZQMFNULQ-UHFFFAOYSA-N pyridin-1-ium-3-amine;chloride Chemical compound Cl.NC1=CC=CN=C1 XNYFAJZQMFNULQ-UHFFFAOYSA-N 0.000 description 1
- FDDQRDMHICUGQC-UHFFFAOYSA-M pyrrole-1-carboxylate Chemical compound [O-]C(=O)N1C=CC=C1 FDDQRDMHICUGQC-UHFFFAOYSA-M 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- JEOIUGLPMJAHBL-HWBMXIPRSA-N tert-butyl n-[(2s)-1-[(2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[(4-methyl-2-oxochromen-7-yl)amino]pentanoyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC(=O)[C@H](CCCN=C(N)N)NC1=CC=C(C(C)=CC(=O)O2)C2=C1 JEOIUGLPMJAHBL-HWBMXIPRSA-N 0.000 description 1
- KNLKRAUJQBLECR-UHFFFAOYSA-N tert-butyl pyridine-2-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=N1 KNLKRAUJQBLECR-UHFFFAOYSA-N 0.000 description 1
- 108010066180 tertiary-butyloxycarbonyl-valyl-prolyl-arginyl-7-amino-4-methylcoumarin Proteins 0.000 description 1
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本申请公开了如下式I或式II所示的吡喃并吡唑类和吡唑并吡啶类化合物:
Description
相关申请的交叉引用
本申请要求于2017年11月29日递交的第62/592,003号美国临时申请的优先权,其全部内容在此通过援引全部并入本申请。
技术领域
本申请涉及抑制凝血因子XIIa的3-氨基-(7H)-4,5-二氢吡喃并吡唑和3-氨基-4,5,6,7-四氢-5-甲基吡唑并吡啶,它们在凝血酶和其他凝血因子存在的情况下对选择性抑制凝血因子XIIa具有特别的优势,这些化合物可用于治疗自身免疫性疾病。
背景技术
趋化性是响应特定化学梯度的定向运动。除了其他关键的生物过程之外,这种细胞能力对于免疫稳态和炎症的响应是必需的。已经识别出几种趋化因子及其受体,它们提供一种分子机制以协调不同细胞类型响应于各种刺激的运动。例如,趋化因子受体7(CCR7)及其配体(CCL19和CCL21)包括T细胞趋化并在淋巴器官内所需的信号转导轴。CCR7介导的趋化性在研究适应性免疫以及维持耐受性和记忆力方面很重要。
趋化因子被广泛分为稳态趋化因子或炎症性趋化因子。对于炎症性趋化因子,急剧增加的产量可能足以控制趋化响应。对于稳态趋化因子,例如CCL19/21,通过改变受体密度或有效配体浓度来进行信号调节。可以直接(例如增加受体表达)或间接(例如配体的非典型趋化因子受体清除)来实现这种信号调节。实际上,对于CCR7,暴露于血清会促进细胞迁移,并且在血清的存在下T细胞对CCL19/21的趋化响应增强。
PCT WO 2017/123518公开了一种来自高分子量激肽原(HK)的片段是用于加速CCL19介导的趋化性的有效辅因子。该HK片段是必需的并且足以加速CCL19的趋化性,而且对于血清或血浆而言,活性取决于凝血因子XIIa。高分子量激肽原(HK)在炎症中的作用是熟知的,特别是作为九肽缓激肽的亲体分子而出名。
从机理上来看,血清加速的趋化性依赖于活性凝血因子XII(FXIIa),该因子以可促进HK的分裂而熟知。用这种HK衍生片段肽预处理天然鼠类淋巴细胞可增强T细胞在体内归集到淋巴结。循环辅因子在炎症和损伤部位被激活,以增强淋巴细胞趋化性,表现出炎症与适应性免疫结合的强大机制。尤其是,小分子治疗剂可以调节FXIIa功能并从而产生HK片段而不会显著影响凝血酶激活,提供了一种通过体液辅因子安全地调节免疫细胞趋化性的方法。
发明内容
一方面,本申请涉及如下式I或式II所示的化合物:
其中
R1是任选被取代的双环系统;
R2选自氢、卤素、羟基、氨基、氰基、(C1-C4)烷基、(C1-C4)烷氧基、(C1-C4)烷基氨基、二(C1-C4)烷基氨基、(C1-C4)酰胺基、(C1-C4)氟烷基、(C1-C4)氟烷氧基和(C1-C6)氧杂烷基;
X1和X2中的一个选自-O-和-N(QR5)-,另一个选自-CR3R4-;
Q选自直接键、-CH2-、-C(=O)-、-C(=O)O-、-C(=O)NR6-、-SO2-和-SO2NR6-;
R3、R4、R6和R7独立地选自氢和(C1-C6)烷基;
R5选自氢、(C1-C6)烷基、羟基(C2-C6)烷基、三至七元碳环和三至七元杂环。
另一方面,本申请涉及一种用于抑制受试者的因子XIIa的方法,包括例如向受试者施用抑制量的上述的式I或式II化合物。
另一方面,本申请涉及一种在凝血酶和激肽释放酶存在的情况下选择性抑制因子XIIa的方法,包括例如使抑制量的上述的式I或式II化合物与因子XIIa接触。
另一方面,本申请涉及一种用于治疗患者的炎症的方法,包括例如向患者施用治疗有效量的上述的式I或式II的化合物。
另一方面,本申请涉及一种用于治疗患者的免疫失调的方法,包括例如向患者施用治疗有效量的上述的式I或式II的化合物。
另一方面,本申请涉及一种用于治疗患者的血管扩张的方法,包括例如向患者施用治疗有效量的上述的式I或式II的化合物。
另一方面,本申请涉及一种用于治疗患者的血栓形成的方法,包括例如向患者施用治疗有效量的上述的式I或式II的化合物。
根据以下对本申请各个方面的详细描述,本申请的这些和其他目的、特征和优点将变得显而易见。
具体实施方式
一方面,本申请涉及如下式I或式II所示的化合物:
在如式I或式II所示的化合物中,R1是任选被取代的双环系统。任选的取代基包括:卤素、羟基、氨基、氰基、氧代、(C1-C6)脂族烃基、(C1-C4)烷氧基、(C1-C4)烷基氨基、二(C1-C4)烷基氨基、(C1-C4)酰胺基、(C1-C4)烷基磺酰基、[(C1-C4)烷基磺酰基]氨基、(C1-C4)氟烷基、(C1-C4)氟烷氧基、(C1-C6)氧杂烷基、芳基和杂芳基。在一些实施例中,R1是6:6或6:5双环。可以任选被取代的双环系统的实例包括,吲哚、异吲哚、羟吲哚、四氢吲哚、四氢化萘、二氢吲哚、异吲哚啉、四氢喹啉、四氢异喹啉、3,4-二氢-1H-异苯并吡喃、3,4-二氢-2H-苯并吡喃、苯并呋喃、二氢苯并呋喃、四氢苯并呋喃、苯并噻吩、四氢苯并噻吩、吲唑、四氢吲唑、2,3-二氢-1H-茚、萘、四氢化萘、萘啶、四氢萘啶和苯并二氢异吡喃。例如,在一些实施例中,R1可以是含氮双环,例如任选地被取代的四氢喹啉、吲哚、四氢萘啶或四氢吲哚。
在一些实施例中,R1可以是双环系统,任选地被选自以下的一个或多个取代基取代:卤素、羟基、氨基、氰基、氧代、(C1-C8)烃基、(C1-C8)烃氧基、(C1-C4)烷氧基、(C1-C4)烷基氨基、二(C1-C4)烷基氨基、(C1-C4)酰胺基、(C1-C4)烷基磺酰基、[(C1-C4)烷基磺酰基]氨基、(C1-C4)氟烷基、(C1-C4)氟烷氧基、(C1-C6)氧杂烷基、(C3-C6)碳环、芳基、杂芳基和(C1-C4)烯基。在某些实施例中,(C1-C8)烃基取代基可以选自:直链(C1-C8)烷基、支链(C1-C8)烷基、(C3-C6)环烷基和(C3-C6)环烷基(C1-C3)烷基。在一些实施例中,R1任选地被选自以下的一个至三个取代基取代:卤素、羟基、氨基、氰基、氧代基、(C1-C6)脂族烃基、(C1-C4)烷氧基、(C1-C4)烷基氨基、二(C1-C4)烷基氨基、(C1-C4)酰胺基、(C1-C4)烷基磺酰基、[(C1-C4)烷基磺酰基]氨基、(C1-C4)氟烷基、(C1-C4)氟烷氧基、(C1-C6)氧杂烷基、芳基和杂芳基。在一些实施例中,R1任选地被选自以下的一个或多个取代基取代:卤素、(C1-C6)脂族烃基、(C1-C4)氟烷基、(C1-C4)烷氧基、(C1-C4)酰胺基、(C1-C4)烷基磺酰基、苯基和吡啶基,并且尤其是被氟、氯、溴、甲基、乙基、丙基、三氟甲基、甲氧基、甲磺酰基、乙酰胺基、苯基和吡啶基中的一个或两个取代。
任选被取代的双环系统的一个示例性实施例包括如式I或式II所示的化合物,其中R1可以是下式中的一个:
其中
R10选自H、卤素、(C1-C4)烷基和(C3-C6)环烷基;
R11选自H和甲氧基;以及
R12选自H和(C1-C4)烷基。
任选被取代的双环系统的另一个示例性实施例包括如式I或式II所示的化合物,其中R1可以是:
其中
R13和R14独立地选自H、卤素、(C1-C4)烷基、氟(C1-C4)烷基、(C1-C4)烷氧基、(C1-C4)酰胺基、(C1-C4)烷基磺酰基、苯基和吡啶基;
R15a和R15b独立地选自-H和-(C1-C4)烷基,或者R15a和R15b一起形成氧代。
在一些实施例中,标有星号的碳可以是外消旋的,或者在(R)绝对构型中>90%e.e,或者在(S)绝对构型中>90%e.e.。
在一些实施例中,R1可以是任选被取代的萘啶,尤其是四氢-1,8-萘啶或四氢-1,6-萘啶。
在一个亚属中,如式I或式II所示的化合物是3-氨基-(7H)-4,5-二氢吡喃并吡唑:
在另一个亚属中,如式I或式II所示的化合物是3-氨基-4,5,6,7-四氢-5-甲基吡唑并吡啶:
在一些实施例中,Q选自直接键、-CH2-、-C(=O)-、-C(=O)O-、-C(=O)NR6-、-SO2-和-SO2NR6-;R6是氢或甲基。
在一些实施例中,R2和R7独立地选自氢和甲基。在一些实施例中,R2和R7都是氢;在另一些实施例中,R2是氢,和R7是甲基。从实施例可以清楚地看出,R2和R7可以连接在六元环的任何碳上,包括都连接在相同的碳上。
在一些实施例中,R3和R4均为氢。
在一些实施例中,R5选自H、(C1-C4)烷基、(C3-C6)环烷基、羟基(C2-C6)烷基、氟甲基、二氟甲基、苯基、吡啶基、氧杂环丁基、四氢呋喃基和四氢吡喃基。
在式I(2-酰基-3-胺类)和式II(1-酰基-3-胺类)的两种主要化合物中,式I是一种通常比其1-酰基-3-胺类同系物更具选择性且更有效的化合物。在2-酰基-3-胺类化合物中,优选的化合物包括其中R3和R4均为氢的那些化合物;Q选自直接键、-CH2-、-C(=O)-、-C(=O)O-、-C(=O)NR6-、-SO2-和-SO2NR6-;R6是氢或甲基,以及R5选自H、(C1-C4)烷基、(C3-C6)环烷基、氟甲基、二氟甲基、苯基、吡啶基、氧杂环丁基、四氢呋喃基和四氢吡喃基。
在本说明书中,术语和取代基保留其定义。
C1-C20烃基(或其任何子集,例如(C1-C6)烃基)包括烷基、环烷基、多环烷基、烯基、炔基、芳基,以及它们的组合。实例包括苄基、苯乙基、环己基甲基、金刚烷基、樟脑基和萘基乙基。烃基是指由氢和碳作为仅有元素组成的任何取代基。脂族烃是非芳族的烃,它们可以是饱和或不饱和的、环状的、直链的或支链的。脂族烃的实例包括异丙基、2-丁烯基、2-丁炔基、环戊基、降冰片基等。芳族烃包括苯(苯基)、萘(萘基)、蒽等。
除非另有说明,否则烷基(或亚烷基)旨在包括直链或支链的饱和烃结构以及它们的组合。烷基是指具有1-20个碳原子,优选1-10个碳原子,进一步优选1-6个碳原子的烷基。烷基的实例包括甲基、乙基、丙基、异丙基、正丁基、仲丁基、叔丁基等。
环烷基是烃的子集并且包括3-8个碳原子的环状烃基。环烷基的实例包括环丙基、环丁基、环戊基、降冰片基等。
除非另有说明,否则术语“碳环”旨在包括其中环原子都是碳但具有任何氧化态的环系统。因此,(C3-C7)碳环是指非芳族系统和芳族系统,包括诸如环丙烷、苯和环己烯等系统;如果没有其他限制,碳环是指单环、双环和多环。
杂环是指脂族或芳族碳环基,其中1-4个碳原子被选自N、O和S的杂原子取代。氮和硫杂原子可任选被氧化,并且氮杂原子可选地被季铵化。除非另有说明,否则杂环可以是非芳族(杂脂族)或芳族(杂芳基)。杂环的实例包括吡咯烷、吡唑、吡咯、吲哚、喹啉、异喹啉、萘啶、四氢异喹啉、苯并呋喃、苯并二恶烷、苯并二氧杂环戊烯(当作为取代基出现时、通常被称为亚甲基二氧苯基)、四唑、吗啉、噻唑、吡啶、哒嗪、嘧啶、噻吩、呋喃、恶唑、恶唑啉、异恶唑、二恶烷、四氢呋喃等。杂环基的实例包括哌嗪基、哌啶基、吡唑烷基、咪唑基、咪唑啉基、咪唑烷基、吡嗪基、恶唑烷基、异恶唑烷基、噻唑烷基、异噻唑基、奎宁环基、异噻唑烷基、苯并咪唑基、噻二唑基、苯并吡喃基、苯并噻唑基、萘啶基、四氢呋喃基、四氢吡喃基、噻吩基(曾经也被称为苯硫基),苯并噻吩基、硫吗啉基、恶二唑基、三唑基和四氢喹啉基。
烃氧基是指通过氧与母体结构连接的具有1-20个碳原子、优选1-10个碳原子、进一步优选1-6个碳原子的基团。烷氧基是烃氧基的子集,并且包括直链或支链构型的基团。实例包括甲氧基、乙氧基、丙氧基、异丙氧基等。低级烷氧基是指含有1-4个碳的基团。术语“卤素”是指氟、氯、溴或碘原子。
除非另有说明,否则酰基是指甲酰基和具有1-8个碳原子的直链、支链、环状构型、饱和、不饱和与芳族,以及它们的组合的基团,通过羰基官能团连接到母体结构上。实例包括乙酰基、苯甲酰基、丙酰基、异丁酰基等。低级酰基是指含有1-4个碳的基团。
当本身被作为取代基时,双键氧被称为“羰基(oxo)”。本领域技术人员将理解,由于羰基是二价自由基,因此在某些情况下(例如在苯基上)它不适合作为取代基,以及其他情况,例如下面的实施例43和44中,可以容纳该取代基。
在本文中,术语“任选被取代”与短语“未被取代或被取代的”可以互换使用。术语“被取代的”是指在特定基团中的一个或多个氢原子被特定取代基取代。例如,被取代的烷基、芳基、环烷基、杂环基等,是指其中每个基团中的一个或多个氢原子被下述取代基取代:卤素、卤代烷基、烃基、酰基、烷氧基烷基、羟基低级烷基、羰基、苯基、杂芳基、苯磺酰基、羟基、烃氧基、卤代烷氧基、氧杂烷基、羧基、烷氧基羰基[-C(=O)O-烷基]、烷氧基羰基氨基[HNC(=O)O-烷基]、氨基羰基(也称为甲酰胺基)[-C(=O)NH2]、烷基氨基羰基[-C(=O)NH-烷基]、氰基、乙酰氧基、硝基、氨基、烷基氨基、二烷基氨基、(烷基)(芳基)氨基烷基、烷基氨基烷基(包括环烷基氨基烷基)、二烷基氨基烷基、二烷基氨基烷氧基、杂环基烷氧基、巯基、烷硫基、亚砜、砜、磺酰基氨基、烷基亚磺酰基、烷基磺酰基、酰基氨基烷基、酰基氨基烷氧基、酰基氨基、脒基、芳基、苄基、杂环基、杂环基烷基、苯氧基、苄氧基、杂芳氧基、羟基亚氨基、烷氧基亚氨基、氧杂烷基、磺酰胺基、三苯甲基、脒基、胍基、脲基、苄氧基苯基和苄氧基。在一个实施例中,1、2或3个氢原子被特定取代基取代。对于烷基和环烷基而言,三个以上的氢原子可以被氟取代;实际上,所有可用的氢原子都可以被氟取代。
氧杂烷基(oxaalkyl)是指其中一个或多个碳(以及与其相关的氢)已被氧取代的烷基。实例包括甲氧基丙氧基和3,6,9-三氧杂癸基等。如本领域所理解的,术语“氧杂烷基”是指氧通过单键与相邻原子键合(形成醚键)的化合物(参看美国化学学会出版的Namingand Indexing of Chemical Substances for Chemical Abstracts第196页,但不受第127(a)条的限制);而不指如羰基那种双键键合的氧。类似地,硫代烷基和氮杂烷基是指其中一个或多个碳已分别被硫或氮取代的烷基。实例包括乙基氨基乙基和甲硫基丙基。
在一些实施例中,取代基R1可以是任选被取代的6,5-、5,6-或6,6双环AB,其中环A是非芳族,并且其连接点处的碳具有如下所示的特定的绝对构型:
在手性中心*处的构型使得环A在纸平面中并且取代基H和羰基位于该平面的上方和下方(如本领域技术人员所理解的,命名(R)或(S)可根据与环中的手性碳相邻的原子的层次而变化)。
本文中的外消旋的、双非外消旋的(ambiscalemic)和非外消旋的(scalemic)或光学纯的化合物的图示采用Maehr J.Chem.Ed.62,114-120(1985)中的表述:实心楔形和虚线楔形用来表示手性元素的绝对构型,波浪线表示对其所代表的键可能产生任何立体化学含义的否认;粗实线和虚实线是表示所示的相对构型,但不表示外消旋特征的几何描述;且楔形轮廓和点线或虚线表示具有不确定的绝对构型的光学纯的化合物。对于文中与楔形轮廓和点线或虚线相对应的命名,将R*和S*定义为表示具有不确定的绝对构型的单一对映异构体。因此,例如,在下面的实施例18和19中,描述了(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮和(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮的合成。(R*)和(S*)旨在表示所述产物是具有所述特征(例如NMR、HPLC保留时间等)的单一对映异构体,其中每个手性中心被认为是基于所示配置的旁证,但尚未确认绝对构型。因此,下述的:
表示产物是以下两个异构体中的一个,很可能是第一个:
当化合物具有不对称中心时,其在本申请权利要求中的描述以简单的线条表示(例如旨在表示该结构包括任何和所有的异构体,而与对映异构体纯度无关。当其在本申请权利要求书中的描述包括楔形、虚线等时(例如),旨在表示该结构包括至少80%ee,优选>90%ee的相对或绝对构型的异构体。
在引入取代基Rn时通常会对其进行定义,并且在整个说明书和权利要求书中都保留该定义。
化合物的制备可涉及各种化学基团的保护和脱保护。本领域技术人员可以容易地确定对保护和脱保护的需求以及对合适的保护基的选择。用于该目的合适基团已在化学领域的标准教科书中有讨论,例如由T.W.Greene和P.G.M.Wuts出版的Protective Groups inOrganic Synthesis(John Wiley&Sons,纽约,1999年)、in Protecting Group Chemistry(第1版,牛津大学出版社,2000年)、以及March出版的Advanced Organic chemistry:Reactions,Mechanisms,and Structure(第5版,Wiley-Interscience Publication,2001年)。
通常,式I或式II的化合物可如方案I-XVI所示的那样制备。用于制备本申请化合物的合适的被取代的起始原料和中间体可市售获得,或者本领域技术人员可以通过文献中已知的方法很容易地制备获得。
所使用的所有溶剂均可市售获得,并且无需进一步纯化即可使用。通常在氮气的惰性气氛下使用无水溶剂进行反应。在配备有Bruker 400BBO探针的Bruker Mercury Plus400NMR光谱仪上以300或400MHz记录质子光谱。所有氘代溶剂都通常含有0.03%至0.05%v/v的四甲基硅烷,用作参比信号(对于1H和13C均设置为d 0.00)。
在由UFLC 20-AD和LCMS 2020MS检测器组成的SHIMADZU LCMS上进行LCMS分析。使用的柱为Shim-pack XR-ODS,2.2μm,3.0×50mm。使用线性梯度,经2.2分钟从95%A(A:在水中0.05%TFA)开始并到100%B(B:在MeCN的0.05%TFA)结束,总运行时间为3.6分钟。柱温为40℃,流速为1.0mL/min。二极管阵列检测器从190-400nm处扫描。质谱仪配备有以正或负模式运行的电喷雾离子源(ESI)。质谱仪在m/z 90-900之间扫描,扫描时间为0.5s至0.7s。
在具有两个LC20 AD泵和SPD-M20A光电二极管阵列检测器的SHIMADZU UFLC上进行HPLC分析。使用的柱是XBridge C18,3.5μm,460×100mm。使用线性梯度,经10分钟从90%A(A:在水中0.05%TFA)开始到95%B(B:在MeCN中0.05%TFA)结束,总运行时间为15分钟。柱温为40℃,流速为1.5mL/min。二极管阵列检测器从200-400nm处扫描。
薄层色谱(TLC)在购自Mancherey-Nagel的(Silica gel 60F254)上进行,并通常利用紫外线观察斑点。在某些情况下,还使用了其他可视化方法。在这些情况下,TLC板是用碘(将约1g的I2加入10g硅胶中并充分混合生成)、茚三酮(可从Aldrich购得)或Magic Stain(通过在450mL水和50mL浓H2SO4中将25g的(NH4)6Mo7O24.4H2O和5g的(NH4)2Ce(IV)(NO3)6充分混合而生成)显影以显示化合物。快速色谱按照以下方法进行:根据与Still,W.C.;Kahn,M.和Mitra,M.在Journal of Organic Chemistry(1978,43,2923)中所公开的类似方法,使用来自Silicycle的40-63μm(230-400目)硅胶来进行。用于快速色谱或薄层色谱的典型溶剂是由氯仿/甲醇、二氯甲烷/甲醇、乙酸乙酯/甲醇、和己烷/乙酸乙酯组成的混合物。
中间体1:3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸叔丁酯
向250mL圆底烧瓶中,加入3-氰基-4-哌啶酮-1-羧酸叔丁酯(5g,22.30mmol,1.00当量)、NH2NH2H2O(11.1g,223mmol,10.00当量)和EtOH(100mL)。所得溶液在25℃下搅拌过夜,所得混合物在真空下浓缩。将残余物施加到具有氯仿/甲醇(95/5)的硅胶柱上。得到4.9g(93%)的3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸叔丁酯,为白色固体。MS(ES,m/z)[M+H]:239。
中间体2:5-甲基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-3-胺
向用氮气的惰性气体吹扫并保持的100mL圆底烧瓶中,0℃下加入3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸叔丁酯(700mg,2.94mmol,1.00当量)、四氢呋喃(15mL)和LiAlH4(334mg,8.80mmol,3.00当量)。所得溶液在60℃下搅拌过夜。然后通过加入水(2ml)和NaOH(1M/l,4ml)以及水(2ml)将反应淬灭。将混合物搅拌30分钟,滤掉固体。粗产物用制备型高效液相色谱(Prep-HPLC)在以下条件下进行纯化:柱,Atlantis Prep T3 OBD柱,19×250mm 10u;流动相:水(0.1%FA)和ACN(15分钟内从0到达30.0%);检测器,UV254nm。得到90mg(20%)的5-甲基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-3-胺,为黄色固体。MS(ES,m/z)[M+H]:153。
中间体3:4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-3-胺的盐酸盐
向100mL三颈圆底烧瓶中,加入3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸叔丁酯(3g,12.59mmol,1.00当量)。然后,在0℃搅拌下逐滴加入在1,4-二恶烷(10mL)中的HCl。所得溶液在25℃下搅拌8小时,将所得混合物在真空下浓缩。得到1.5g(68%)的4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-3-胺盐酸盐的HCl盐,为黄色固体。MS(ES,m/z)[M+H]+:139。
中间体4:3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸苄酯
向100mL圆底烧瓶中,加入4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-3-胺盐酸盐(200mg,1.15mmol,1.00当量)、碳酸钾(476mg,3.44mmol,3.00当量)、水(2mL)、和1,4-二恶烷(10mL)。然后在0℃搅拌下逐滴加入Cbz-Cl(165mg,0.97mmol,0.90当量)。所得溶液在25℃下搅拌过夜,用H2O(10mL)稀释所得溶液。用二氯甲烷(80mL×3)萃取所得溶液并合并有机层和在真空下浓缩。将残余物施加到具有二氯甲烷/甲醇(10/1)的硅胶柱上。得到150mg(48%)的3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸苄酯,为黄色油状物。MS(ES,m/z)[M+H]+:273。
中间体5:6-苄基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺
步骤1:2-(苄基(3-氰基丙基)氨基)乙酸乙酯
向500mL圆底烧瓶中,加入CH3CN(300mL)、2-(苄氨基)乙酸乙酯(32g,167.40mmol,1.00当量)、碳酸钾(64.4g,465.96mmol,3.00当量)、和4-溴丁腈(27.4g,185.13mmol,1.20当量)。所得溶液在80℃下搅拌过夜。冷却至室温后,将固体滤掉。滤液在真空下浓缩。将残余物施加到具有乙酸乙酯/石油醚(0-100%)的硅胶柱上。得到40g(97%)的2-[苄基(3-氰基丙基)氨基]乙酸乙酯,为黄色油状物。MS(ES,m/z)[M+H]+:261。
步骤2:1-苄基-3-哌啶酮-4-甲腈
向用氮气的惰性气体吹扫并保持的500mL三颈圆底烧瓶中,加入2-[苄基(3-氰基丙基)氨基]乙酸乙酯(20g,76.83mmol,1.00当量)和四氢呋喃(300mL)。之后在0℃下分批加入t-BuOK(12.9g,114.96mmol,1.50当量)。所得溶液在室温搅拌过夜,用DCM:MeOH(4:1,1000mL)稀释所得溶液。所得混合物用盐水(1000mL×3)洗涤。有机相经无水硫酸钠干燥并真空浓缩。得到13.6g(83%)的1-苄基-3-哌啶酮-4-甲腈,为红色油状物。MS(ES,m/z)[M+H]+:215。
步骤3:6-苄基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺
向250mL圆底烧瓶中,加入1-苄基-3-哌啶酮-4-甲腈(13.6g,63.47mmol,1.00当量)、乙醇(100mL)、NH2NH2H2O(14mL)。所得溶液在室温下搅拌过夜,所得混合物在真空下浓缩。将残余物施加到具有甲醇/二氯甲烷(0-10%)的硅胶柱上。得到8.5g(59%)的6-苄基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-3-胺,为黄色油状物。MS(ES,m/z)[M+H]+:229。
中间体6:步骤1:4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺
向250mL圆底烧瓶中,加入6-苄基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(15g,65.71mmol,1.00当量)、甲醇(100mL)、和钯碳(10%,10g)。向其中引入氢气。所得溶液在室温搅拌38小时,滤掉固体,滤液在真空下浓缩。得到8.2g(90%)的4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-3-胺,为黄色固体。MS(ES,m/z)[M+H]+:139。
中间体7:3-氨基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-6-羧酸叔丁酯
向50mL圆底烧瓶中,加入4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(350mg,2.53mmol,1.00当量)、二恶烷(8mL)、和氢氧化钠(203mg,5.08mmol,2.00当量)在水(2mL)中的溶液。然后在0℃搅拌下逐滴加入在二恶烷(3mL)中的(Boc)2O(442mg,2.03mmol,0.80当量)溶液。所得溶液在室温下搅拌3小时,所得混合物在真空下浓缩。通过制备型TLC(EA:PE=1:1)对残余物进行纯化。得到410mg(68%)的3-氨基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-6-羧酸叔丁酯,为黄色固体。MS(ES,m/z)[M+H]+:239。
中间体8:6-甲基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺
向用氮气的惰性气体吹扫并保持的100mL三颈圆底烧瓶中,加入3-氨基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-6-羧酸叔丁酯(320mg,1.34mmol,1.00当量)和四氢呋喃(40mL)。随后在0℃下分批加入LiAlH4(102mg,2.69mmol,2.00当量)。所得溶液在70℃下搅拌过夜,所得混合物在真空下浓缩。通过制备型TLC(DCM:MeOH=10:1)对残余物进行纯化。得到50mg(24%)的6-甲基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺,为白色固体。MS(ES,m/z)[M+H]+:153。
中间体9:6-(甲基磺酰基)-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺
向250mL圆底烧瓶中,加入4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(5g,36.19mmol,1.00当量)、1,4-二恶烷(40mL)以及在水(10mL)中的碳酸钾(10g,72.35mmol,2.00当量)溶液。然后在0℃搅拌下逐滴加入在二恶烷(5mL)中的甲磺酰氯(2g,17.46mmol,0.50当量)溶液。所得溶液在室温下搅拌2小时,所得混合物在真空下浓缩。将残余物施加到具有甲醇/二氯甲烷(0-10%)的硅胶柱上。得到3.2g(41%)的6-甲磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺,为白色固体。MS(ES,m/z)[M+H]+:217。
实施例1:3-氨基-2-[(2-甲基-1H-吲哚-4-基)羰基]叔丁基]-4,5,6,7-四氢-2H-吡唑并[4,3-c]-5-羧酸叔丁酯
向50mL圆底烧瓶中,加入2-甲基-1H-吲哚-4-羧酸(52mg,0.30mmol,1.00当量)、3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸叔丁酯(85mg,0.36mmol,1.20当量)、HOBt(61mg,0.45mmol,1.50当量)、EDCI(86mg,0.45mmol,1.50当量)、N,N-二甲基甲酰胺(3mL)和TEA(194mg,1.92mmol,5.00当量)。所得溶液在25℃下搅拌过夜。用DCM(80mL)稀释反应混合物,用H2O(50mL×3)和盐水(50mL×3)洗涤并用Na2SO4干燥。过滤后,对滤液进行减压浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱,XSelect CSH Prep C18OBD柱,5μm,19×150mm;流动相:水(0.1%FA)和ACN(ACN在9分钟内从30.0%达到49.0%);检测器,UV 254nm。将收集的部分冻干,得到1.4mg(2%)的3-氨基-2-[(2-甲基-1H-吲哚-4-基)羰基]-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸叔丁酯,为灰白色固体。MS(ES,m/z)[M+H]+:396;(300MHz,DMSO-d6,ppm):δ11.22(s,1H),7.57(d,J=7.5Hz,1H),7.48(d,J=7.8Hz,1H),7.09-7.04(m,1H),6.65(s,2H),6.29(s,1H),4.27(s,2H),3.58-2.54(m,2H),2.49-2.45(m,2H),2.41(s,3H),1.44(s,9H)。
实施例2:(3-氨基-4,5,6,7-四氢吡唑并[4,3-c]吡啶-2-基)(2-甲基-1H-吲哚-4-基)甲酮
向50mL圆底烧瓶中,加入3-氨基-2-[(2-甲基-1H-吲哚-4-基)羰基]-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸叔丁酯(70mg,0.18mmol,1.00当量)、二氯甲烷(8mL)和TFA(2mL)。所得溶液在25℃下搅拌20分钟,用2mL的H2O稀释所得溶液。用碳酸氢钠(1mol/L)将溶液的pH值调节至8。用乙酸乙酯萃取该溶液,用水和盐水洗涤并浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱,XBridge C18 OBD制备柱,5μm,19mm×250mm;流动相:水(0.1%FA)和ACN(ACN在7分钟内从38.0%达到58.0%);检测器,UV/质量254&220nm。将收集的部分冻干,得到1.8mg(3%)的(3-氨基-4,5,6,7-四氢吡唑并[4,3-c]吡啶-2-基)(2-甲基-1H-吲哚-4-基)甲酮,为粉红色固体。MS(ES,m/z)[M+H]+:296;(400MHz,DMSO-d6,ppm):δ11.30(s,1H),8.25-8.23(m,1H),7.56-7.46(m,2H),7.08-7.04(m,1H),6.53(d,J=12.0Hz,2H),6.27(s,1H),3.67-3.64(m,2H),3.09-2.96(m,2H),2.51-2.50(m,2H),2.40(s,3H)。
实施例3:(3-氨基-5-甲基-4,5,6,7-四氢吡唑并[4,3-c]吡啶-2-基)(2-氯-4,5,6,7-四氢-1H-吲哚-4-基)甲酮
步骤1:1-[(4-甲基苯基)磺酰基]-4,5,6,7-四氢-1H-吲哚-4-酮
向5000mL的圆底烧瓶中,加入在二氯甲烷(3000mL)中的4,5,6,7-四氢-1H-吲哚-4-酮(200g,1.48mol,1.00当量)的溶液、4-甲基苯基-1-磺酰氯(290g,1.52mol,1.03当量)、TEA(600mL)和4-二甲基氨基吡啶(18g,147.34mmol,0.10当量)。所得溶液在25℃下搅拌16小时,然后通过加入水将反应淬灭。用乙酸乙酯(4000ml)萃取所得溶液。有机层用盐水(1000mL×4)洗涤并在真空下浓缩。收集分离的固体并通过用PE/EA结晶来对其进行纯化。得到130g(30%)的1-[(4-甲基苯)磺酰基]-4,5,6,7-四氢-1H-吲哚-4-酮,为白色固体。MS[M+H]+(ES,m/z):290。
步骤2:1-[(4-甲基苯基)磺酰基]-4-[(三甲基甲硅烷基)氧基]-4,5,6,7-四氢-1H-吲哚-4-甲腈
向用氮气的惰性气体吹扫并保持的2000mL的圆底烧瓶中,加入在CH3CN(1000mL)中的1-[(4-甲基苯基)磺酰基]-4,5,6,7-四氢-1H-吲哚-4-酮(130g,449.28mmol,1.00当量)溶液、TMSCN(120mL)和ZnI2(13g,40.72mmol,0.09当量)。所得溶液在25℃下搅拌3小时。然后加水将反应淬灭,用乙酸乙酯(4000mL)萃取所得溶液。所得混合物用盐水(1000mL×4)洗涤,混合物经无水硫酸钠干燥,滤掉固体,将所得混合物浓缩。得到170g的1-[(4-甲基苯基)磺酰基]-4-[(三甲基硅烷基)氧基]-4,5,6,7-四氢-1H-吲哚-4-甲腈,为黄色油状物。MS[M+H]+(ES,m/z):389。
步骤3:1-[(4-甲基苯基)磺酰基]-6,7-二氢-1H-吲哚-4-甲腈
向3000mL圆底烧瓶中,加入在甲苯(2000mL)中的1-[(4-甲基苯基)磺酰基]-4-[(三甲基甲硅烷基)氧基]-4,5,6,7-四氢-1H-吲哚-4-甲腈(170g,粗品)溶液和4-甲基苯基-1-磺酸(5g)。所得溶液在110℃下搅拌5小时,然后加水将反应淬灭,用乙酸乙酯(4000mL)萃取所得溶液。所得混合物用盐水(1000mL×4)洗涤,混合物经无水硫酸钠干燥,滤掉固体,浓缩所得混合物。收集分离的固体并通过用PE/EA结晶来对其进行纯化。得到110g(粗品)的1-[(4-甲基苯基)磺酰基]-6,7-二氢-1H-吲哚-4-甲腈,为黄色固体。MS[M+H]+(ES,m/z):
步骤4:1-[(4-甲基苯基)磺酰基]-4,5,6,7-四氢-1H-吲哚-4-甲腈
向2L圆底烧瓶中,加入在乙醇(1000中)中的1-[(4-甲基苯基)磺酰基]-6,7-二氢-1H-吲哚-4-甲腈(110g,粗品)溶液和硼氢化钠(45g,1.22mol)。所得溶液在80℃下搅拌6小时,然后加入水/冰将反应淬灭。用乙酸乙酯(4000mL)萃取所得溶液,有机层用盐水(1L×4)洗涤并用无水硫酸钠干燥,滤掉固体并在真空下对其浓缩。收集分离的固体并通过用PE/EA结晶来对其进行纯化。得到89g的1-[(4-甲基苯)磺酰基]-4,5,6,7-四氢-1H-吲哚-4-甲腈,为白色固体。MS[M+H]+(ES,m/z):301。
步骤5:1-[(4-甲基苯基)磺酰基]-4,5,6,7-四氢-1H-吲哚-4-羧酸乙酯
向2L圆底烧瓶中,加入在乙醇(1000mL)中的2-[(4-甲基苯基)磺酰基]-4,5,6,7-四氢-1H-吲哚-4-甲腈(89g,296.30mmol)溶液和磺酰二氯(350g,2.94mol,9.93当量)。所得溶液在90℃下搅拌16小时,然后通过加入水/冰将反应淬灭。所得溶液用乙酸乙酯(4000mL)萃取,所得混合物用盐水(1L×4)洗涤。将所得混合物在真空下浓缩,残余物施加到硅胶柱(PE/EA)上,得到70g(68%)的1-[(4-甲基苯基)磺酰基]-4,5,6,7-四氢-1H-吲哚-4-羧酸乙酯,为白色固体。MS[M+H]+(ES,m/z):348。
步骤6:4,5,6,7-四氢-1H-吲哚-4-羧酸
向2L圆底烧瓶中,加入1-[(4-甲基苯基)磺酰基]-4,5,6,7-四氢-1H-吲哚-4-羧酸乙酯(60g,172.70mmol,1.00当量)、甲醇(240mL)、四氢呋喃(240mL)和氢氧化钾(5N)(420mL)。所得溶液在85℃下搅拌26小时,所得混合物在真空下浓缩以去除MeOH和THF,用乙酸乙酯(1L×3)萃取所得溶液。用HCl(1N)将水相的pH值调节至6。所得混合物用盐水(1L×4)洗涤并用无水硫酸钠干燥。滤掉固体并在真空下对其进行浓缩。收集分离的固体,并通过用PE/EA结晶来对其进行纯化。得到26g(91%)的4,5,6,7-四氢-1H-吲哚-4-羧酸,为白色固体。MS[M+H]+(ES,m/z):166。
步骤7:2-氯-4,5,6,7-四氢-1H-吲哚-4-羧酸
向用氮气的惰性气体吹扫并保持的500mL圆底烧瓶中,加入在四氢呋喃(210mL)中的4,5,6,7-四氢-1H-吲哚-4-羧酸溶液(7.5g,45.40mmol,1.00当量)溶液。然后在-78℃搅拌下逐滴加入在THF(20mL)中的1-氯吡咯烷-2,5-二酮(6.6g,49.43mmol,1.09当量)溶液,所得溶液在-78℃下搅拌3小时,然后加入水将反应淬灭。用乙酸乙酯(800mL×3)萃取所得溶液,合并有机层并用无水硫酸钠干燥,滤掉固体,用DMF(150mL)稀释所得溶液。将所得混合物在真空下浓缩(除去EA)。得到9g(转化)的2-氯-4,5,6,7-四氢-1H-吲哚-4-羧酸。MS[M+H]+(ES,m/z):200和202。
步骤8:5-甲基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-3-胺
向用氮气的惰性气体吹扫并保持的100mL圆底烧瓶中,加入3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸叔丁酯(700mg,2.94mmol,1.00当量)和四氢呋喃(15mL),0℃下加入LiAlH4(334mg,8.80mmol,3.00当量),所得溶液在60℃下搅拌过夜。然后通过加水(2ml)、NaOH(1M/l,4ml)和水(2ml)将反应猝灭。将混合物搅拌30分钟,滤掉固体。将粗产物用Prep-HPLC在以下条件下进行纯化:柱,Atlantis Prep T3 OBD柱,19×250mm10u;流动相:水(0.1%FA)和ACN(15分钟内从0达到30.0%);检测器,UV254nm。得到90mg(20%)的5-甲基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-3-胺,为黄色固体。MS(ES,m/z)[M+H]:153。
步骤9:(3-氨基-5-甲基-4,5,6,7-四氢吡唑并[4,3-c]吡啶-2-基)(2-氯-4,5,6,7-四氢-1H-吲哚-4-基)甲酮
向50mL圆底烧瓶中,加入2-氯-4,5,6,7-四氢-1H-吲哚-4-羧酸(60mg,0.30mmol,1.00当量)、5-甲基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-3-胺(50mg,0.33mmol,1.10当量)、HOBT(61mg,0.45mmol,1.50当量)、EDCI(86mg,0.45mmol,1.50当量)、TEA(92mg,0.91mmol,3.00当量)和N,N-二甲基甲酰胺(8mL),所得溶液在室温下搅拌过夜,然后加入水(30mL)将反应淬灭。所得溶液用乙酸乙酯(30mL×3)萃取,用盐水(80mL×2)洗涤,经无水硫酸钠干燥并在真空下浓缩。粗产物用Prep-HPLC在以下条件下进行纯化:柱:XBridge C18OBD Prep柱,5μm,19mm×250mm;流动相A:水(10MMOL/L NH4HCO3),流动相B:ACN;流速:20mL/min;梯度:7分钟内从5%B到20%B;254&220nm;Rt:7分钟。将收集的部分冻干,得到2.3mg(2%)的(3-氨基-5-甲基-4,5,6,7-四氢吡唑并[4,3-c]吡啶-2-基)(2-氯-4,5,6,7-四氢-1H-吲哚-4-基)甲酮,为黄色固体。MS(ES,m/z)[M+H]+:334;(DMSO-d6,300MHz,ppm):δ11.07(s,1H),6.50(s,2H),5.54(s,1H),4.70-4.67(m,1H),3.42-3.40(m,2H),2.79-2.70(m,2H),2.66-2.65(s,2H),2.48-2.45(m,2H),1.99-1.81(m,3H),1.70-1.68(m,1H)。
实施例4和5:3-氨基-2-(2-乙基-4,5,6,7-四氢-1H-吲哚-4-羰基)-6,7-二氢-2H-吡唑并[4,3-c]吡啶-5(4H)-羧酸苄酯和3-氨基-1-(2-乙基-4,5,6,7-四氢-1H-吲哚-4-羰基)-6,7-二氢-1H-吡唑并[4,3-c]吡啶-5(4H)-羧酸苄酯
步骤1:2-乙基-5-甲酰基-1H-吡咯-1-羧酸叔丁酯
向用氮气的惰性气体吹扫并保持的250mL三颈圆底烧瓶中,加入5-乙基-1H-吡咯-2-甲醛(2.0g,16.24mmol,1.00当量)和N,N-二甲基甲酰胺(150mL)。然后在0℃搅拌下分批加入氢化钠(780mg,19.50mmol,1.20当量,60%)。在5℃搅拌下向其中逐滴加入在N,N-二甲基甲酰胺(8mL)中的(Boc)2O(3.9g,17.87mmol,1.10当量)溶液。所得溶液在25℃下搅拌过夜。然后通过加入冰/水(250mL)将反应淬灭。用乙酸乙酯(250mL×2)萃取所得溶液并合并有机层。所得混合物用饱和盐水(200mL×3)洗涤,混合物经无水硫酸钠干燥,滤掉固体,将所得混合物在真空下浓缩。残余物施加到硅胶柱上并用乙酸乙酯或石油醚(1:10)洗脱。浓缩所收集的部分,得到3.7g(97.2%)的2-乙基-5-甲酰基-1H-吡咯-1-羧酸叔丁酯,为黄色油状物。MS(ES,m/z)[M+H]+:224。
步骤2:2-乙基-5-乙烯基-1H-吡咯-1-羧酸叔丁酯
向用氮气的惰性气体吹扫并保持的250mL三颈圆底烧瓶中,加入四氢呋喃(80mL),随后在5℃下加入氢化钠(1.0g,41.67mmol,1.50当量)。在5℃下向其中加入甲基三苯基溴化膦(8.9g,24.91mmol,1.50当量)。混合物在70℃下搅拌1.5小时,然后冷却至35℃以下,向混合物中加入在四氢呋喃(8mL)中的2-乙基-5-甲酰基-1H-吡咯-1-羧酸叔丁酯(3.7g,16.57mmol,1.00当量)溶液,所得溶液在70℃下搅拌3小时。
冷却至室温后,将固体滤掉。用乙酸乙酯/石油醚(1/7)将残余物施加到硅胶柱上,得到2.6g(71%)的2-乙烯基-5-乙基-1H-吡咯-1-羧酸叔丁酯,为黄色油状物。MS(ES,m/z)[M+H]+:222。
步骤3:1-叔丁基4-甲基-2-乙基-4,5,6,7-四氢吲哚-1,4-二羧酸酯
向用氮气的惰性气体吹扫并保持的8个25mL均质密封管中,加入2-乙烯基-5-乙基-1H-吡咯-1-羧酸叔丁酯(2.0g,9.04mmol,1.00当量)、二恶烷(60mL)和丙-2-烯酸甲酯(3.1g,36.01,4.00当量)。所得溶液在120℃下搅拌过夜。冷却至室温后,所得混合物在真空下浓缩。得到500mg(18%)的1-叔丁基4-甲基-2-乙基-4,5,6,7-四氢-1H-吲哚-1,4-二羧酸酯,为黄色油状物。MS(ES,m/z)[M+H]+:308。
步骤4:2-乙基-4,5,6,7-四氢-1H-吲哚-4-羧酸甲酯
向100mL圆底烧瓶中,加入1-叔丁基4-甲基2-乙基-2-乙基-4,5,6,7-四氢-1H-吲哚-1,4-二羧酸酯(300mg,0.98mmol,1.00当量)、二氯甲烷(10g,117.74mmol,120.64当量)和CF3COOH(1.5g,13.16mmol,13.48当量)。所得溶液在25℃下搅拌2小时,然后加入水(80mL)将反应淬灭。用二氯甲烷(8 0mL×2)萃取所得溶液并合并有机层,并用无水硫酸钠干燥。滤掉固体,滤液在真空下浓缩。得到200mg(99%)的2-乙基-4,5,6,7-四氢-1H-吲哚-4-羧酸甲酯,为浅黄色原油状物。MS(ES,m/z)[M+H]+:208。
步骤5:2-乙基-4,5,6,7-四氢-1H-吲哚-4-羧酸
向50mL圆底烧瓶中,加入2-乙基-4,5,6,7-四氢-1H-吲哚-4-羧酸甲酯(200mg,0.96mmol,1.00当量)、四氢呋喃(8mL)、甲醇(4mL)和在H2O(3mL)中的LiOH(139.1mg,5.81mmol,6.00当量)溶液。所得溶液在15℃下搅拌过夜,所得混合物真空浓缩。用H2O(3mL)稀释所得溶液,用乙酸乙酯(40mL)萃取所得溶液并合并水层。用HCl(1mol/L)将pH值调节至5-6,用乙酸乙酯(80mL×2)萃取所得溶液并合并有机层,并用无水硫酸钠干燥。滤掉固体,将所得混合物真空浓缩。得到170mg(91%)的2-乙基-4,5,6,7-四氢-1H-吲哚-4-羧酸,为红色晶体状物。(ES,m/z)[M+H]+:194。
步骤6:3-氨基-2-(2-乙基-4,5,6,7-四氢-1H-吲哚-4-羰基)-6,7-二氢-2H-吡唑并[4,3-c]吡啶-5(4H)-羧酸苄酯和3-氨基-1-(2-乙基-4,5,6,7-四氢-1H-吲哚-4-羰基)-6,7-二氢苄基1H-吡唑并[4,3-c]吡啶-5(4H)-羧酸苄酯
向50mL圆底烧瓶中,加入2-乙基-4,5,6,7-四氢-1H-吲哚-4-羧酸(150mg,0.78mmol,1.20当量)、3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸苄酯(90mg,0.33mmol,1.00当量)、HOBT(90mg,0.67mmol,1.20当量)、EDCI(190mg,0.99mmol,1.50当量)、N,N-二甲基甲酰胺(5mL)和TEA(140mg,1.38mmol,3.00当量),所得溶液在25℃下搅拌4小时。用DCM(80mL)稀释反应混合物,用H2O(50mL×3)和盐水(50mL×3)洗涤并用Na2SO4干燥。过滤后,将滤液减压浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱:XBridge Prep OBD C18柱;150mm 5um;流动相A:水(10mM NH4HCO3),流动相B:ACN;流速:60mL/min;梯度:7分钟内从25%B到55%B;254nm。
组分A:将收集的组分冻干,得到2.0mg(1%)的3-氨基-2-(2-乙基-4,5,6,7-四氢-1H-吲哚-4-羰基)-6,7-二氢-2H-吡唑并[4,3-c]吡啶-5(4H)-羧酸苄酯,为白色固体。Rt2:6.32分钟。MS(ES,m/z)[M+H]+:448;(300MHz,DMSO-d6,ppm):δ10.10(s,1H),7.40-7.38(m,5H),6.60(s,2H),5.28(s,1H),5.13(m,2H),4.74-4.69(m,1H),4.30(s,2H),3.32(s,2H),2.51-2.50(m,2H),2.41-2.39(m,3H),1.98-1.61(m,5H),1.09-1.04(m,3H)。
组分B:将收集的组分冻干,得到1.5mg(1%)的3-氨基-2-(2-乙基-4,5,6,7-四氢-1H-吲哚-4-羰基)-6,7-二氢-1H-吡唑并[4,3-c]吡啶-5(4H)-羧酸苄酯,为白色固体。Rt1:5.69分钟。MS(ES,m/z)[M+H]+:448;(300MHz,DMSO-d6,ppm):δ10.06(s,1H),7.39-7.38(m,5H),5.65(s,2H),5.30(d,J=2.1Hz,1H),5.13(m,2H),4.65-4.61(m,1H),4.28(s,2H),3.63(s,2H),2.49-2.36(m,3H),1.86-1.64(m,5H),1.10-1.05(m,3H)。
实施例6:(3-氨基-4,5,6,7-四氢吡唑并[4,3-c]吡啶-2-基)(2-乙基-4,5,6,7-四氢-1H-吲哚-4-基)甲酮
向25mL圆底烧瓶中,加入3-氨基-2-[(2-乙基-4,5,6,7-四氢-1H-吲哚-4-基)羰基]-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸苄酯(30mg,0.07mmol,1.00当量)、甲醇(3mL),AcOH(0.2mL)和钯碳(10%,30mg),向其中引入氢气。所得溶液在室温下搅拌40分钟,滤掉固体,滤液在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱:XBridge Prep OBD C18柱;150mm 5um;流动相A:水(10mM NH4HCO3),流动相B:ACN;流速:60mL/min;梯度:7分钟内从25%B到55%B;254nmRt:6.32分钟。将收集的组分冻干,得到1.3mg(6%)的(3-氨基-4,5,6,7-四氢吡唑并[4,3-c]吡啶-2-基)(2-乙基-4,5,6,7-四氢-1H-吲哚-4-基)甲酮,为白色固体。MS(ES,m/z)[M+H]+:314。(DMSO-d6,400MHz,ppm):δ10.11(s,1H),6.37(s,2H),5.28(s,1H),4.74-4.72(m,1H),3.52-3.51(m,2H),2.92-2.84(m,2H),2.47-2.39(m,7H),2.01-1.84(m,3H),1.75-1.68(m,1H),1.09-1.05(m,3H)。
实施例7和8:3-氨基-2-(2-甲基-1H-吲哚-4-羰基)-4,5-二氢-2H-吡唑并[3,4-c]吡啶-6(7H)-羧酸叔丁酯和3-氨基-1-(2-甲基-1H-吲哚-4-羰基)-4,5-二氢-1H-吡唑并[3,4-c]吡啶-6(7H)-羧酸叔丁酯
向50mL圆底烧瓶中,加入3-氨基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-6-羧酸叔丁酯(30mg,0.13mmol,1.00当量)、N,N-二甲基甲酰胺(5mL)、HOBt(26mg,0.19mmol,1.50当量)、EDCI(37mg,0.19mmol,1.50当量)、TEA(64mg,0.63mmol,5.00当量)和2-甲基-1H-吲哚-4-羧酸(27mg,0.15mmol,1.20当量)。所得溶液在室温下搅拌16小时,然后加入水(30mL)将反应淬灭。所得溶液用乙酸乙酯(30mL×3)萃取,用盐水(100mL×3)洗涤并在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱,XBridge C18 OBD制备柱,5μm,19mm×250mm;流动相,水(0.1%FA)和ACN(ACN在7分钟内从10.0%达到30.0%);检测器,UV/质量254&220nm。
组分A:将收集的组分冻干,得到0.8mg(2%)的3-氨基-2-(2-甲基-1H-吲哚-4-羰基)-4,5-二氢-2H-吡唑并[3,4-c]吡啶-6(7H)-羧酸叔丁酯,为黄色固体状。Rt2:6.42分钟。MS(ES,m/z)[M+H]+:396;(DMSO-d6,300MHz,ppm):δ11.22(s,1H),7.55(d,J=6.9Hz,1H),7.52(d,J=12.9Hz,1H),7.09-7.04(m,1H),6.55(s,2H),6.27(s,1H),4.27(s,2H),3.54-3.16(m,2H),2.52-2.49(m,5H),1.4(s,9H)。
组分B:将收集的组分冻干,得到2.5mg(5%)的3-氨基-1-(2-甲基-1H-吲哚-4-羰基)-4,5-二氢-1H-吡唑并[3,4-c]吡啶-6(7H)-羧酸叔丁酯,为黄色固体。Rt1:5.78分钟。MS(ES,m/z)[M+H]+:396;(DMSO-d6,400MHz,ppm):δ11.16(s,1H),7.56(d,J=7.2Hz,1H);7.44(d,J=8.0Hz,1H),7.06-7.02(m,1H),6.27(s,1H),5.53(s,2H),4.78(s,2H),3.60-3.57(m,2H),2.51-2.49(m,3H),2.39-2.38(m,2H),1.44(s,9H)。
实施例9:(3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(2-甲基-1H-吲哚-4-基)甲酮
向50mL圆底烧瓶中,加入6-苄基-2-[(2-甲基-1H-吲哚-4-基)羰基]-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(60mg,0.16mmol,1.00当量)、钯碳(10%,60mg)、甲醇(10mL)和AcOH(0.5mL)。所得溶液在室温下搅拌1.5小时,滤掉固体,滤液在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱:XBridge Shield RP18 OBD柱,5μm,19mm×150mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:7分钟内从25%B到50%B;254nm;Rt:6.3分钟。将收集的组分冻干,得到6mg(13%)的(3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(2-甲基-1H-吲哚-4-基)甲酮,为褐色固体。MS(ES,m/z)[M+H]+:295;(DMSO-d6,300MHz,ppm):δ11.20(s,1H),8.19(s,1H),7.53(d,J=7.5Hz,1H),7.46(d,J=7.8Hz,1H),7.07-7.02(m,1H),6.47(s,2H),6.27(s,1H),3.63(s,2H),2.91-2.89(m,2H),2.40-2.34(m,5H)。
实施例10和11:(3-氨基-6-苄基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(2-甲基-1H-吲哚-4-基)甲酮和(3-氨基-6-苄基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(2-甲基-1H-吲哚-4-基)甲酮。
向50mL圆底烧瓶中,加入2-甲基-1H-吲哚-4-羧酸(91mg,0.52mmol,1.00当量)、6-苄基-4,5,6,7-四氢2H-吡唑并[3,4-c]吡啶-3-胺(119mg,0.52mmol,1.00当量)、N,N-二甲基甲酰胺(5mL)、HOBT(135mg,1.00mmol,1.50当量)、EDCI(150mg,0.78mmol,1.50当量)和TEA(262mg,2.59mmol,5.00当量)。所得溶液在30℃下搅拌18小时,然后加入水(10mL)将反应淬灭。用乙酸乙酯(10mL×3)萃取所得溶液并合并有机层和在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物(10mg)进行纯化:柱,XBridge C18 OBD制备柱,100×5μm,19mm×250mm;流动相,水(10mmoL/L NH4HCO3)和ACN(ACN在12分钟内从5.0%达到20.0%);检测器,UV/质量254和220nm。
组分A:将收集的组分冻干,得到4.1mg(2%)的(3-氨基-6-苄基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基(2-甲基-1H-吲哚-4-基)甲酮,为黄色固体状。Rt2:11.02分钟。MS(ES,m/z)[M+H]+:386;(DMSO-d6,400MHz,ppm):δ11.21(s,1H),7.54(d,J=11.2Hz,1H),7.46(d,J=10.4Hz,1H),7.38-7.26(m,5H),7.06-7.00(m,1H),6.49(s,2H),6.26(s,1H),3.63-3.61(m,2H),3.35-3.34(m,2H),2.52-2.49(m,2H),2.40-2.38(m,5H)。
组分B:将收集的组分冻干,得到3.6mg(2%)的(3-氨基-6-苄基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(2-甲基-1H-吲哚-4-基)甲酮,为白色固体。Rt1:10.13min。MS(ES,m/z)[M+H]+:386;(DMSO-d6,400MHz,ppm):δ11.13(s,1H),7.52(d,J=9.6Hz,1H),7.42-7.35(m,5H),7.42-7.35(m,1H);7.05-7.02(m,1H),6.20(s,1H),5.46(s,2H),3.82-3.80(m,2H),3.74-3.72(m,2H),2.73-2.71(m,2H),2.51-2.47(m,5H)。
实施例12和13:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:6-甲基喹啉-4-羧酸甲酯
向用氩气的惰性气体吹扫并保持的30mL压力罐反应器(60atm)中,加入4-溴-6-甲基喹啉(1g,4.50mmol,1.00当量)、Pd(dppf)Cl2CH2Cl2(1.84g,2.25mmol,0.50当量)、TEA(2.86g,28.26mmol,1.50当量)和甲醇(20mL)。所得溶液在70℃下搅拌过夜,冷却至室温后,将所得混合物在真空下浓缩。用乙酸乙酯/石油醚(1/1)将残余物施加到硅胶柱上,得到610mg(67%)的6-甲基喹啉-4-羧酸甲酯,为黄色固体。MS(ES,m/z)[M+H]+:202。
步骤2:6-甲基喹啉-4-羧酸
向50mL圆底烧瓶中,加入6-甲基喹啉-4-羧酸甲酯(200mg,0.99mmol,1.00当量)、氢氧化钠(200mg,6.24mmol,5.00当量)、水(2mL)、和甲醇(10mL),所得溶液在25℃下搅拌过夜。所得混合物在真空下浓缩,所得混合物用EA(50mL×2)洗涤,用盐酸(1mol/L)将溶液的pH值调至6。用二氯甲烷(50mL×2)萃取所得溶液并进行浓缩,得到145mg(78%)的6-甲基喹啉-4-羧酸,为黄色固体。MS(ES,m/z)[M+H]+:188。
步骤3:6-甲基-1,2,3,4-四氢喹啉-4-羧酸
向用氢气的惰性气体吹扫并保持的100mL圆底烧瓶中,加入6-甲基喹啉-4-羧酸(145mg,0.77mmol,1.00当量)、钯碳(10%,100mg)和甲醇(10mL)。所得溶液在25℃下搅拌过夜,滤掉固体,滤液在真空下浓缩,得到120mg(81%)的6-甲基-1,2,3,4-四氢喹啉-4-羧酸,为白色油状物。MS(ES,m/z)[M+H]+:192。
步骤4:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
向100mL圆底烧瓶中,加入6-甲基-1,2,3,4-四氢喹啉-4-羧酸(54mg,0.28mmol,1.00当量)、6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(60mg,0.28mmol,1.00当量)、EDCI(80.6mg,0.42mmol,1.50当量)、HOBt(56.7mg,0.42mmol,1.50当量)、N,N-二甲基甲酰胺(10mL)和TEA(141.4mg,1.40mmol,5.00当量)。所得溶液在室温下搅拌3小时,用H2O(50mL)稀释所得混合物,用乙酸乙酯(100mL×3)萃取所得溶液并在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱:XBridge C18 OBD制备柱,100 10μm,19mm×250mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:7分钟内从20%B到45%B;254&220nm。
组分A:将收集的组分冻干,得到2.8mg(3%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:6.77分钟。MS(ES,m/z)[M+H]+:390。(DMSO-d6,400MHz,ppm):δ6.74-6.70(m,1H),6.63-6.57(m,3H),6.44-6.42(d,J=8.4,1H),5.63(s,1H),4.98-4.97(m,1H),4.23(s,2H),3.42-3.40(m,2H),3.23-3.27(m,1H),3.13-3.18(m,1H),2.97(s,3H),2.47-2.45(m,2H),2.09-2.06(m,3H),2.02-2.01(m,2H)。
组分B:将收集的组分冻干,得到4.7mg(5%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:6.19分钟。MS(ES,m/z)[M+H]+:390。(DMSO-d6,400MHz,ppm):δ6.73-6.70(m,1H),6.59(s,1H),6.42-6.40(d,J=8.0,1H),5.81-5.78(m,2H),5.60(s,1H),4.90-4.87(m,1H),4.56-4.52(m,2H),3.47-3.45(m,3H),3.39-3.37(m,1H),3.16-3.13(m,1H),2.96(s,3H),2.47-2.41(m,1H),2.09-2.07(m,3H),2.00-1.99(m,2H)。
实施例14和15:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氯-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-氯-1,2,3,4-四氢喹啉-4-基)甲酮
向40mL圆底烧瓶中,加入6-氯-1,2,3,4-四氢喹啉-4-羧酸(28mg,0.13mmol,1.00当量)(以市售的6-氯喹啉-4-羧酸开始并利用Pt2O,通过类似于6-甲基-1,2,3,4-四氢喹啉-4-羧酸(实施例12)的方法制得)、HOBt(27mg,0.20mmol,1.50当量)、EDCI(38mg,0.20mmol,1.50当量)、TEA(100mg,0.99mmol,7.50当量)、N,N-二甲基甲酰胺(6.0mL)和6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(29mg,0.13mmol,1.00当量)。所得溶液在20℃下搅拌5小时,然后加入水/冰(20mL)将反应淬灭。用乙酸乙酯(30ml×3)萃取所得溶液并合并有机层,并用无水硫酸钠干燥以及在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱,XBridge Shield RP18 OBD柱,5μm,19×150mm;流动相,水(0.1%FA)和ACN(ACN在7分钟内从35.0%达到55.0%);检测器,UV 254nm。
组分A:将收集的组分冻干,得到0.9mg(2%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为灰色固体。MS(ES,m/z)[M+H]+:410;(400MHz,DMSO-d6,ppm)δ6.95-6.93(m,1H),6.84(d,J=2.5Hz,1H),6.67(s,2H),6.53(d,J=8.7Hz,1H),6.12(s,1H),4.98-4.97(m,1H),4.24(s,2H),3.42-3.39(m,2H),3.22-3.20(m,2H),2.98(s,3H),2.50-2.43(m,2H),2.04-1.98(m,2H)。
组分B:将收集的组分冻干,得到5.1mg(9%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1(6-氯-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。MS(ES,m/z)[M+H]+:410;(400MHz,DMSO-d6,ppm)δ6.94-6.92(m,1H),6.86(d,J=2.5Hz,1H),6.52(d,J=8.6Hz,1H),6.09(s,1H),5.83(s,2H),4.89-4.86(m,1H),4.57-4.51(m,2H),3.52-3.34(m,2H),3.19-3.17(m,2H),2.97(s,3H),2.11-1.94(m,2H)。
实施例16、17、18和19:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮、(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮和(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮以及(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:6-氟喹啉-4-羧酸甲酯
向300mL压力罐反应器(60atm)中,加入4-溴-6-氟喹啉(10g,44.24mmol,1.00当量)、Pd(dppf)Cl2CH2Cl2(3.3g,4.04mmol,0.10当量)和甲醇(100ml),向其中引入一氧化碳(g)。所得溶液在120℃下搅拌过夜,冷却至室温后,将所得混合物在真空下浓缩。用乙酸乙酯/石油醚(0-20%)将残余物施加到硅胶柱上,得到7.5g(83%)的6-氟喹啉-4-羧酸甲酯,为黄色固体。MS(ES,m/z)[M+H]+:206。
步骤2:6-氟-1,2,3,4-四氢喹啉-4-羧酸甲酯
向250mL圆底烧瓶中,加入6-氟喹啉-4-羧酸甲酯(4g,19.49mmol,1.00当量)、甲醇(50mL)和钯碳(10%,3g),抽空烧瓶并用氮气吹扫3次,然后用氢气吹扫。混合物在室温下在氢气气氛(气球)中搅拌2小时,滤掉固体,滤液在真空下浓缩,得到3.5g(86%)的6-氟-1,2,3,4-四氢喹啉-4-羧酸甲酯,为黄色油状物。MS(ES,m/z)[M+H]+:210。
步骤3:6-氟-1,2,3,4-四氢喹啉-4-羧酸
向250mL圆底烧瓶中,加入6-氟-1,2,3,4-四氢喹啉-4-羧酸甲酯(3.5g,16.73mmol,1.00当量)、氢氧化钠(2g,50.00mmol,3.00当量),CH3OH(30mL)和H2O(30mL)。所得溶液在室温下搅拌12小时,用盐酸(1mol/L)将溶液的pH值调至6。用EA(150ml×3)萃取所得溶液并合并有机层,和用无水硫酸钠干燥并在真空下浓缩。得到2.3g(70%)的6-氟-1,2,3,4-四氢喹啉-4-羧酸,为黄色油状物。MS(ES,m/z)[M+H]+:196。
步骤4:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮
向100mL圆底烧瓶中,加入6-氟-1,2,3,4-四氢喹啉-4-羧酸(60mg,0.31mmol,1.00当量)、6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(80mg,0.37mmol,1.20当量)、DECI(88mg,1.50当量)、HOBt(62mg,0.46mmol,1.50当量)、N,N-二甲基甲酰胺(10mL)和TEA(156mg,1.54mmol,5.00当量)。所得溶液在室温下搅拌3小时,所得溶液在室温下搅拌12小时,然后加入水(50mL)将反应淬灭。用乙酸乙酯(100mL×2)萃取所得溶液并在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱:XBridge Shield RP18 OBD柱,5μm,19mm×250mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:10分钟内从25%B到65%B;254nm。
第一洗脱化合物:将收集的组分冻干,得到8.2mg(7%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-白色固体的2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:9.78分钟。MS(ES,m/z)[M+H]+:394。(DMSO-d6,400MHz,ppm):δ6.79-6.78(m,1H),6.68-6.64(m,3H),6.52-6.49(m,1H),5.80(s,1H),4.98-4.97(m,1H),4.24(s,2H),3.43-3.40(m,2H),3.27-3.15(m,2H),2.97(s,3H),2.47-2.45(m,2H),2.06-1.98(m,2H)。
第二洗脱化合物:将收集的组分冻干,得到16.7mg(14%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:8.35分钟。MS(ES,m/z)[M+H]+:394。(DMSO-d6,400MHz,ppm):δ6.77-6.74(m,1H),6.70-6.67(m,1H),6.51-6.48(m,1H),5.81-5.78(m,3H),4.89-4.86(m,1H),4.52(s,2H),3.44-3.40(m,2H),3.27-3.15(m,2H),2.95(s,3H),2.51-2.47(m,2H),2.07-2.04(m,2H)。
步骤5:(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮和(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮
通过制备-手性-高效液相色谱(Prep-chiral-HPLC),按照以下条件分离出(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮(50mg,0.13mmol,1.00当量),柱:Chiralpak IA,2×25cm,5μm;流动相A:Hex--HPLC,流动相B:EtOH--HPLC;流速:17mL/min;梯度:24分钟内从50B到50B;220/254nm。
对映异构体A,第一洗脱化合物。实施例19:得到17.0mg(34%)的(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:9.64分钟。MS(ES,m/z)[M+H]+:394;(DMSO-d6,400MHz,ppm):δ6.82-6.77(m,1H),6.69-6.65(m,3H),6.54-6.49(m,1H),5.82(s,1H),4.99-4.96(m,1H),4.24(s,2H),3.42-3.40(m,2H),3.25-3.14(m,2H),2.97(s,3H),2.47-2.45(m,2H),2.09-1.99(m,2H)。
对映异构体B,第二洗脱化合物。实施例18:得到13.9mg(28%)的(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:11.58分钟。MS(ES,m/z)[M+H]+:394;(DMSO-d6,400MHz,ppm):δ6.82-6.77(m,1H),6.69-6.65(m,3H),6.53-6.49(m,1H),5.82(s,1H),4.99-4.96(m,1H),4.24(s,2H),3.43-3.41(m,2H),3.26-3.14(m,2H),2.97(s,3H),2.47-2.45(m,2H),2.10-1.98(m,2H)。
实施例20和21:(3-氨基-6-乙基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-乙基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:3-氨基-6-苄基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-羧酸叔丁酯
向50mL圆底烧瓶中,加入6-苄基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(500mg,2.19mmol,1.00当量)、二氯甲烷(10mL)、TEA(665mg,6.60mmol,3.00当量)和二碳酸二叔丁酯(478mg,2.19mmol,1.00当量)。所得溶液在室温下搅拌16小时,所得混合物真空浓缩。通过制备型TLC(EA:PE=1:1)对残余物进行纯化。得到548mg(76%)的3-氨基-6-苄基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-羧酸叔丁酯,为黄色油状物。MS(ES,m/z)[M+H]+:329。
步骤2:3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-羧酸叔丁酯
向50mL圆底烧瓶中,加入3-氨基-6-苄基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-羧酸叔丁酯(548mg,1.67mmol,1.00当量)、甲醇(20mL)和钯碳(10%,500mg)。抽空烧瓶并用氮气吹扫3次,然后用氢气吹扫。混合物在室温下在氢气气氛(气球)下搅拌16小时,滤掉固体。将所得混合物在真空下浓缩,得到392mg(99%)的3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-羧酸叔丁基酯,为黄色油状物。MS(ES,m/z)[M+H]+:239。
步骤3:3-氨基-6-乙基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-羧酸叔丁酯
向50mL圆底烧瓶中,加入3-氨基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-2-羧酸叔丁酯(150mg,0.63mmol,1.00当量)、四氢呋喃(10mL)和碳酸钾(148mg,1.07mmol,1.10当量)。然后在室温下加入在四氢呋喃(5mL)中的碘乙烷(261mg,1.67mmol,3.00当量)溶液。所得溶液在40℃下搅拌16小时,所得混合物真空浓缩。通过制备型TLC(PE:EA=1:1)对残余物进行纯化。得到78mg(47%)的3-氨基6-氨基-6-乙基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-羧酸叔丁基酯,为黄色油状物。MS(ES,m/z)[M+H]+:267。
步骤4:6-乙基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺
向50mL圆底烧瓶中,加入3-氨基-6-乙基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-羧酸叔丁酯(61mg,0.23mmol,1.00当量)、二氯甲烷(4mL)和三氟乙酸(1mL)。所得溶液在室温下搅拌2.5小时,将所得混合物在真空下浓缩。然后加入水(30ml)和盐酸(1moL/L)(0.2mL),将混合物冷冻,得到57.9mg(152%)的6-乙基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺盐,为白色固体。MS(ES,m/z)[M+H]+:167。
步骤5:(3-氨基-6-乙基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-乙基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(1,2,3,4-四氢喹啉-4-基)甲酮
向100mL圆底烧瓶中,加入6-乙基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺盐(57mg,0.34mmol,1.00当量)、N,N-二甲基甲酰胺(10mL)、HOBt(36mg,0.27mmol,1.50当量)、EDCI(50mg,0.26mmol,1.50当量)、TEA(89mg,0.88mmol,5.00当量)和1,2,3,4-四氢喹啉-4-羧酸(37mg,0.21mmol,1.20当量)。所得溶液在室温下搅拌7小时,然后加入水(30mL)将反应淬灭。用乙酸乙酯(30mL×3)萃取所得溶液并并合并有机层,所得混合物用盐水(100mL×3)洗涤,将混合物在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱,XBridge C18 OBD制备柱,5μm,19mm×250mm;流动相,水(0.1%FA)和ACN(ACN在10分钟内从30.0%达到55.0%);检测器,UV 254nm。
组分A:将收集的组分冻干,得到3.2mg(3%)的(3-氨基-6-乙基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:7.07分钟。MS(ES,m/z)[M+H]+:326。(300MHz,DMSO-d6,ppm):δ6.93-6.90(m,1H),6.87(d,J=1.2Hz,1H),6.77-6.75(m,2H),6.52-6.49(m,1H),5.84(s,1H),5.01-5.00(m,1H),3.32-3.20(m,6H),2.79-2.28(m,3H),2.09(s,2H),1.09(s,3H)。
组分B:将收集的组分冻干,得到2.8mg(3%)的(3-氨基-6-乙基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:6.73分钟。MS(ES,m/z)[M+H]+:326。(300MHz,DMSO-d6,ppm):δ6.94-6.88(m,1H),6.76(d,J=7.2Hz,1H),6.50(d,J=0.9Hz,1H),5.78-5.80(m,1H),5.64(s,1H),4.90-4.91(m,1H),3.67(s,2H),3.32(s,2H),3.30(s,2H),2.73-2.27(m,4H),2.02-1.99(m,2H),1.12-1.04(m,3H)。
实施例22和23:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:6-甲氧基喹啉-4-羧酸甲酯
向用CO的惰性气体吹扫并保持的50mL压力罐反应器(60atm)中,加入4-溴-6-甲氧基喹啉(4g,16.80mmol,1.00当量)、TEA(5.11g,50.50mmol,3.00当量)、Pd(dppf)Cl2CH2Cl2(4.13g,5.05mmol,0.30当量)和甲醇(30mL)。所得溶液在120℃下搅拌过夜,冷却至室温后,将所得混合物在真空下浓缩,用乙酸乙酯/石油醚(1/5)将残余物施加到硅胶柱上,得到2g(55%)的6-甲氧基喹啉-4-羧酸甲酯,为白色固体。MS(ES,m/z)[M+H]+:218。
步骤2:6-甲氧基-1,2,3,4-四氢喹啉-4-羧酸甲酯
向用氢气的惰性气体吹扫并保持的100mL圆底烧瓶中,加入6-甲氧基喹啉-4-羧酸甲酯(217mg,1.00mmol,1.00当量)、钯碳(10%,217mg)、甲醇(12mL)和AcOH(2mL)。所得溶液在20℃下搅拌过夜,滤掉固体。所得混合物在真空下浓缩,得到230mg(粗品)的6-甲氧基-1,2,3,4-四氢喹啉-4-羧酸甲酯,为棕色油状物。MS(ES,m/z)[M+H]+:222。
步骤3:6-甲氧基-1,2,3,4-四氢喹啉-4-羧酸
向100mL圆底烧瓶中,加入6-甲氧基-1,2,3,4-四氢喹啉-4-羧酸甲酯(221mg,1.00mmol,1.00当量)、甲醇(8mL)、四氢呋喃(2mg,0.03mmol,0.03当量)、LiOH(120mg,5.01mmol,5.00当量)和水(1ml)。所得溶液在25℃下搅拌过夜,所得混合物在真空下浓缩。用H2O(20mL)稀释所得溶液,用盐酸(1mol/L)将溶液的pH值调至4。用乙酸乙酯(20mL×3)萃取所得溶液并合并有机层和在真空下浓缩。用二氯甲烷/甲醇(10/1)将残余物施加到硅胶柱上,得到40mg(19%)的6-甲氧基-1,2,3,4-四氢喹啉-4-羧酸盐,为棕色固体。MS(ES,m/z)[M+H]+:208。
步骤4:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮
向50mL圆底烧瓶中,加入6-甲氧基-1,2,3,4-四氢喹啉-4-羧酸(60mg,0.29mmol,1.00当量)、HOBt(59mg,0.44)mmol,1.50当量)、EDCI(84mg,0.44mmol,1.50当量)、N,N-二甲基甲酰胺(3mL)、6-甲磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(75mg,0.35mmol,1.20当量)和TEA(88mg,0.87mmol,3.00当量)。所得溶液在25℃下搅拌3小时,用DCM(80mL)稀释反应混合物,用H2O(50mL×3)和盐水(50mL×3)洗涤并用Na2SO4干燥。过滤后将滤液减压浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化(分析HPLC-SHIMADZU):柱:XBridge Prep C18 OBD柱;19×150mm 5um;流动相A:水(10mM NH4HCO3),流动相B:ACN;流速:20mL/min;梯度:7分钟内从25%B到25%B;254/220nm。
组分A:将收集的组分冻干,得到1.3mg(1%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:6.73分钟。MS(ES,m/z)[M+H]+:406。(300MHz,DMSO-d6,ppm):δ6.61-6.57(m,3H),6.48(s,2H),5.42(s,1H),4.98-4.95(m,1H),4.23(s,2H),3.54(s,3H),3.43-3.41(m,2H),3.22-3.09(m,2H),2.95(s,3H),2.49-2.44(s,2H),2.03-1.97(m,2H)。
组分B:将收集的组分冻干,得到4.5mg(4%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:7.13分钟。MS(ES,m/z)[M+H]+:406。(300MHz,DMSO-d6,ppm):δ6.60-6.56(m,1H),6.46-6.43(m,2H),5.77(s,2H),5.39(s,1H),4.89-4.86(m,1H),4.51(s,2H),3.54(s,3H),3.43-3.41(m,2H),3.22-3.10(m,2H),2.94(s,3H),2.49-2.44(s,2H),2.03-1.97(m,2H)。
实施例24和25:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-(三氟甲基)-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-(三氟甲基)-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:6-(三氟甲基)喹啉-4-基三氟甲磺酸酯
向500mL圆底烧瓶中,加入6-(三氟甲基)喹啉-4-醇(2.0g,9.38mmol,1.00当量)、二氯甲烷(150mL)和吡啶(1.5g,18.96mmol,2.00当量)。然后在0℃搅拌下逐滴加入(三氟甲烷)磺酰基三氟甲磺酸酯(3.18g,11.27mmol,1.20当量),所得溶液在室温下搅拌过夜。用盐酸(1mol/L,100ml×2)萃取所得溶液并合并有机层和用无水硫酸钠干燥。将残余物施加到具有乙酸乙酯/石油醚(0-20%)的硅胶柱上,得到0.8g(25%)的6-(三氟甲基)喹啉-4-基三氟甲磺酸酯,为白色固体。MS(ES,m/z)[M+H]+:346。
步骤2:6-(三氟甲基)喹啉-4-羧酸甲酯
向用CO的惰性气体吹扫并保持的50mL压力罐反应器(60atm)中,加入6-(三氟甲基)喹啉-4-基三氟甲磺酸酯(820mg,2.38mmol,1.00当量)、Pd(dppf)Cl2﹒CH2Cl2(388mg,0.47mmol,0.20当量)、TEA(1.2g,11.88mmol,5.00当量)和甲醇(10mL)。所得溶液在80℃下并在油浴中搅拌过夜。冷却至室温后,然后加入DCM(50mL)将反应淬灭。用水(50ml×3)洗涤所得溶液,合并有机层并用无水硫酸钠干燥。过滤后,滤液减压浓缩。通过制备型TLC(EtOAc:PE=1:2)对残余物进行纯化。得到210mg(35%)的6-(三氟甲基)喹啉-4-羧酸甲酯,为白色固体。MS(ES,m/z)[M+H]+:256。
步骤3:6-(三氟甲基)-1,2,3,4-四氢喹啉-4-羧酸甲酯
向100mL圆底烧瓶中,加入6-(三氟甲基)喹啉-4-羧酸甲酯(100mg,0.39mmol,1.00当量)、甲醇(10mL)和钯碳(10%,100mg)。抽空烧瓶并用氮气吹扫3次,然后用氢气吹扫。混合物在室温下在氢气气氛(气球)中搅拌4小时,滤掉固体。将所得混合物在真空下浓缩,得到98.2mg(97%)的6-(三氟甲基)-1,2,3,4-四氢喹啉-4-羧酸甲酯,为无色油状物。MS(ES,m/z)[M+H]+:260。
步骤4:6-(三氟甲基)-1,2,3,4-四氢喹啉-4-羧酸
向100mL圆底烧瓶中,加入6-(三氟甲基)-1,2,3,4-四氢喹啉-4-羧酸甲酯(98mg,0.38mmol,1.00当量)、四氢呋喃(20mL)、水(5mL)和LiOH(45mg,1.88mmol,5.00当量)。所得溶液在室温下搅拌过夜,然后加入水/冰(20mL)将反应淬灭。用二氯甲烷(25mL×3)萃取所得溶液并合并水层。用盐酸(1mol/L)将溶液的pH值调至4-6。用二氯甲烷(40mL×3)萃取所得溶液并合并有机层,和用无水硫酸钠干燥,并在真空下浓缩,得到87mg(94%)的6-(三氟甲基)-1,2,3,4-四氢喹啉-4-羧酸,为红色固体。MS(ES,m/z)[M+H]+:246。
步骤5:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-(三氟甲基)-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-(三氟甲基)-1,2,3,4-四氢喹啉-4-基)甲酮
向40mL圆底烧瓶中,加入6-(三氟甲基)-1,2-二氢喹啉-4-羧酸(60mg,0.25mmol,1.00当量)、HOBt(49mg,0.36mmol,1.50当量)、EDCI(70.2mg,0.37mmol,1.50当量)、TEA(185mg,1.83mmol,7.50当量)、N,N-二甲基甲酰胺(8.0mL)和6-甲磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(53mg,0.25mmol,1.00当量)。所得溶液在20℃下搅拌4小时,然后加入水/冰(30mL)将反应淬灭。用乙酸乙酯(30mL×3)萃取所得溶液并合并有机层,和用无水硫酸钠干燥。滤掉固体,将所得混合物在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱,XSelect CSH Prep C18 OBD柱,5μm,19×150mm;流动相,水(0.1%FA)和ACN(ACN在10分钟内从30.0%达到60.0%);检测器,UV 254/220nm。
组分A:将收集的组分冻干,得到2.8mg(3%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-(三氟甲基)-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:9.65分钟。MS(ES,m/z)[M+H]+:444。(400MHz,DMSO-d6,ppm)δ7.23-7.21(m,1H),7.16-7.15(m,1H),6.69-6.61(m,4H),5.03-5.00(m,1H),4.24(s,2H),3.43-3.40(m,2H),3.28-3.26(m,2H),2.97(s,3H),2.46-2.42(m,2H),2.11-2.08(m,1H),2.03-1.99(m,1H)。
组分B:将收集的组分冻干,得到9.8mg(9%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-(三氟甲基)-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:8.78分钟。MS(ES,m/z):[M+H]+.444。(300MHz,DMSO-d6,ppm)δ7.23-7.15(m,2H),6.67-6.60(m,2H),5.85(s,2H),4.94-4.90(m,1H),4.53(s,2H),3.50-3.36(m,2H),3.27-3.22(m,2H),2.96(s,3H),2.47-2.43(m,2H),2.15-2.09(m,1H),2.03-1.96(m,1H)。
实施例26和27:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(2-甲基-4,5,6,7-四氢-2H-异吲哚-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(2-甲基-4,5,6,7-四氢-2H-异吲哚-4-基)甲酮
步骤1:6,7-二氢-2H-异吲哚-4(5H)-酮
向用氮气的惰性气体吹扫并保持的500mL三颈圆底烧瓶中,加入在四氢呋喃(50mL)中的氢化钠(5.1g,1.50当量,60%)溶液、环己-2-烯-1-酮(7.8g,81.14mmol,1.00当量和在四氢呋喃(50mL)中的TosMic(16g,1.00当量)溶液。在0℃搅拌下加入DMSO(80mL),所得溶液在室温下搅拌15小时。然后加入水/冰(100mL)将反应淬灭,用乙酸乙酯(150mL×3)萃取所得溶液并合并有机层和在真空下浓缩。用乙酸乙酯/己烷(1:10)将残余物施加到硅胶柱上,得到6.1g(56%)的6,7-二氢-2H-异吲哚-4(5H)-酮,为浅黄色固体。MS(ES,m/z)[M+H]+:136。
步骤2:2-甲基-6,7-二氢-2H-异吲哚-4(5H)-酮
向250mL圆底烧瓶中,加入4,5,6,7-四氢-2H-异吲哚-4-酮(6.1g,45.13mmol,1.00当量)、CH3I(13g,91.59mmol,2.00当量)、CH3CN(100mL)和甲烷过氧化钾(19g,137.47mmol,3.00当量)。所得溶液在85℃下搅拌15小时,冷却至室温后,将固体滤掉。所得混合物真空浓缩,用乙酸乙酯/己烷(1:3)将残余物施加到硅胶柱上,得到5g(74%)的2-甲基-6,7-二氢-2H-异吲哚-4(5H)-酮,为黄色液体。MS(ES,m/z)[M+H]+:150。
步骤3:2-甲基-6,7-二氢-2H-异吲哚-4-基三氟甲磺酸酯
向用氮气的惰性气体吹扫并保持的250mL三颈圆底烧瓶中,加入2-甲基-4,5,6,7-四氢-2H-异吲哚-4-酮(2g,13.41mmol,1.00当量)和四氢呋喃(80ml)。在-78℃搅拌下加入LiHMDS(25mL,25.48mmol,1.90当量)。
以上混合物在-78℃下搅拌5分钟。在-78℃下缓慢加入在四氢呋喃中(10mL)的1,1,1-三氟-N-苯基-N-(三氟甲烷)磺酰基甲磺酰胺(4.5g,25.50mmol,1.90当量)溶液。使温度自然升至室温,所得溶液在室温下搅拌15小时,然后加入水/冰(100mL)将反应淬灭。用乙酸乙酯(100ml×3)萃取所得溶液并合并有机层,和用无水硫酸钠干燥并在真空下浓缩。得到6g(粗品)的2-甲基-6,7-二氢-2H-异吲哚-4-基三氟甲磺酸酯,为棕色油状物。MS(ES,m/z)[M+H]+:282。
步骤4:2-甲基-6,7-二氢-2H-异吲哚-4-羧酸甲酯
向30mL压力罐反应器(CO,60atm)中,加入2-甲基-6,7-二氢-2H-异吲哚-4-基三氟甲磺酸盐(6g,21.33mmol,1.00当量)、pd(dppf)Cl2CH2Cl2(0.46g,0.10当量)、甲醇(10mL)和TEA(7.3mg,5.00当量)。所得溶液在75℃下搅拌15小时,冷却至室温后,将反应混合物浓缩并将残余物施加到具有乙酸乙酯/PE(1:10)的硅胶柱上,得到3g(74%)的2-甲基-6,7-二氢-2H-异吲哚-4-羧酸甲酯,为棕色油状物。MS(ES,m/z)[M+H]+:192。
步骤5:2-甲基-4,5,6,7-四氢-2H-异吲哚-4-羧酸甲酯
向100mL圆底烧瓶中,加入2-甲基-6,7-二氢-2H-异吲哚-4-羧酸甲酯(100mg,0.52mmol,1.00当量)、甲醇(10mL)和钯碳(10%,50mg)。将烧瓶抽真空并用氮气吹扫3次,然后用氢气吹扫。混合物在室温下在氢气气氛(气球)中搅拌4小时,滤掉固体,滤液在真空下浓缩。得到100mg(99%)的2-甲基-4,5,6,7-四氢-2H-异吲哚-4-羧酸甲酯,为黄色油状物。MS(ES,m/z)[M+H]+:194。
步骤6:2-甲基-4,5,6,7-四氢-2H-异吲哚-4-羧酸
向100mL圆底烧瓶中,加入2-甲基-4,5,6,7-四氢-2H-异吲哚-4-羧酸甲酯(110mg,0.57mmol,1.00当量)、氢氧化钠(45.6mg,1.14mmol,2.00当量)、水(10mL)和甲醇(20mL)。所得溶液在室温下搅拌15小时,用盐酸(1mol/L)将溶液的pH值调至6。用乙酸乙酯(80mL×3)萃取所得溶液并合并有机层和在真空下浓缩。得到30mg(29%)的2-甲基-4,5,6,7-四氢-2H-异吲哚-4-羧酸,为黄色固体。MS(ES,m/z)[M+H]+:180。
步骤7:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(2-甲基-4,5,6,7-四氢-2H-异吲哚-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(2-甲基-4,5,6,7-四氢-2H-异吲哚-4-基)甲酮
向100mL圆底烧瓶中,加入2-甲基-4,5,6,7-四氢-2H-异吲哚-4-羧酸(30mg,0.17mmol,1.00当量)、6-甲基甲磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(36.2mg,0.17mmol,1.00当量)、EDCI(48.3mg,0.25mmol,1.50当量)、HOBt(33.8mg,0.25mmol,1.50当量)、N,N-二甲基甲酰胺(10mL)和TEA(85.9mg,0.85mmol,5.00当量)。所得溶液在室温下搅拌6小时,然后加水(100mL)将反应淬灭。用乙酸乙酯(150mL×3)萃取所得溶液并合并有机层和在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱,XBridge Shield RP18 OBD柱,5μm,19×150mm;流动相,水(0.1%FA)和ACN(ACN在9分钟内从25.0%达到60.0%);检测器,UV 254nm。
组分A:将收集的组分冻干,得到2.8mg(4%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(2-甲基-4,5,6,7-四氢-2H-异吲哚-4-基)甲酮,为白色固体。Rt2:6.20分钟。MS(ES,m/z)[M+H]+:378。(DMSO-d6,300MHz,ppm):δ6.59(s,1H),6.37-6.36(m,1H),6.18-6.17(m,1H),4.75-4.76(m,1H),4.23-4.22(m,2H),3.46(s,3H),3.43-3.40(m,2H),2.97(s,3H),2.47-2.43(m,4H),1.91-1.88(m,3H),1.63-1.57(m,1H)。
组分B:将收集的组分冻干,得到1.1mg(2%)的(3-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(2-甲基-4,5,6,7-四氢-2H-异吲哚-4-基)甲酮,为白色固体。Rt1:5.60分钟。MS(ES,m/z)[M+H]+:378。(DMSO-d6,300MHz,ppm):δ6.36-6.35(m,1H),6.20-6.19(m,1H),5.70(s,2H),4.68-4.63(m,1H),4.52(s,2H),3.47(s,3H),3.46-3.36(m,2H),2.96(s,3H),2.53-2.52(m,1H),2.47-2.43(m,3H),1.93-1.82(m,3H),1.58-1.55(m,1H)。
实施例28和29:(3-氨基-6-苯基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-苯基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:3-氨基-6-苯基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-羧酸叔丁酯
向100mL圆底烧瓶中,加入3-氨基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-2-羧酸叔丁酯(720mg,3.02mmol,1.00当量)、苯基硼酸(293mg,2.40mmol,0.80当量)、二氯甲烷(20mL)、TEA(1.53g,15.12mmol,5.00当量)、Cu(OAc)2(821mg,4.52mmol,1.50当量)和MS(1.4g)。所得溶液在室温下搅拌16小时,将所得混合物在真空下浓缩,用二氯甲烷/甲醇(10:1)将残余物施加到硅胶柱上。得到72mg(8%)3-氨基-6-苯基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-羧酸叔丁酯,为黄色油状物。MS(ES,m/z)[M+H]+:315。
步骤2:6-苯基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺的盐酸盐
向50mL圆底烧瓶中,加入3-氨基-6-苯基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-2-羧酸叔丁酯(72mg,0.33mmol,1.00当量)、二氯甲烷(4mL)和三氟乙酸(1mL)。所得溶液在室温下搅拌1小时,将所得混合物在真空下浓缩。用3mL ACN、10ml H2O和2ml盐酸(1mol/L)稀释所得溶液。将所得混合物冻干,得到15mg(49%)的6-苯基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺的盐酸盐,为黄色固体。MS(ES,m/z)[M+H]+:215。
步骤3:(3-氨基-6-苯基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-苯基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮
向25mL圆底烧瓶中,加入6-苯基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺的盐酸盐(15mg,0.07mmol,1.00当量)、6-氟-1,2,3,4-四氢喹啉-4-羧酸(15mg,0.08mmol,1.00当量)、HOBt(14mg,0.10mmol,1.50当量)、EDCI(20mg,0.10mmol,1.50当量)、TEA(21mg,0.21mmol,3.00当量)和N,N-二甲基甲酰胺(3mL)。所得溶液在室温下搅拌5小时,然后加水(10mL)将反应淬灭。用乙酸乙酯(10mL×3)萃取所得溶液并合并有机层和在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱:XBridge C18OBD制备柱,5μm,19mm×250mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:15分钟内从25%B到45%B;254/220nm。
组分A:将收集的组分冻干,得到1.1mg(4%)的(3-氨基-6-苯基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:13.70分钟。MS(ES,m/z)[M+H]+:392;(DMSO-d6,300MHz,ppm):δ7.24-7.18(m,2H),7.03-7.01(m,2H),6.82-6.66(m,3H),6.53-6.48(m,3H),5.79(s,1H),5.03-4.99(m,1H),4.27(s,2H),3.58-3.55(m,2H),3.31-3.18(m,2H),2.45-2.42(m,2H),2.11-2.00(m,2H)。
组分B:将收集的组分冻干,得到2.5mg(9%)的(3-氨基-6-苯基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:12.50分钟。MS(ES,m/z)[M+H]+:392。(DMSO-d6,300MHz,ppm):δ7.24-7.19(m,2H),6.97-6.94(m,2H),6.81-6.67(m,3H),6.53-6.48(m,1H),5.77(s,1H),5.74(s,2H),4.92-4.89(m,1H),4.48(s,2H),3.55-3.52(m,2H),3.31-3.27(m,1H),3.18-3.12(m,1H),2.46-2.44(m,2H),2.11-1.97(m,2H)。
实施例30、31、32和33:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-乙基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-乙基-1,2,3,4-四氢喹啉-4-基)甲酮以及(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-乙基-1,2,3,4-四氢喹啉-4-基)甲酮和(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-乙基-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:6-乙烯基喹啉-4-羧酸
向用氮气的惰性气体吹扫并保持的250mL圆底烧瓶中,加入6-溴喹啉-4-羧酸(2g,7.93mmol,1.00当量),2-乙烯基-4,4,5,5-四甲基-1,3,2-二氧杂硼烷(1.8g,11.69mmol,1.50当量)、Pd(dppf)Cl2CH2Cl2(1.3g,0.20当量)、碳酸钾(3.3g,23.88mml,3.00当量)、水(6mL)和二恶烷(60mL)。所得溶液在100℃下搅拌过夜,将混合物冷却至20℃。用H2O(60mL)稀释所得溶液。所得混合物用DCM(100mL×2)洗涤,用盐酸(1mol/L)将溶液的pH值调至3-4。用二氯甲烷(100mL×5)萃取所得溶液并合并有机层和在真空下浓缩,得到880mg(56%)的6-乙烯基喹啉-4-羧酸,为棕色固体。MS(ES,m/z)[M+H]+:200。
步骤2:6-乙基-1,2,3,4-四氢喹啉-4-羧酸
向用氢气的惰性气体吹扫并保持的100mL圆底烧瓶中,加入6-乙烯基喹啉-4-羧酸(620mg,3.11mmol,1.00当量)、乙酸乙酯(40mL)、钯碳(10%,600mg)和AcOH(0.25mL)。所得溶液在25℃下搅拌1小时,滤掉固体。加入Pt2O(300mg)。所得溶液在25℃下搅拌6小时,滤掉固体。将滤液浓缩并将残余物施加到具有二氯甲烷/甲醇(10/1)的硅胶柱上。得到100mg(16%)的6-乙基-1,2,3,4-四氢喹啉-4-羧酸,为黄色固体。MS(ES,m/z)[M+H]+:206。
步骤3:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-乙基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-乙基-1,2,3,4-四氢喹啉-4-基)甲酮
向50mL圆底烧瓶中,加入6-乙基-1,2,3,4-四氢喹啉-4-羧酸(150mg,0.72mmol,1.00当量)、1H-1,2,3-苯并三唑-1-醇(150mg,1.11mmol,1.50当量)、EDCI(210mg,1.11mmol,1.50当量)、TEA(222mg,2.19mmol,3.00当量)、N,N-二甲基甲酰胺(10mL)和6-甲磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(210mg,0.96mmol,1.30当量)。所得溶液在20℃下搅拌2小时,然后加水(30mL)将反应淬灭。用乙酸乙酯(30mL×3)萃取所得溶液并合并有机层和用无水硫酸钠干燥。滤掉固体,所得混合物真空浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱:XSelect CSH Prep C18 OBD柱,5μm,19mm×250mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:7分钟内从15%B到50%B;254nm。
组分A:将收集的组分冻干,得到15mg(13%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-乙基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:6.05分钟。MS(ES,m/z)[M+H]+:404。(DMSO-d6,300MHz,ppm):δ6.79-6.76(m,1H),6.63-6.61(m,3H),6.47-6.44(m,1H),5.65(s,1H),5.00-4.97(m,1H),4.24(s,2H),3.44-3.40(m,2H),3.26-3.16(m,2H),2.97(s,3H),2.47-2.45(m,2H),2.39-2.31(m,2H),2.03-2.01(m,2H),1.07-1.02(m,3H)。
组分B:将收集的组分冻干,得到9.4mg(9%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-乙基1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:5.8分钟。MS(ES,m/z)[M+H]+:404。(DMSO-d6,300MHz,ppm):δ6.78-6.75(m,1H),6.62-6.61(m,1H),6.46-6.43(m,1H),5.79(s,2H),5.65(s,1H),4.91-4.88(m,1H),4.53(s,2H),3.44-3.39(m,3H),3.27-3.23(m,2H),3.15-3.11(m,1H),2.96(s,3H),2.39-2.31(m,2H),2.01-1.99(m,2H),1.07-1.02(m,3H)。
步骤4:(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-乙基-1,2,3,4-四氢喹啉-4-基)甲酮和(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-乙基-1,2,3,4-四氢喹啉-4-基)甲酮
通过Prep-HPLC按照以下条件分离出(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-乙基-1,2,3,4-四氢喹啉-4-基)甲酮(15mg,0.05mmol,1.00当量),柱:CHIRALPAK IA,2.12×15cm,5μm;流动相A:Hex--HPLC,流动相B:EtOH--HPLC;流速:20mL/min;梯度:15分钟内从50B到50B;254/220nm。
对映异构体A,实施例32:得到2.8mg(15%)的(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-乙基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:10.45分钟。MS(ES,m/z)[M+H]+:404。(DMSO-d6,300MHz,ppm):δ6.77-6.74(m,1H),6.61-6.59(m,3H),6.45-6.42(m,1H),5.62(s,1H),4.98-4.97(m,1H),4.22(s,2H),3.42-3.39(m,2H),3.26-3.14(m,2H),2.95(s,3H),2.37-2.29(m,4H),2.02-1.98(m,2H),1.06-1.00(m,3H)。
对映异构体B,实施例33:得到3.4mg(18%)的(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-乙基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:6.36分钟。MS(ES,m/z)[M+H]+:404。(DMSO-d6,300MHz,ppm):δ6.79-6.76(m,1H),6.69-6.61(m,3H),6.47-6.44(m,1H),5.66(s,1H),5.01-4.97(m,1H),4.24(s,2H),3.42-3.40(m,2H),3.17-3.13(m,2H),2.97(s,3H),2.39-2.27(m,4H),2.03-2.01(m,2H),1.06-1.02(m,3H)。
实施例34、35和36:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮以及(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:4-溴-8-甲基喹啉
向100mL圆底烧瓶中,加入8-甲基喹啉-4-醇(500mg,3.14mmol,1.00当量)和N,N-二甲基甲酰胺(20mL)。然后在室温搅拌下逐滴加入三溴化磷(85 1mg,3.14mmol,1.20当量),所得溶液在室温下搅拌15小时。然后加入水/冰(100mL)将反应淬灭。用氢氧化钠(2mol/L)将溶液的pH值调至10。过滤收集固体,得到660mg(95%)的4-溴-8-甲基喹啉,为浅黄色固体。MS(ES,m/z)[M+H]+:222。
步骤2:8-甲基喹啉-4-羧酸甲酯
向50mL压力罐反应器(CO,60atm)中,加入4-溴-8-甲基喹啉(600mg,2.70mmol,1.00当量)、Pd(dppf)Cl2CH2Cl2(444mg,0.54mmol,0.20当量)、TEA(1.4g,13.86mmol,5.00当量)和甲醇(15mL)。所得溶液在80℃下搅拌16小时,冷却至室温后,将反应混合物浓缩并将残余物施加到具有乙酸乙酯/己烷(0-30%)的硅胶柱上。得到350mg(64%)的8-甲基喹啉-4-羧酸甲酯,为白色固体。MS(ES,m/z)[M+H]+:202.
步骤3:8-甲基喹啉-4-羧酸
向100mL圆底烧瓶中,加入8-甲基喹啉-4-羧酸甲酯(350mg,1.74mmol,1.00当量)、氢氧化钠(209mg,5.23mmol,3.00当量)、水(20mL)和甲醇(20mL)。所得溶液在室温下搅拌14小时,将所得混合物在真空下浓缩。用乙酸乙酯(20mL×2)萃取所得溶液并合并水层。用盐酸(6mol/L)将溶液的pH值调至5-6,用乙酸乙酯(30mL×3)萃取所得溶液并合并有机层。将所得混合物在真空下浓缩,得到250mg(77%)的8-甲基喹啉-4-羧酸,为黄色固体状。MS(ES,m/z)[M+H]+:188。
步骤4:8-甲基-1,2,3,4-四氢喹啉-4-羧酸
向100mL圆底烧瓶中,加入8-甲基喹啉-4-羧酸(250mg,1.34mmol,1.00当量)、PtO2(40mg)和甲醇(20mL)。将烧瓶抽真空并用氮气吹扫3次,然后用氢气吹扫。混合物在室温下在氢气气氛(气球)下搅拌1小时,滤掉固体。将所得混合物在真空浓缩,得到220mg(86%)的8-甲基-1,2,3,4-四氢喹啉-4-羧酸,为黄色固体。MS(ES,m/z)[M+H]+:192。
步骤5:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
向250mL圆底烧瓶中,加入8-甲基-1,2,3,4-四氢喹啉-4-羧酸(1.8g,9.41mmol,1.00当量)、6-甲磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(2.2g,10.17mmol,1.10当量)、EDCI(2.7g,14.08mmol,1.50当量)、HOBt(1.9g,14.06mmol,1.50当量)、TEA(4.7g,46.45mmol,5.00当量)和N,N-二甲基甲酰胺(30mL)。所得溶液在室温下搅拌2小时,然后加水(200mL)将反应淬灭,用乙酸乙酯(300mL×3)萃取所得溶液并合并有机层和在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱,XBridge Prep OBDC18柱,150mm 5um;流动相,水(0.1%FA)和ACN(ACN在9分钟内从15.0%达到45.0%);检测器,UV 220nm。将收集的组分冻干,得到150mg(5%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为浅黄色固体。Rt:6.50分钟。MS(ES,m/z)[M+H]+:390。(DMSO-d6,300MHz,ppm):δ6.83-6.81(m,1H),6.66-6.62(m,3H),6.37-6.32(m,1H),5.23(s,1H),5.05-5.01(m,1H),4.20(s,2H),3.43-3.39(m,2H),3.32-3.30(m,1H),3.27-3.26(m,1H),2.9(s,3H),2.49-2.45(m,2H),2.11-1.98(m,5H)。
步骤6:(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
通过制备型-手性HPLC按照以下条件分离出6-甲基磺酰基-2-[(8-甲基-1,2,3,4-四氢喹啉-4-基)羰基]-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(150mg)。柱:CHIRALPAK IG,20 250mm,5um;流动相A:Hex--HPLC,流动相B:EtOH--HPLC;流速:18mL/min;梯度:26分钟内从50B到50B;254/220nm。
对映异构体A,实施例35:得到55.9mg(37%)的(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为浅黄色固体。Rt1:16.47分钟。MS(ES,m/z)[M+H]+:390。(DMSO-d6,300MHz,ppm):δ6.83-6.81(m,1H),6.66-6.62(m,3H),6.37-6.32(m,1H),5.23(s,1H),5.05-5.01(m,1H),4.20(s,2H),3.43-3.39(m,2H),3.32-3.30(m,1H),3.27-3.26(m,1H),2.97(s,3H),2.49-2.45(m,2H),2.07-1.98(m,5H)。
对映异构体B,实施例36:得到43.8mg(29%)的(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为浅黄色固体。Rt2:20.84min。MS(ES,m/z)[M+H]+:390。(DMSO-d6,300MHz,ppm):δ6.83-6.81(m,1H),6.66-6.62(m,3H),6.37-6.32(m,1H),5.23(s,1H),5.05-5.01(m,1H),4.20(s,2H),3.43-3.39(m,2H),3.32-3.30(m,1H),3.27-3.26(m,1H),2.96(s,3H),2.49-2.45(m,2H),2.07-1.96(m,5H)。
实施例37和38:3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氟-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-氟-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:4-溴-8-氟喹啉
向100mL圆底烧瓶中,加入8-氟喹啉-4-醇(1g,6.13mmol,1.00当量)和N,N-二甲基甲酰胺(20mL)。随后在室温搅拌下逐滴添加PBr3(1.8g,6.65mmol,1.10当量)。所得溶液在室温下搅拌1小时,然后加水(50mL)将反应淬灭。用氢氧化钾水溶液将溶液的pH值调至8。过滤收集固体,得到1.1g的4-溴-8-氟喹啉,为黄色固体。MS(ES,m/z)[M+H]+:226。
步骤2:8-氟喹啉-4-羧酸甲酯
向50mL密封管(60atm)中,加入4-溴-8-氟喹啉(1.1g,4.87mmol,1.00当量)、Pd(dppf)Cl2CH2Cl2(800mg,0.98mmol,0.20当量)、TEA(2g,19.80mmol,4.00当量)和甲醇(15mL)。向其中引入一氧化碳,所得溶液在75℃下搅拌过夜。冷却至室温后,将固体滤掉,滤液在真空下浓缩。将残余物施加到具有乙酸乙酯/石油醚(0-50%)的硅胶柱上,得到890mg(89%)的8-氟喹啉-4-羧酸甲酯,为白色固体。MS(ES,m/z)[M+H]+:206。
步骤3:8-氟喹啉-4-羧酸
向50mL圆底烧瓶中,加入8-氟喹啉-4-羧酸甲酯(890mg,4.34mmol,1.00当量)、甲醇(15mL)和在水(8mL)中的氢氧化钠(520mg,13.00mmol,3.00当量)溶液。所得溶液在室温下搅拌过夜,将所得混合物在真空下浓缩。用水(20mL)稀释所得溶液,用乙酸乙酯(30mL×2)洗涤所得溶液,用盐酸(1mol/L)将溶液的pH值调至5-6。过滤收集固体,得到710mg(86%)的8-氟喹啉-4-羧酸,为白色固体。MS(ES,m/z)[M+H]+:192。
步骤4:8-氟-1,2,3,4-四氢喹啉-4-羧酸
向50mL的圆底烧瓶中,加入8-氟喹啉-4-羧酸(150mg,0.78mmol,1.00当量)、甲醇(8mL)和Pt2O(30mg)。向其中引入氢气,所得溶液在室温下搅拌50分钟,滤掉固体。将所得混合物真空浓缩,得到140mg(91%)的8-氟-1,2,3,4-四氢喹啉-4-羧酸,为黄色固体。MS(ES,m/z)[M+H]+:196。
步骤5:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氟-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-氟-1,2,3,4-四氢喹啉-4-基)甲酮
向50mL圆底烧瓶中,加入6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(95mg,0.44mmol,1.20当量)、8-氟喹啉-4-羧酸(70mg,0.37mmol,1.00当量)、HOBT(75mg,0.56mmol,1.50当量)、EDCI(105mg,0.55mmol,1.50当量)、TEA(110mg,1.09mmol,3.00当量)和N,N-二甲基甲酰胺(5mL)。所得溶液在室温下搅拌2小时,然后加水(30mL)将反应淬灭。用乙酸乙酯(30mL×3)萃取所得溶液并合并有机层。将所得混合物在真空下浓缩,通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱:XSelect CSH Prep C18 OBD柱,5μm,19mm×250mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:7分钟内从25%B到60%B;254nm。
对映异构体A,实施例37:将收集的组分冻干,得到1.8mg(1%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氟-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:6.63分钟。MS(ES,m/z)[M+H]+:394。(DMSO-d6,400MHz,ppm):δ6.91-6.86(m,1H),6.74-6.64(m,3H),6.42-6.38(m,1H),5.79(s,1H),5.08-5.05(m,1H),4.24-4.20(m,2H),3.45-3.42(m,2H),3.29-3.26(m,2H),2.97(s,3H),2.48-2.45(m,2H),2.10-2.02(m,2H)。
组分B,实施例38:将收集的组分冻干,得到4.3mg(3%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-氟-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:5.95分钟。MS(ES,m/z)[M+H]+:394。(DMSO-d6,400MHz,ppm):δ6.90-6.85(m,1H),6.69-6.67(m,1H),6.41-6.36(m,1H),5.81(s,2H),5.76(s,1H),4.97-4.94(m,1H),4.57-4.47(m,2H),3.46-3.40(m,2H),3.29-3.24(m,2H),2.96(s,3H),2.47-2.44(m,2H),2.11-1.99(m,2H)。
实施例39和40:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(2,2-二甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(2,2-二甲基-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:4-(2-氨基苯基)-2-甲基-3-炔-2-醇
向用氮气的惰性气体吹扫并保持的250mL圆底烧瓶中,加入2-碘苯胺(5g,22.83mmol,1.00当量)、2-甲基-3-丁炔-2-醇(2.87g,34.12mmol,1.50当量)、Pd(PPh3)2Cl2(798mg,1.14mmol,0.05当量)、PPh3(3g,11.54mmol,0.50当量)、CuI(216.6mg,1.14mmol,0.05当量)、TEA(50mL)和吡啶(50mL)。所得溶液在100℃下搅拌15小时,冷却至室温后,将所得溶液用水(100mL)稀释,用乙酸乙酯(150mL×3)萃取所得溶液并合并有机层和在真空下浓缩。将残余物施加到具有乙酸乙酯/PE(1:3)的硅胶柱上,得到3.1g(77%)的4-(2-氨基苯基)-2-甲基-3-丁炔-2-醇,为黄色液体。MS(ES,m/z)[M+H]+:176。
步骤2:2,2-二甲基-2,3-二氢喹啉-4(1H)-酮
向250mL圆底烧瓶中,加入4-(2-氨基苯基)-2-甲基-3-丁炔-2-醇(3.1g,17.69mmol,1.00当量)、盐酸(90mL)和水(90mL)。所得溶液在120℃下搅拌1.5小时,冷却至室温后,用饱和NaHCO3水溶液将溶液的pH值调至7。用乙酸乙酯(200mL×3)萃取所得溶液并合并有机层和在真空下浓缩。将残余物施加到具有乙酸乙酯/PE(3/1)的硅胶柱上,得到2.91g(94%)的2,2-二甲基-2,3-二氢喹啉-4(1H)-酮,为褐色固体。MS(ES,m/z)[M+H]+:176。
步骤3:2,2-二甲基-4-(三甲基甲硅烷基氧基)-1,2,3,4-四氢喹啉-4-甲腈
向100mL圆底烧瓶中,加入2,2-二甲基-1,2,3,4-四氢喹啉-4-酮(1.5g,8.56mmol,1.00当量)、乙腈(30mL)、TMCSN(16.8g,170.12mmol,20.00当量)和ZnI2(5.5g,17.23mmol,2.00当量)。所得溶液在室温下搅拌15小时,然后加水(100mL)将反应淬灭。用乙酸乙酯(100mL×3)萃取所得溶液并合并有机层和在真空下浓缩,得到2g(85%)的2,2-二甲基-4-(三甲基甲硅烷基氧基)-1,2,3,4-四氢喹啉-4-甲腈,为棕色油状物。MS(ES,m/z)[M+H]+:275。
步骤4:2,2-二甲基-1,2,3,4-四氢喹啉-4-羧酸
向250mL圆底烧瓶中,加入2,2-二甲基-4-[(三甲基甲硅烷基)氧基]-1,2,3,4-四氢喹啉-4-甲腈(1.9g,6.92mmol,1.00当量)、AcOH(10mL)、盐酸(12mol/L,10mL)和二氯-2-锡烷水合物(1.88g,9.05mmol,1.20当量)。所得溶液在室温下搅拌15小时,通过反相柱在以下条件下对粗产物进行纯化:柱,C18硅胶,120g,20-45μm,100A;流动相,具有0.05%TFA和ACN的水(30分钟内从5%至65%ACN);检测器,UV 220/254nm。得到280mg(20%)的2,2-二甲基-1,2,3,4-四氢喹啉-4-羧酸,为紫色固体。MS(ES,m/z)[M+H]+:206。
步骤4:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(2,2-二甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(2,2-二甲基-1,2,3,4-四氢喹啉-4-基)甲酮
向100mL圆底烧瓶中,加入2,2-二甲基-1,2,3,4-四氢喹啉-4-羧酸(150mg,0.73mmol,1.00当量)、6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(159mg,0.74mmol,1.00当量)、HOBt(150mg,1.11mmol,1.50当量)、EDCI(210mg,1.10mmol,1.50当量)、N,N-二甲基甲酰胺(10mL)和TEA(375mg,3.71mmol,5.00当量)。所得溶液在室温下搅拌2小时,然后加水(50mL)将反应淬灭。用乙酸乙酯(60mL×3)萃取所得溶液并合并有机层和在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱:XBridge C18 OBD制备柱,100 10μm,19mm×250mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:7分钟内从20%B到45%B;254/220nm。
组分A,实施例39:将收集的组分冻干,得到10.4mg(3.5%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(2,2-二甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:6.25分钟。MS(ES,m/z)[M+H]+:404。(DMSO-d6,300MHz,ppm):δ6.93-6.88(m,1H),6.68-6.60(m,3H),6.52-6.50(m,1H),6.42-6.37(m,1H),5.69(s,1H),5.14-5.08(m,1H),4.23(s,2H),3.44-3.41(m,2H),2.97(s,3H),2.47-2.44(m,2H),1.94-1.84(m,2H),1.22(s,3H),1.11(s,3H)。
组分B,实施例40:将收集的组分冻干,得到14.7mg(5%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(2,2-二甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:5.77分钟。MS(ES,m/z)[M+H]+:404。(DMSO-d6,300MHz,ppm):δ6.91-6.86(m,1H),6.64-6.66(m,1H),6.51-6.48(m,1H),6.41-6.36(m,1H),5.79(s,2H),5.66(s,1H),5.05-4.99(m,1H),4.57(s,2H),3.44-3.42(m,2H),2.98(s,3H),2.47-2.44(m,2H),1.91-1.85(m,2H),1.23(s,3H),1.12(s,3H)。
实施例41和42:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(1,2,3,4-四氢-1,8-萘啶-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(1,2,3,4-四氢-1,8-萘啶-4-基)甲酮
步骤1:3-(吡啶-2-基氨基)丙酸
向250mL圆底烧瓶中,加入吡啶-2-胺(4g,42.50mmol,1.00当量)、AcOH(752mg,12.52mmol,0.52当量)和丙-2-烯酸丁酯(3.7g,28.87mmol,1.20当量)。所得溶液在70℃下搅拌过夜,加入氢氧化钾(3.37g,60.06mmol,2.50当量)和水(10mL)。所得溶液在25℃下搅拌过夜,所得混合物在真空下浓缩。所得混合物用DCM(200mL×6)洗涤,滤掉固体,浓缩滤液,得到4g(57%)的3-(吡啶-2-基氨基)丙酸,为棕色油状物。MS(ES,m/z)[M+H]+:167。
步骤2:2,3-二氢-1,8-萘啶-4(1H)-酮
向250mL圆底烧瓶中,加入3-[(吡啶-2-基)氨基]丙酸(4g,24.07mmol,1.00当量)和硫酸(70mL)。所得溶液在80℃下搅拌过夜,将混合物冷却至30℃。用氢氧化钠(100%)将溶液的pH值调至12。用乙酸乙酯(400mL×4)萃取所得溶液并浓缩,将残余物施加到具有乙酸乙酯/石油醚(1/1)的硅胶柱上。将收集的组分合并和在真空下浓缩,得到400mg(11%)的2,3-二氢-1,8-萘啶-4(1H)-酮,为黄色固体。MS(ES,m/z)[M+H]+:149。
步骤3:4-(三甲基甲硅烷氧基)-1,2,3,4-四氢-1,8-萘啶-4-甲腈
向250mL圆底烧瓶中,加入1,2,3,4-四氢-1,8-萘啶-4-酮(680mg,4.59mmol,1.00当量)、ACN(20mL)、ZnI2(380mg,5.51mmol,1.20当量)和TMCSN(4.5g,46.10mmol,10.00当量)。所得溶液在25℃下搅拌过夜,然后加水(50mL)将反应淬灭。用二氯甲烷(50mL×3)萃取所得溶液并合并有机层和在真空下浓缩,得到880mg(78%)的4-(三甲基甲硅烷氧基)-1,2,3,4-四氢-1,8-萘啶-4-甲腈,为黄色固体。MS(ES,m/z)[M+H]+:248。
步骤4:1,2,3,4-四氢-1,8-萘啶-4-羧酸
向250mL圆底烧瓶中,加入4-[(三甲基甲硅烷基)氧基]-1,2,3,4-四氢-1,8-萘啶-4-甲腈(880mg,3.56mmol,1.00当量)、SnCl2H2O(3.22g,14.25mmol,4.00当量)、AcOH(10mL)和盐酸(12mol/L,10mL)。所得溶液在115℃下搅拌过夜,将混合物冷却至30℃,然后加水(100mL)将反应淬灭。用二氯甲烷(150mL×6)萃取所得溶液并合并有机层和在真空下浓缩,得到1.26g(粗品)的1,2,3,4-四氢-1,8-萘啶-4-羧酸,为黄色固体。MS(ES,m/z)[M+H]+:179。
步骤5:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(1,2,3,4-四氢-1,8-萘啶-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(1,2,3,4-四氢-1,8-萘啶-4-基)甲酮
向25mL圆底烧瓶中,加入1,2,3,4-四氢-1,8-萘啶-4-羧酸(66mg,0.37mmol,1.00当量)、6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(96mg,0.44mmol,1.20当量)、HOBt(76mg,0.56mmol,1.50当量)、EDCI(107mg,0.56mmol,1.50当量),N,N-二甲基甲酰胺(10mL)和TEA(187mg,1.85mmol,5.00当量)。得到的溶液在25℃下搅拌4小时,用DCM(80mL)稀释反应混合物,用H2O(50mL×3)和盐水(50mL×3)洗涤,并用Na2SO4干燥。过滤后,将滤液进行减压浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化(分析HPLC-SHIMADZU):柱:XBridge Prep OBD C18柱;150mm 5um;流动相A:水(10mM NH4HCO3),流动相B:ACN;流速:60mL/min;梯度:8分钟内从5%B到35%B;220nm。
组分A,实施例41:将收集的组分冻干,得到(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(1,2,3,4-四氢-1,8-萘啶-4-基)甲酮,为白色固体。Rt2:7.27分钟。MS(ES,m/z)[M+H]+:377。(400MHz,DMSO-d6,ppm):δ7.83-7.82(m,1H),7.14-7.13(m,1H),6.65(s,2H),6.59(s,1H),6.43-6.40(m,1H),5.00-4.96(m,1H),4.23(s,2H),3.43-3.35(m,2H),3.32-3.30(m,2H),2.90(s,3H),2.49-2.46(m,2H),2.33-2.00(m,2H)。
组分B,实施例42:将收集的组分冻干,得到15mg(11%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(1,2,3,4-四氢-1,8-萘啶-4-基)甲酮,为白色固体。Rt1:6.57分钟。MS(ES,m/z)[M+H]+:377。(400MHz,DMSO-d6,ppm):δ7.82-7.80(m,1H),7.14-7.12(m,1H),6.60(s,1H),6.42-6.40(m,1H),5.82(s,2H),4.90-4.87(m,1H),4.48(s,2H),3.47-3.41(m,3H),3.28-3.27(m,1H),2.90(s,3H),2.49-2.47(m,2H),2.10-1.98(m,2H)。
实施例43和44:4-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-2-羰基)-6-氟-3,4-二氢喹啉-2(1H)-酮和4-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢-1H-吡唑并[3,4-c]吡啶-1-羰基)-6-氟-3,4-二氢喹啉-2(1H)-酮
向50mL圆底烧瓶中,加入6-氟-2-氧代-1,2,3,4-四氢喹啉-4-羧酸(市售,ChemBridge,200mg,0.96mmol,1.00当量)、6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(210mg,0.97mmol,1.10当量)、HOBT(195mg,1.44mmol,1.50当量)、EDCI(175mg,0.91mmol,1.50当量)、TEA(290mg,2.87mmol,3.00当量)和N,N-二甲基甲酰胺(5mL)。所得溶液在室温下搅拌2小时,然后加水(30mL)将反应淬灭。用乙酸乙酯(30mL×3)萃取所得溶液并合并有机层和在真空下浓缩,通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱:XBridge Shield RP18 OBD柱,5μm,19mm×250mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:11分钟内从20%B到40%B;254/220nm。
组分A,实施例43:将收集的组分冻干,得到7.7mg(2%)的4-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-2-羰基)-6-氟-3,4-二氢喹啉-2(1H)-酮,为灰白色固体。Rt2:9.48分钟。MS(ES,m/z)[M+H]+:408。(DMSO-d6,300MHz,ppm):δ10.11(s,1H),7.23-7.19(m,1H),7.06-6.99(m,1H),6.88-6.82(m,1H),6.59(s,2H),5.13-5.10(m,1H),4.23(s,2H),3.39-3.35(m,2H),2.94(s,3H),2.87-2.79(m,1H),2.68-2.62(m,1H),2.48-2.39(m,2H)。
组分B,实施例44:将收集的组分冻干,得到11.7mg(3%)的4-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢-1H-吡唑并[3,4-c]吡啶-1-羰基)-6-氟-3,4-二氢喹啉-2(1H)-酮,为白色固体。Rt1:8.33分钟,MS(ES,m/z)[M+H]+:408。(DMSO-d6,300MHz,ppm):δ10.10(s,1H),7.31-7.28(m,1H),7.07-7.02(m,1H),6.89-6.86(m,1H),5.88(s,2H),5.04-5.02(m,1H),4.55-4.41(m,1H),3.48-3.42(m,1H),3.37-3.32(m,1H),2.94(s,3H),2.85-2.79(m,1H),2.69-2.64(m,1H),2.49-2.45(m,2H)。
实施例45和46:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-异丙基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-异丙基-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:6-(丙-1-烯-2-基)喹啉-4-羧酸
向250mL圆底烧瓶中,加入6-溴喹啉-4-羧酸(1.0g,3.97mmol,1.00当量)、碳酸钾(1.65g,11.94mmol,3.00当量)、Pd(dppf)Cl2CH2Cl2(294mg,0.40mmol,0.10当量)、4,4,5,5-四甲基-2-(丙-1-烯-2-基)-1,3,2-二氧杂硼烷(1.08g,6.43mmol,1.50当量)、二恶烷(50mL)和水(5.0mL)。所得溶液在85℃油浴中搅拌过夜,冷却至室温后,将将固体滤掉。用水(50mL)稀释所得溶液,并用乙酸乙酯(50mL×2)萃取,合并水层。用盐酸(1mol/L)将溶液的pH值调至5-6,过滤收集固体。得到700mg(83%)的6-(丙-1-烯-2-基)喹啉-4-羧酸,为灰白色固体。MS(ES,m/z)[M+H]+:214。
步骤2:6-异丙基喹啉-4-羧酸
向500mL圆底烧瓶中,加入6-(丙-1-烯-2-基)喹啉-4-羧酸(700mg,3.28mmol,1.00当量)、甲醇(200mL)和钯碳(10%,700mg)。将烧瓶抽真空并用氮气吹扫3次,然后用氢气吹扫。混合物在室温氢气气氛(气球)中搅拌2小时,滤掉固体。将所得混合物在真空下浓缩,得到300mg(42%)6-(丙-2-基)-1,2,3,4-四氢喹啉-4-羧酸,为白色固体。MS(ES,m/z)[M+H]+:216。
步骤3:6-异丙基-1,2,3,4-四氢喹啉-4-羧酸
向100mL圆底烧瓶中,加入6-(丙-2-基)喹啉-4-羧酸(90mg,0.42mmol,1.00当量)、甲醇(15.0mL)、和二氧化铂(90mg,0.40mmol,0.95当量)。将烧瓶抽真空并用氮气吹扫3次,然后用氢气吹扫。混合物在室温(20℃)氢气气氛(气球)中搅拌2小时。将所得混合物在真空下浓缩,残余物溶解于10.0mL甲醇中。将残余物施加到具有MeCN/H2O(0-40%)的硅胶柱上。得到50mg(55%)的6-(丙烷-2-基)-1,2,3,-四氢喹啉-4-羧酸,为白色固体。MS(ES,m/z)[M+H]+:220。
步骤4:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-异丙基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-异丙基-1,2,3,4-四氢喹啉-4-基)甲酮
向100mL圆底烧瓶中,加入6-(丙-2-基)-1,2,3,4-四氢喹啉-4-羧酸(219mg,1.00mmol,1.00当量)、6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(216mg,1.00mmol,1.00当量)、1H-1,2,3-苯并三唑-1-醇(202mg,1.49mmol,1.50当量)、EDCI(287mg,1.50mmol,1.50当量)、TEA(505mg,4.99mmol,5.00当量)和N,N-二甲基甲酰胺(15mL)。所得溶液在20℃下搅拌2小时,然后加水(20mL)将反应淬灭。用乙酸乙酯(30mL×3)萃取所得溶液并合并有机层和用无水硫酸钠干燥,滤掉固体。将所得混合物在真空下浓缩,通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱,XBridge C18 OBD制备柱,10μm,19mm×250mm;流动相,水(0.1%FA)和ACN(ACN在9分钟内从20.0%达到40.0%);检测器,UV254nm。
组分A:将收集的组分冻干,得到11.1mg(3%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-异丙基-1,2,3,4-四氢喹啉-4-基)甲酮,为灰白色固体。Rt2:7.03分钟,MS(ES,m/z)[M+H]+:418。(DMSO-d6,400MHz,ppm):δ6.81(d,J=8.4Hz,1H),6.65-6.63(m,3H),6.45(d,J=8.4Hz,1H),5.85(s,1H),4.99-4.97(m,1H),4.23(s,2H),3.46-3.39(m,2H),3.26-3.21(m,1H),3.16-3.13(m,1H),2.97(s,3H),2.67-2.59(m,1H),2.47-2.41(m,2H),2.07-1.99(m,2H),1.06-1.05(m,6H)。
组分B:将收集的组分冻干,得到13.2mg(3%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1(6-异丙基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:6.52分钟,MS(ES,m/z)[M+H]+:418。(DMSO-d6,400MHz,ppm):δ6.81(d,J=8.4Hz,1H),6.66-6.65(m,1H),6.45(d,J=8.4Hz,1H),5.78(s,3H),4.91-4.88(m,1H),4.52(s,2H),3.45-3.38(m,2H),3.27-3.24(m,1H),3.16-3.11(m,1H),2.97(s,3H),2.67-2.59(m,1H),2.47-2.45(m,2H),2.07-1.99(m,2H),1.07-1.05(m,6H)。
实施例47和48:N-(4-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-2-羰基)-1,2,3,4-四氢喹啉-6-基)乙酰胺和N-(4-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢-1H-吡唑并[3,4-c]吡啶-1-羰基)-1,2,3,4-四氢喹啉-6-基)乙酰胺
步骤1:6-氨基喹啉-4-羧酸甲酯
向用CO的惰性气体吹扫并保持的50mL压力罐反应器(50atm)中,加入在甲醇(20mL)中的4-溴-6-硝基喹啉(2.0g,7.90mmol,1.00当量)溶液、TEA(4.0g,39.60mmol,5.00当量)和Pd(dppf)Cl2CH2Cl2(1.29g,1.58mmol,0.20当量)。所得溶液在70℃下搅拌24小时,将反应混合物用水浴冷却至20℃。将所得混合物在真空下浓缩,通过反相柱在以下条件下对粗产物进行纯化:柱,C18硅胶,120g,20-45μm,100A;流动相,含0.05%FA和ACN的水(15分钟内从5%至40%ACN);检测器,UV 220/254nm。得到322mg(20%)的6-氨基喹啉-4-羧酸甲酯,为黄色固体。MS(ES,m/z)[M+H]+:203。
步骤2:6-乙酰胺基喹啉-4-羧酸甲酯
向100mL圆底烧瓶中,加入在二氯甲烷(15mL)中的6-氨基喹啉-4-羧酸甲酯(350mg,1.73mmol,1.00当量)溶液、乙酸乙酰酯(195mg,1.91mmol,1.10当量)和吡啶(273mg,3.46mmol,2.00当量)。所得溶液在20℃下搅拌4小时,将所得混合物在真空下浓缩。通过反相柱在以下条件下对粗产物进行纯化:柱,C18硅胶,80g,20-45μm,100A;流动相,含0.05%FA和ACN的水(20分钟内从2%至40%ACN);检测器,UV 220/254nm。得到417mg(99%)的6-乙酰胺基喹啉-4-羧酸甲酯,为黄色固体。MS(ES,m/z)[M+H]+:245。
步骤3:6-乙酰胺基-1,2,3,4-四氢喹啉-4-羧酸甲酯
向50mL圆底烧瓶中,加入在甲醇(15mL)中的6-乙酰胺基喹啉-4-羧酸甲酯(392mg,1.60mmol,1.00当量)溶液和PtO2(196mg)。将烧瓶抽真空并用氮气吹扫3次,然后用氢气吹扫。混合物在20℃下在氢气气氛(气球)中搅拌1小时,然后加入PtO2(200mg)。所得溶液在搅拌下在20℃下继续反应1小时。滤掉固体,滤液在真空下浓缩。得到338mg(85%)的6-乙酰氨基-1,2,3,4-四氢喹啉-4-羧酸甲酯,为黄色油状物。MS(ES,m/z)[M+H]+:249。
步骤4:6-乙酰氨基-1,2,3,4-四氢喹啉-4-羧酸
向用氮气的惰性气体吹扫并保持的50mL圆底烧瓶中,加入在甲醇(6mL)中的6-乙酰胺基-1,2,3,4-四氢喹啉-4-羧酸甲酯(338mg,1.36mmol,1.00当量)溶液、水(6.0mL)和氢氧化钠(272mg,6.80mmol,5.0当量)。所得溶液在20℃下搅拌2小时,用盐酸(1.0mol/L)将溶液的pH值调至5-6,将所得混合物在真空下浓缩。通过反相柱在以下条件下对粗产物进行纯化:柱,C18硅胶,80g,20-45μm,100A;流动相,含0.05%FA和ACN的水(20分钟内从2%至20%ACN);检测器,UV 220/254nm。得到254mg(80%)6-乙酰氨基-1,2,3,4-四氢喹啉-4-羧酸,为棕色固体。MS(ES,m/z)[M+H]+:249。
步骤5:N-(4-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-2-羰基)-1,2,3,4-四氢喹啉-6-基)乙酰胺和N-(4-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢-1H-吡唑啉[3,4-c]吡啶-1-羰基)-1,2,3,4-四氢喹啉-6-基)乙酰胺
向50mL圆底烧瓶中,加入6-乙酰胺基-1,2,3,4-四氢喹啉-4-羧酸(16mg,0.07mmol,1.50当量)、6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(10mg,0.05mmol,1.00当量)、HOBt(9.3mg,0.07mmol,1.50当量)、EDCI(13mg,0.07mmol,1.50当量)、TEA(14mg,0.14mmol,3.00当量)和N,N-二甲基甲酰胺(10ml)。所得溶液在室温下搅拌2小时,然后加水(20mL)将反应淬灭。用二氯甲烷(20mL×3)萃取所得溶液并合并有机层和在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱,XBridge Prep OBDC18柱,19×250mm 5um;流动相,水(10mM NH4HCO3)和ACN(ACN在7分钟内从25.0%达到50.0%);检测器,UV 254nm。
组分A:将收集的组分冻干,得到4.2mg(21%)的N-(4-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢-2H-吡唑并[3,4]-c]吡啶-2-羰基)-1,2,3,4-四氢喹啉-6-基)乙酰胺,为粉红色固体。Rt2:6.48分钟,MS(ES,m/z)[M+H]+:433。(DMSO,400MHz,ppm):δ9.42(s,1H),7.42-7.13(m,1H),6.98(s,1H),6.64(s,1H),6.46-6.440(m,1H),5.67(s,1H),5.01(m,1H),4.25-4.24(m,2H),3.43-3.41(m,2H),3.31-3.28(m,2H),2.97(s,3H),2.50-2.46(m,2H),2.02-2.01(m,2H),1.90(s,3H)。
组分B:将收集的组分冻干,得到2.3mg(11.5%)的N-(4-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢-1H-吡唑并[3,4-c]吡啶-1-羰基)1,2,3,4-四氢喹啉-6-基)乙酰胺,为粉红色固体。Rt1:6.01分钟,MS(ES,m/z)[M+H]+:433。(DMSO,400MHz,ppm):δ9.43(s,1H),7.42-7.13(m,1H),6.92-6.92(s,1H),6.45-6.43(s,1H),5.81(s,1H),5.67(s,1H),4.93-4.90(m,1H),4.53(s,2H),3.43-3.40(m,2H),3.33-3.26(m,1H),3.25(m,1H),2.97(s,3H),2.54-2.34(m,2H),2.02-1.99(m,2H),1.90(s,3H)。
实施例49和50:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-苯基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-苯基-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:6-苯基喹啉-4-羧酸
向100mL圆底烧瓶中,加入6-溴喹啉-4-羧酸(500mg,1.98mmol,1.00当量)、碳酸钾(828mg,5.99mmol,3.00当量)、Pd(dppf)Cl2CH2Cl2(147mg,0.20mmol,0.10当量)、苯基硼酸(366mg,3.00mmol,1.50当量)、二恶烷(30mL)和水(3mL)。向其中引入N2,所得溶液在85℃在油浴中搅拌过夜。冷却至室温后,将固体滤掉。将所得混合物在真空下浓缩,残余物溶解于50.0mL水中,用乙酸乙酯(30mL×2)萃取所得溶液并合并水层。用盐酸(1mol/L)将溶液的pH值调至6,收集分离的固体。得到180mg(36%)的6-苯基喹啉-4-羧酸,为白色固体。MS(ES,m/z)[M+H]+:250。
步骤2:6-苯基-1,2,3,4-四氢喹啉-4-羧酸
向250mL圆底烧瓶中,加入6-苯基喹啉-4-羧酸(500mg,2.01mmol,1.00当量)、甲醇(90mL)、乙酸(20mL)和钯碳(10%,500mg)。将烧瓶抽真空并用氮气吹扫3次,然后用氢气吹扫,混合物在20℃下在氢气气氛(气球)中搅拌过夜。将所得混合物过滤并将滤液在真空下浓缩,得到100mg(20%)的6-苯基-1,2,3,4-四氢喹啉-4-羧酸,为黄色固体。MS(ES,m/z)[M+H]+:254。
步骤3:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-苯基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-苯基-1,2,3,4-四氢喹啉-4-基)甲酮
向40mL小瓶中,加入6-苯基-1,2,3,4-四氢喹啉-4-羧酸(120mg,0.47mmol,1.00当量)、1H-1,2,3-苯并三唑-1-醇(96mg,0.71mmol,1.50当量)、EDCI(138mg,0.72mmol,1.50当量)、TEA(144mg,1.42mmol,3.00当量)、N,N-二甲基甲酰胺(10.0mL)和6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(102mg,0.47mmol,1.00当量)。所得溶液在20℃下搅拌6小时,然后加水(20mL)将反应淬灭。用乙酸乙酯(30mL×3)萃取所得溶液并合并有机层和用无水硫酸钠干燥,滤掉固体,将所得混合物在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱,XSelect CSH Prep C18 OBD柱,5μm,19×150mm;流动相,水(0.1%FA)和ACN(ACN在7分钟内从35.0%达到70.0%);检测器,UV 254nm。
组分A:将收集的组分冻干,得到13.6mg(6%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-苯基-1,2,3,4-四氢喹啉-4-基)甲酮,为灰白色固体。Rt2:6.12分钟,MS(ES,m/z)[M+H]+:452。(DMSO,400MHz,ppm):δ7.45-7.43(m,2H),7.35-7.28(m,3H),7.19-7.17(m,2H),6.63-6.60(m,3H),6.10(s,1H),5.07-5.05(m,1H),4.26(s,2H),3.44-3.42(m,2H),3.29-3.23(m,2H),2.97(s,3H),2.44-2.40(m,2H),2.14-2.08(m,2H)。
组分B:将收集的组分冻干,得到32.5mg(15%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-苯基-1,2,3,4-四氢喹啉-4-基)甲酮,为灰白色固体。Rt1:5.50分钟,MS(ES,m/z)[M+H]+:452。(DMSO,400MHz,ppm):δ7.46-7.44(m,2H),7.34-7.31(m,2H),7.28-7.25(m,1H),7.19-7.16(m,2H),6.61-6.59(m,1H),6.07(s,1H),5.82(s,2H),4.99-4.97(m,1H),4.53(s,2H),3.46-3.42(m,1H),3.39-3.35(m,2H),3.22-3.20(m,1H),2.98(s,3H),2.44-2.41(m,2H),2.11-2.03(m,2H)。
实施例51、52、53和54:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮以及(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:2-((4-氟-2-甲基苯基氨基)亚甲基)丙二酸二乙酯
向500mL圆底烧瓶中,加入4-氟-2-甲基苯胺(25g,200mmol,1.00当量)、甲苯(30mL)和2-(乙氧基亚甲基)丙二酸1,3-二乙酯(65g,300mmol,1.50当量)。所得溶液在110℃下搅拌过夜,将混合物冷却至35℃。所得混合物在真空下浓缩,将残余物施加至具有乙酸乙酯/石油醚(1/10)的硅胶柱上。得到50g(85%)的2-((4-氟-2-甲基苯基氨基)亚甲基)丙二酸二乙酯,为粉红色固体。MS(ES,m/z)[M+H]+:295。
步骤2:6-氟-8-甲基-4-氧代-1,4-二氢喹啉-3-羧酸乙酯
向1000mL三颈圆底烧瓶中,加入1,3-二乙基2-[[(4-氟-2-甲基苯基)氨基]亚甲基]丙二酸酯(30g,101.59mmol,1.00当量)。随后加入苯氧基苯(500mL),所得溶液在240℃下搅拌1小时。冷却至室温后,加入正己烷使产物沉淀,过滤收集固体。得到21g(83%)的6-氟-8-甲基-4-氧代-1,4-二氢喹啉-3-羧酸乙酯,为灰色固体。MS(ES,m/z)[M+H]+:250。
步骤3:6-氟-8-甲基喹啉-4(1H)-酮
向500mL三颈圆底烧瓶中,加入6-氟-8-甲基-4-氧代-1,4-二氢喹啉-3-羧酸乙酯(500g,21g,84.26mmol,1.00当量)、乙烷-1,2-二醇(200mL)、氢氧化钠(17g,425.00mmol,5.00当量)和水(5mL)。所得溶液在190℃下搅拌2小时,冷却至室温后,将所得溶液用水(300mL)稀释。使用盐酸(3mol/L)将pH值调至5-6,过滤收集固体。得到14.5g(97%)的6-氟-8-甲基喹啉-4(1H)-酮,为白色固体。MS(ES,m/z)[M+H]+:178。
步骤4:4-溴-6-氟-8-甲基喹啉
向500mL圆底烧瓶中,加入6-氟-8-甲基-1,4-二氢喹啉-4-酮(14.5g,81.84mmol,1.00当量)和N,N-二甲基甲酰胺(150mL)。随后在0℃搅拌下逐滴添加PBr3(24g,88.66mmol,1.10当量)。所得溶液在室温下搅拌3小时,然后加水/冰(300mL)将反应淬灭。用氢氧化钠(20%)将pH值调至8-9。过滤收集固体,得到16g(81%)的4-溴-6-氟-8-甲基喹啉,为白色固体。MS(ES,m/z)[M+H]+:240。
步骤5:6-氟-8-甲基喹啉-4-羧酸甲酯
向用CO的惰性气体吹扫并保持的300mL压力罐反应器(50atm)中,加入4-溴-6-氟-8-甲基喹啉(16g,66.65mmol,1.00当量)、甲醇(100mL)、Pd(dppf)Cl2CH2Cl2(8g,9.79mmol,0.15当量)和TEA(20g,197.65mmol,3.00当量)。所得溶液在70℃下搅拌过夜,冷却至室温后,将所得混合物在真空下浓缩。将残余物施加至具有乙酸乙酯/石油醚(0-30%)的硅胶柱上。得到10g(68%)的6-氟-8-甲基喹啉-4-羧酸甲酯,为白色固体。MS(ES,m/z)[M+H]+:220。
步骤6:6-氟-8-甲基-1,2,3,4-四氢喹啉-4-羧酸甲酯
向250mL圆底烧瓶中,加入6-氟-8-甲基喹啉-4-羧酸甲酯(2g,9.75mmol,1.00当量)、甲醇(50mL)和PtO2(1g)。向其中引入氢气,所得溶液在室温下搅拌1小时,滤掉固体。将所得混合物在真空下浓缩。得到1.5g(74%)6-氟-8-甲基-1,2,3,4-四氢喹啉-4-羧酸甲酯,为黄色油状物。MS(ES,m/z)[M+H]+:222。
步骤7:6-氟-8-甲基-1,2,3,4-四氢喹啉-4-羧酸
向250mL圆底烧瓶中,加入6-氟-8-甲基-1,2,3,4-四氢喹啉-4-羧酸甲酯(1.5g,6.72mmol,1.00当量)、甲醇(80mL)和在水(40mL)中的氢氧化钠(800mg,20.00mmol,3.00当量)溶液。所得溶液在室温下搅拌过夜,将所得混合物在真空下浓缩。用乙酸乙酯(40mL×2)萃取所得溶液并合并水层。使用盐酸(3mol/L)将pH值调至5-6。用乙酸乙酯(50mL×3)萃取所得溶液并合并有机层,将所得混合物在真空下浓缩。得到1.3g(92%)的6-氟-8-甲基-1,2,3,4-四氢喹啉-4-羧酸,为黄色固体。MS(ES,m/z)[M+H]+:208。
步骤8:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
向50mL圆底烧瓶中,加入6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(115mg,0.53mmol,1.10当量)、6-氟-8-甲基-1,2,3,4-四氢喹啉-4-羧酸(100mg,0.48mmol,1.00当量)、HOBt(100mg,0.74mmol,1.50当量)、EDCI(140mg,0.73mmol,1.50当量)、TEA(145mg,1.43mmol,3.00当量)和N,N-二甲基甲酰胺(5mL)。所得溶液在室温下搅拌2小时,然后加水(30mL)将反应淬灭。用乙酸乙酯(30mL×3)萃取所得溶液,合并有机层并在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱:XSelect CSH PrepC18 OBD柱,5μm,19mm×250mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:8分钟内从25%B到54.6%B;254nm。
组分A,实施例43:将收集的组分冻干,得到4.1mg(2%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为灰白色固体。Rt2:7.23分钟,MS(ES,m/z)[M+H]+:408。(DMSO-d6,400MHz,ppm):δ6.78-6.73(m,1H),6.65(s,2H),6.56-6.53(m,1H),5.15(s,1H),5.01-4.98(m,1H),4.24(s,2H),3.45-3.40(m,2H),3.28-3.21(m,2H),2.96(s,3H),2.49-2.46(m,2H),2.11-1.98(m,5H)。
组分B,实施例52:将收集的组分冻干,得到14.6mg(7%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为灰白色固体。Rt1:6.27分钟,MS(ES,m/z)[M+H]+:408。(DMSO-d6,300MHz,ppm):δ6.75-6.71(m,1H),6.58-6.54(m,1H),5.80(s,2H),5.11(s,1H),4.93-4.89(m,1H),4.53(s,2H),3.49-3.36(m,2H),3.23-3.19(m,2H),2.96(s,3H),2.49-2.45(m,2H),2.07-1.96(m,5H)。
步骤9:(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
通过Prep-HPLC在以下条件下分离出(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮(130mg,0.32mmol,1.00当量),柱:CHIRAL ART Cellulose-SB S-5um,2×25cm,5um;流动相A:Hex--HPLC,流动相B:EtOH--HPLC;流速:20mL/min;梯度:13分钟内从50B到50B;220/254nm。
对映异构体A,实施例53:得到49.6mg(38%)的(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c[吡啶-2-基](6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:11.39分钟,MS(ES,m/z)[M+H]+:408。(DMSO-d6,400MHz,ppm):δ6.76-6.73(m,1H),6.65(s,2H),6.56-6.53(m,1H),5.15(s,1H),5.01-4.98(m,1H),4.24(s,2H),3.47-3.41(m,2H),3.29-3.22(m,2H),2.97(s,3H),2.49-2.46(m,2H),2.12-1.90(m,5H)。
对映异构体B,实施例54:得到43.6mg(34%)的(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:9.81分钟,MS(ES,m/z)[M+H]+:408。(DMSO-d6,400MHz,ppm):δ6.76-6.73(m,1H),6.64(s,2H),6.56-6.53(m,1H),5.15(s,1H),5.01-4.98(m,1H),4.24(s,2H),3.47-3.41(m,2H),3.29-3.21(m,2H),2.97(s,3H),2.49-2.46(m,2H),2.11-1.95(m,5H)。
实施例55和56:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:8-甲基-6-乙烯基喹啉-4(1H)-酮
向1L圆底烧瓶中,加入6-溴-8-甲基-1,4-二氢喹啉-4-酮(11.8g,49.56mmol,1.00当量)、2-乙烯基-4,4,5,5-四甲基-1,3,2-二氧杂硼烷(15.4g,99.99mmol,2.00当量)、Pd(dppf)Cl2(4.1g,5.60mmol,0.10当量)、碳酸钾(20.7g,3.00当量)、二恶英(dioxone)(600mL)和水(60mL)。所得溶液在80℃下搅拌15小时,冷却至室温后,将残余物施加到具有二氯甲烷/甲醇(10:1)的硅胶柱上。得到5.3g(58%)的8-甲基-6-乙烯基喹啉-4(1H)-酮,为褐色固体。MS(ES,m/z)[M+H]+:186。
步骤2:4-溴-8-甲基-6-乙烯基喹啉
向250mL的圆底烧瓶中,加入8-甲基-6-乙烯基喹啉-4(1H)-酮(3.2g,17.28mmol,1.00当量)、N,N-二甲基甲酰胺(50mL)和三溴化磷(5.6g,20.69mmol,1.20当量)。所得溶液在室温下搅拌15小时,然后加水/冰(100mL)将反应淬灭。用氢氧化钠(6mol/L)将溶液的pH值调至9,过滤收集固体。得到3.5g(87%)的4-溴-8-甲基-6-乙烯基喹啉,为白色固体。MS(ES,m/z)[M+H]+:248。
步骤3:8-甲基-6-乙烯基喹啉-4-羧酸甲酯
向50mL压力罐反应器(CO,60atm)中,加入4-溴-8-甲基-6-乙烯基喹啉(1g,4.27mmol,1.00当量)、Pd(dppf)Cl2CH2Cl2(0.66g,0.20当量)、TEA(2.02g,5.00当量)和甲醇(20mL)。所得溶液在室温下搅拌15小时,将残余物施加到具有乙酸乙酯/己烷(1:3)的硅胶柱上。得到600mg(62%)的8-甲基-6-乙烯基喹啉-4-羧酸甲酯,为黄色固体。MS(ES,m/z)[M+H]+:228。
步骤4:6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-羧酸甲酯
向100mL圆底烧瓶中,加入6-乙烯基-8-甲基喹啉4-羧酸甲酯(700mg,3.08mmol,1.00当量)、甲醇(30mL)和钯碳(10%,350mg)。所得溶液在室温下搅拌15小时,将烧瓶抽真空并用氮气吹扫3次,然后用氢气吹扫。混合物在室温下在氢气气氛(气球)中搅拌2小时,滤掉固体,滤液在真空下浓缩。得到500mg(70%)的6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-羧酸甲酯,为黄色油状物。MS(ES,m/z)[M+H]+:234。
步骤5:6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-羧酸钠
向100mL圆底烧瓶中,加入6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-羧酸甲酯(360mg,1.54mmol,1.00当量)、甲醇(30mL)、水(15mL)和氢氧化钠(185mg,4.64mmol,3.00当量)。所得溶液在室温下搅拌15小时,通过真空蒸馏除去反应液。得到200mg(54%)的6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-羧酸钠,为黄色固体。MS(ES,m/z)[M+H]+:242。
步骤6:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
向100mL圆底烧瓶中,加入6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-羧酸钠(150mg,0.62mmol,1.00当量)、6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(148mg,0.68mmol,1.10当量)、HATU(353mg,0.93mmol,1.50当量)、DIEA(340mg,2.63mmol,129.00当量)和N,N-二甲基甲酰胺(10mL)。所得溶液在室温下搅拌2小时,然后加水(50mL)将反应淬灭。用乙酸乙酯(50mL×3)萃取所得溶液并合并有机层和在真空下浓缩。通过反相柱在以下条件下对粗产物进行纯化:柱:XBridge Shield RP18 OBD柱,30×150mm,5um;流动相A:水(0.1%FA);流动相B:ACN;流速:60mL/min;梯度:9分钟内从10%B到50%B;254.220nm。
组分A:将收集的组分冻干,得到5mg(2%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7四氢吡唑并[3,4-c]吡啶-2-基)(6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:8.45分钟,MS(ES,m/z)[M+H]+:418。(DMSO-d6,300MHz,ppm):δ6.70(s,1H),6.63(s,2H),6.49(s,1H),5.04-5.00(m,2H),4.24(s,2H),3.44-3.40(m,2H),3.25-3.23(m,2H),2.97(s,3H),2.47-2.45(m,2H),2.38-2.30(m,2H),2.09-1.98(m,5H),1.07-1.02(m,3H)。
组分B:将收集的组分冻干,得到10.3mg(4%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1基)(6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:6.67分钟,MS(ES,m/z)[M+H]+:418。(DMSO-d6,300MHz,ppm):δ6.73(s,1H),6.54(s,1H),5.80(s,3H),4.95-4.92(m,1H),4.52(s,2H),3.44-3.41(m,2H),3.32-3.31(m,1H),3.25-3.22(m,1H),2.96(s,3H),2.47-2.45(m,2H),2.39-2.34(m,2H),2.05-1.97(m,5H),1.08-1.03(m,3H)。
实施例57、58、59和60:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮以及(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮和(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:8-氯喹啉-4-羧酸甲酯
向用CO的惰性气体吹扫并保持的250mL压力罐反应器(50atm)中,加入4-溴-8-氯喹啉(4g,16.49mmol,1.00当量)、Pd(dppf)Cl2CH2Cl2(2g,2.45mmol,0.15当量)、甲醇(70mL)和TEA(5g,49.50mmol,3.00当量)。所得溶液在70℃下搅拌38小时,将反应冷却至室温。将所得混合物在真空下浓缩,将残余物施加到具有乙酸乙酯/石油醚(0-30%,30分钟)的硅胶柱上。得到3.5g(96%)的8-氯喹啉-4-羧酸甲酯,为黄色固体。MS(ES,m/z)[M+H]+:222。
步骤2:8-氯-1,2,3,4-四氢喹啉-4-羧酸甲酯
向100mL圆底烧瓶中,加入8-氯喹啉-4-羧酸甲酯(400mg,1.80mmol,1.00当量)、甲醇(20mL)和PtO2(200mg)。向其中引入氢气,所得溶液在室温下搅拌1小时。滤掉固体,将所得混合物在真空下浓缩,得到320mg(79%)的8-氯-1,2,3,4-四氢喹啉-4-羧酸甲酯,为白色固体。MS(ES,m/z)[M+H]+:226。
步骤3:8-氯-1,2,3,4-四氢喹啉-4-羧酸
向100mL圆底烧瓶中,加入8-氯-1,2,3,4-四氢喹啉-4-羧酸甲酯(320mg,1.42mmol,1.00当量)、甲醇(15mL)和在水(10mL)中的氢氧化钠(175mg,4.38mmol,3.00当量)溶液。所得溶液在室温下搅拌过夜,将所得混合物在真空下浓缩。用H2O(20mL)稀释所得溶液,用乙酸乙酯(30mL×2)萃取所得溶液并合并水层。用盐酸(6mol/L)将溶液的pH值调至5-6。用乙酸乙酯(40mL×3)萃取所得溶液并合并有机层。将所得混合物在真空下浓缩,得到220mg(73%)的8-氯-1,2,3,4-四氢喹啉-4-羧酸,为黄色固体。MS(ES,m/z)[M+H]+:212。
步骤4:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮
向50mL圆底烧瓶中,加入8-氯-1,2,3,4-四氢喹啉-4-羧酸(100mg,0.47mmol,1.00当量)、6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(150mg,0.69mmol,1.50当量)、HOBt(95mg,0.70mmol,1.50当量)、EDCI(135mg,0.70mmol,1.50当量)、TEA(145mg,1.43mmol,3.00当量)和N,N-二甲基甲酰胺(5mL)。所得溶液在室温下搅拌2小时,然后加水(30mL)将反应淬灭。用乙酸乙酯(30mL×3)萃取所得溶液并合并有机层,所得混合物用盐水(100mL×2)洗涤。混合物经无水硫酸钠干燥,滤掉固体。将所得混合物在真空下浓缩,通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱:XBridge C18OBD Prep柱;19mm×250mm;流动相A:水(10mM NH4HCO3),流动相B:ACN;流速:20mL/min;梯度:7分钟内从30%B到50%B;254nm。
组分A:将收集的组分冻干,得到10.5mg(5%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮,为灰白色固体。Rt2:6.48分钟,MS(ES,m/z)[M+H]+:410。(DMSO-d6,400MHz,ppm):δ7.12(d,J=9.2Hz,1H),6.82(d,J=7.2Hz,1H),6.64(s,2H),6.45-6.41(m,1H),5.77(s,1H),5.07-5.04(m,1H),4.28-4.20(m,2H),3.43-3.40(m,2H),3.36-3.34(m,1H),3.29-3.27(m,1H),2.97(s,3H),2.49-2.45(m,2H),2.14-2.11(m,1H),2.07-1.98(m,1H)。
组分B:将收集的组分冻干,得到15.4mg(8%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮,为灰白色固体。Rt1:5.61分钟,MS(ES,m/z)[M+H]+:410。(DMSO-d6,400MHz,ppm):δ7.10(d,J=9.2Hz,1H),6.82(d,J=7.6Hz,1H),6.45-6.41(m,1H),5.81(s,2H),5.74(s,1H),4.97-4.94(m,1H),4.57-4.51(m,2H),3.47-3.37(m,3H),3.31-3.28(m,1H),2.96(s,3H),2.49-2.47(m,2H),2.12-2.07(m,1H),2.03-1.98(m,1H)。
步骤5:(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮和(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮
通过制备-手性-HPLC在以下条件下分离(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-甲基)甲酮(7mg,0.02mmol,1.00当量),柱:CHIRALPAK IG,20×250mm,5μm;流动相A:Hex--HPLC,流动相B:EtOH--HPLC;流速:20mL/min;梯度:23分钟内从50B到50B;254/220nm。
对映异构体A,实施例59:得到2.9mg(41%)的(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。RT2:18.74分钟,MS(ES,m/z)[M+H]+:410。(DMSO-d6,400MHz,ppm):δ7.13-7.11(m,1H),6.83-6.81(m,1H),6.65(s,2H),6.45-6.41(m,1H),5.79(s,1H),5.08-5.04(m,1H),4.24(s,2H),3.43-3.37(m,2H),3.28-3.26(m,2H),2.97(s,3H),2.48-2.42(m,2H),2.14-2.04(m,2H)。
对映异构体B,实施例60:得到2.5mg(36%)的(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。RT1:14.75分钟,MS(ES,m/z)[M+H]+:410。(DMSO-d6,400MHz,ppm):δ7.13-7.11(m,1H),6.83-6.82(m,1H),6.65(s,2H),6.45-6.41(m,1H),5.79(s,1H),5.08-5.04(m,1H),4.24(s,2H),3.43-3.40(m,2H),3.28-3.26(m,2H),2.97(s,3H),2.48-2.45(m,2H),2.14-1.96(m,2H)。
实施例61、62、63和64:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮以及(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮和(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:4-溴-8-甲氧基喹啉
向100mL圆底烧瓶中,加入8-甲氧基喹啉-4-醇(2g,11.42mmol,1.00当量)和N,N-二甲基甲酰胺(20mL)。之后在室温搅拌下逐滴加入PBr3(3.4g,12.56mmol,1.10当量)。所得溶液在室温下搅拌1小时。然后加水(70mL)将反应淬灭。用氢氧化钾将溶液的pH值调至7-8。用乙酸乙酯(80mL×3)萃取所得溶液并合并有机层和在真空下浓缩。得到2g(74%)的4-溴-8-甲氧基喹啉,为灰色固体。MS(ES,m/z)[M+H]+:238。
步骤2:8-甲氧基喹啉-4-羧酸甲酯
向用CO的惰性气体吹扫并保持的50mL压力罐反应器(50atm)中,加入4-溴-8-甲氧基喹啉(1g,4.20mmol,1.00当量)、Pd(dppf)Cl2CH2Cl2(0.5g,0.15当量)、TEA(1.3g,12.6mmol,3.00当量)和甲醇(15ml)。所得溶液在70℃下搅拌36小时,冷却至室温后,将所得混合物在真空下浓缩。将残余物施加到具有乙酸乙酯/石油醚(0-40%)的硅胶柱上。得到800mg(88%)的8-甲氧基喹啉-4-羧酸甲酯,为红色固体。MS(ES,m/z)[M+H]+:218。
步骤3:8-甲氧基-1,2,3,4-四氢喹啉-4-羧酸甲酯
向50mL圆底烧瓶中,加入8-甲氧基喹啉-4-羧酸甲酯(400mg,1.84mmol,1.00当量)、甲醇(20mL)和PtO2(200mg)。向其中引入氢气,所得溶液在室温下搅拌2小时。滤掉固体,将所得混合物在真空下浓缩。得到360mg(88%)的8-甲氧基-1,2,3,4-四氢喹啉-4-羧酸甲酯,为红色固体。MS(ES,m/z)[M+H]+:222。
步骤4:8-甲氧基-1,2,3,4-四氢喹啉-4-羧酸
向50mL圆底烧瓶中,加入8-甲氧基-1,2,3,4-四氢喹啉-4-羧酸甲酯(360mg,1.63mmol,1.00当量)、甲醇(10mL)和在水(10mL)中的氢氧化钠(200mg,5.00mmol,3.00当量)溶液。所得溶液在室温下搅拌过夜,将所得混合物在真空下浓缩。用乙酸乙酯(10mL×2)萃取所得溶液并合并水层。用盐酸(6mol/L)将溶液的pH值调节至5-6。用乙酸乙酯(20mL×3)萃取所得溶液并合并有机层,将所得混合物在真空下浓缩,得到200mg(59%)的8-甲氧基-1,2,3,4-四氢喹啉-4-羧酸,为白色固体。MS(ES,m/z)[M+H]+:208。
步骤5:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮
向50mL圆底烧瓶中,加入8-甲氧基-1,2,3,4-四氢喹啉-4-羧酸(100mg,0.48mmol,1.00当量)、6-甲基磺酰基-45,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(160mg,0.74mmol,1.50当量)、HOBt(97mg,0.72mmol,1.50当量)、EDCI(140mg,0.73mmol,1.50当量)、TEA(150mg,1.48mmol,3.00当量)和N,N-二甲基甲酰胺(5mL)。所得溶液在室温下搅拌2小时,然后加入水(30mL)将反应淬灭。用乙酸乙酯(30mL×3)萃取所得溶液并合并有机层,所得混合物用盐水(100mL×2)洗涤,混合物经无水硫酸钠干燥,滤掉固体,将所得混合物在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱:XSelect CSH Prep C18 OBD柱,5μm,19mm×250mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:7分钟内从15%B到55%B;254nm。
组分A:将收集的组分冻干,得到11.1mg(6%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-酰基)(8-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮,为黄色固体。Rt2:6.9分钟,MS(ES,m/z)[M+H]+:406。(DMSO-d6,400MHz,ppm):δ6.69-6.62(m,3H),6.46-6.37(m,2H),5.21(s,1H),5.06-5.03(m,1H),4.28-4.20(m,2H),3.76(s,3H),3.43-3.40(m,2H),3.28-3.22(m,2H),2.97(s,3H),2.49-2.45(m,2H),2.09-2.01(m,2H)。
组分B:将收集的组分冻干,得到20mg(10%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-酰基)(8-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮,为黄色固体。Rt1:6.12分钟,MS(ES,m/z)[M+H]+:406。(DMSO-d6,400MHz,ppm):δ6.74-6.71(m,1H),6.55-6.51(m,2H),6.00-6.50(m,3H),4.98-4.95(m,1H),4.57-4.85(m,2H),3.78(s,3H),3.45-3.36(m,3H),3.29-3.21(m,1H),2.97(s,3H),2.49-2.47(m,2H),2.10-1.98(m,2H)。
步骤6:(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮和(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮
通过制备-手性-HPLC按照以下条件下分离出(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲氧基-1,2,3,4-四氢喹啉-4-甲基)甲酮(10mg,0.02mmol,1.00当量),柱:CHIRAL ART Cellulose-SB S-5um,2×25cm,5um;流动相A:Hex--HPLC,流动相B:EtOH--HPLC;流速:20mL/min;梯度:25分钟内从50B到50B;220/254nm。
对映异构体A,实施例63:得到3.4mg(34%)的(S*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:22.96分钟,MS(ES,m/z)[M+H]+:406。(DMSO-d6,400MHz,ppm):δ6.68-6.66(m,1H),6.63(s,2H),6.48-6.37(m,2H),5.21(s,1H),5.06-5.03(m,1H),4.24(s,2H),3.76(s,3H),3.43-3.40(m,2H),3.31-3.28(m,2H),2.97(s,3H),2.47-2.45(m,2H),2.09-1.97(m,2H)。
对映异构体B,实施例64:得到3.5mg(35%)的(R*)-(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲氧基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:17.57分钟,MS(ES,m/z)[M+H]+:406。(DMSO-d6,400MHz,ppm):δ6.68-6.67(m,1H),6.63(s,2H),6.46-6.37(m,2H),5.21(s,1H),5.06-5.03(m,1H),4.24(s,2H),3.76(s,3H),3.43-3.40(m,2H),3.30-3.28(m,2H),2.97(s,3H),2.47-2.45(m,2H),2.09-1.97(m,2H)。
实施例65和66:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-乙基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-乙基-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:2-((2-乙基苯基氨基)亚甲基)丙二酸二乙酯
向500mL圆底烧瓶中,加入2-乙基苯胺(25g,200mmol,1.00当量)、甲苯(30mL)和1,3-二乙基2-(乙氧基亚甲基)丙二酸酯(65g,300mmol,1.50当量)。所得溶液在110℃下搅拌过夜,将混合物冷却至25℃,将得到的混合物在真空下浓缩。将残余物施加到具有乙酸乙酯/石油醚(1/10)是硅胶柱上,得到50g(85%)的2-((2-乙基苯基氨基)亚甲基)丙二酸二乙酯,为黄色固体。MS(ES,m/z)[M+H]+:292。
步骤2:8-乙基-4-氧代-1,4-二氢喹啉-3-羧酸乙酯
向1000mL三颈圆底烧瓶中加入Ph2O(500g),之后在250℃下分批加入1,3-二乙基2-[[(2-乙基苯基)氨基]亚甲基]丙二酸(25g,85.81mmol,1.00当量)。所得溶液在250℃下搅拌4小时,用水浴将反应混合物冷却至20℃,得到16g(76%)的8-乙基-4-氧代-1,4-二氢喹啉-3-羧酸乙酯,为棕色固体。MS(ES,m/z)[M+H]+:246。
步骤3:8-乙基喹啉-4(1H)-酮
向500mL三颈圆底烧瓶中,加入8-乙基-4-氧代-1,4-二氢喹啉-3-羧酸乙酯(16g,65.23mmol,1.00当量)、氢氧化钠(13.06g,326.50mmol,5.00当量)、水(5mL)和HOCH2CH2OH(240mL)。所得溶液在160℃下搅拌4小时,用水浴将反应混合物冷却至25℃。用H2O(100mL)稀释所得溶液,将残余物施加到具有二氯甲烷/甲醇(20/1)的硅胶柱上,得到10g(89%)的8-乙基喹啉-4(1H)-酮,为黄色油状物。MS(ES,m/z)[M+H]+:174。
步骤4:4-溴-8-乙基喹啉
向250mL圆底烧瓶中,加入8-乙基-1,4-二氢喹啉-4-酮(10g,57.73mmol,1.00当量)、N,N-二甲基甲酰胺(150mL)和PBr3(47g,173.63mmol,3.00当量)。所得溶液在25℃下搅拌过夜,然后加水(200mL)将反应淬灭。用氢氧化钾将溶液的pH值调节至8,用二氯甲烷(400mL×4)萃取所得溶液并合并有机层,所得混合物用氯化钠(100mL×8)洗涤,将得到的混合物在真空下浓缩,得到9g(66%)的4-溴-8-乙基喹啉,为棕色油状物。MS(ES,m/z)[M+H]+:236。
步骤5:8-乙基喹啉-4-羧酸甲酯
向用CO的惰性气体吹扫并保持的50mL压力罐反应器(60atm)中,加入4-溴-8-乙基喹啉(2g,8.47mmol,1.00当量)、TEA(2.58g,25.50mmol,3.00当量)、甲醇(30mL)和Pd(dppf)Cl2CH2Cl2(1.04g,1.27mmol,0.15当量)。所得溶液在120℃下搅拌过夜,将混合物冷却至25℃。将得到的混合物在真空下浓缩,将残余物施加到具有乙酸乙酯/石油醚(1/10)的硅胶柱上,得到1.3g(71%)的8-乙基喹啉-4-羧酸甲酯,为黄色油状物。MS(ES,m/z)[M+H]+:216。
步骤6:8-乙基-1,2,3,4-四氢喹啉-4-羧酸甲酯
向100mL圆底烧瓶中,加入8-乙基喹啉-4-羧酸甲酯(1.3g,6.04mmol,1.00当量)、甲醇(20mL)、AcOH(2.5mL)和PtO2(1.3g)。将烧瓶抽真空并用氮气吹扫3次,然后用氢气吹扫。混合物在室温下在氢气气氛(气球)中搅拌2小时,滤掉固体。将得到的混合物在真空下浓缩,得到1.3g(98%)的8-乙基-1,2,3,4-四氢喹啉-4-羧酸甲酯,为黄色油状物。MS(ES,m/z)[M+H]+:220。
步骤7:8-乙基-1,2,3,4-四氢喹啉-4-羧酸
向250mL圆底烧瓶中,加入8-乙基-1,2,3,4-四氢喹啉-4-羧酸甲酯(1.57g,7.16mmol,1.00当量)、水(5mL)、甲醇(40mL)和氢氧化钠(1.43g,35.75mmol,5.00当量)。所得溶液在25℃下搅拌过夜,用H2O(40mL)稀释所得溶液。所得混合物用DCM(100mL×3)洗涤,用盐酸(1mol/L)将溶液的pH值调节至3-4。用二氯甲烷(150mL×4)萃取所得溶液并合并有机层和在真空下浓缩。得到1.1g(75%)的8-乙基-1,2,3,4-四氢喹啉-4-羧酸,为黄色固体状。MS(ES,m/z)[M+H]+:206。
步骤8:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-乙基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-乙基-1,2,3,4-四氢喹啉-4-基)甲酮
向100mL圆底烧瓶中,加入8-乙基喹啉-4-羧酸(150mg,0.75mmol,1.00当量)、6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(238mg,1.10mmol,1.50当量)、HOBt(149mg,1.10mmol,1.50当量)、EDCI(210mg,1.10mmol,1.50当量)、N,N-二甲基甲酰胺(8mL)和TEA(220mg,2.17mmol,3.00当量)。所得溶液在25℃下搅拌3小时,用DCM(80mL)稀释反应混合物,用H2O(50mL×3)和盐水(50mL×3)洗涤并用Na2SO4干燥。过滤后,将滤液减压浓缩,使用Prep-HPLC在以下条件下对粗产物进行纯化(分析HPLC-SHIMADZU),柱:XSelect CSHPrep C18 OBD柱,5μm,19mm×250mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:7分钟内从35%B到65%B;254nm。
组分A:将收集的组分冻干,得到26.7mg(5%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-乙基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:5.93分钟,MS(ES,m/z)[M+H]+:404。(300MHz,DMSO-d6,ppm):δ6.83(d,J=6.9Hz,1H),6.67-6.62(m,3H),6.42-6.37(m,1H),5.29(s,1H),5.06-5.03(m,1H),4.24(s,2H),3.44-3.10(m,4H),3.20(s,3H),2.50-2.37(m,4H),2.10-1.99(m,2H),1.16-1.11(m,3H)。
组分B:将收集的组分冻干,得到41mg(14%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1酰基)(8-乙基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:5.28分钟,MS(ES,m/z)[M+H]+:404。(300MHz,DMSO-d6,ppm):δ6.82(d,J=6.9Hz,1H),6.68-6.66(m,1H),6.41-6.36(m,1H),5.77(m,2H),5.26(s,1H),4.97-4.93(m,1H),4.52(s,2H),3.47-3.10(m,4H),2.95(s,3H),2.50-2.37(m,4H),2.07-1.99(m,2H),1.15-1.10(m,3H)。
实施例67和68:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-(三氟甲基)-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-(三氟甲基)-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:4-溴-8-(三氟甲基)喹啉
向250mL圆底烧瓶中,加入8-(三氟甲基)喹啉-4-醇(2g,9.38mmol,1.00当量)、N,N-二甲基甲酰胺(30mL)和PBr3(2.8g,10.34mmol,1.10当量)。所得溶液在室温下搅拌1小时,然后加水(200mL)将反应淬灭。用饱和氢氧化钾水溶液将溶液的pH值调节至8。过滤收集固体,得到2.1g(81%)的4-溴-8-(三氟甲基)喹啉,为灰白色固体。MS(ES,m/z)[M+H]+:276。
步骤2:8-(三氟甲基)喹啉-4-羧酸甲酯
向CO的惰性气体吹扫并保持的50mL压力罐反应器(60atm)中,加入4-溴8-(三氟甲基)喹啉(1g,3.62mmol,1.00当量)、Pd(dppf)Cl2CH2Cl2(445mg,0.54mmol,0.15当量)、TEA(1.1g,10.89mmol,3.00当量)和甲醇(15mL)。所得溶液在室温下搅拌过夜,将得到的混合物在真空下浓缩。将残余物施加到具有乙酸乙酯/石油醚(0-30%,40分钟)的硅胶柱上,得到820mg(89%)的8-(三氟甲基)喹啉-4-羧酸甲酯,为白色固体。MS(ES,m/z)[M+H]+:256。
步骤3:8-(三氟甲基)-1,2,3,4-四氢喹啉-4-羧酸甲酯
向50mL圆底烧瓶中,加入8-(三氟甲基)喹啉-4-羧酸甲酯(350mg,1.37mmol,1.00当量)、甲醇(15mL)和二氧化铂(200mg,0.88mmol,0.64当量)。所得溶液在室温下搅拌1小时,滤掉固体。将得到的混合物在真空下浓缩,得到300mg(84%)的8-(三氟甲基)-1,2,3,4-四氢喹啉-4-羧酸甲酯,为黄色固体。MS(ES,m/z)[M+H]+:260。
步骤4:8-(三氟甲基)-1,2,3,4-四氢喹啉-4-羧酸
向100mL的圆底烧瓶中,加入8-(三氟甲基)-1,2,3,4-四氢喹啉-4-羧酸甲酯(300mg,1.16mmol,1.00当量)、甲醇(20mL)和在水(10mL)中的氢氧化钠(140mg,3.50mmol,3.00当量)溶液。所得溶液在室温下搅拌过夜,将得到的混合物在真空下浓缩,用乙酸乙酯(10mL×2)萃取所得溶液并合并水层,用盐酸(3mol/L)将pH值调节至5-6。用乙酸乙酯(20mL×3)萃取所得溶液并合并有机层,将得到的混合物在真空下浓缩,得到280mg(99%)的8-(三氟甲基)-1,2,3,4-四氢喹啉-4-羧酸,为黄色固体。MS(ES,m/z)[M+H]+:246。
步骤5:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-(三氟甲基)-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-(三氟甲基)-1,2,3,4-四氢喹啉-4-基)甲酮
向50mL圆底烧瓶中,加入8-(三氟甲基)-1,2,3,4-四氢喹啉-4-羧酸(100mg,0.41mmol,1.00当量)、6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(135mg,0.62mmol,1.50当量)、HOBt(85mg,0.63mmol,1.50当量)、EDCI(120mg,0.63mmol,1.50当量)、TEA(125mg,1.24mmol,3.00当量)和N,N-二甲基甲酰胺(3mL)。所得溶液在室温下搅拌2小时,然后加水(30mL)将反应淬灭。用乙酸乙酯(30mL×3)萃取所得溶液并合并有机层,所得混合物用盐水(100mL×2)洗涤,混合物经无水硫酸钠干燥,滤掉固体,将得到的混合物在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化:柱:XSelect CSH PrepC18 OBD柱,5μm,19mm×250mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:7分钟内从40%B到75%B;254nm。
组分A:将收集的组分冻干,得到16.7mg(9%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-(三氟甲基)-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:5.60分钟,MS(ES,m/z)[M+H]+:444。(DMSO-d6,400MHz,ppm):δ7.28(d,J=7.2Hz,1H),7.09(d,J=7.6Hz,1H),6.66(s,2H),6.58-6.51(m,1H),5.90(s,1H),5.07-5.04(m,1H),4.24(s,2H),3.43-3.40(m,2H),3.37-3.36(m,1H),3.29-3.24(m,1H),2.98(s,3H),2.48-2.45(m,2H),2.15-2.02(m,2H)。
组分B:将收集的组分冻干,得到61.8mg(34%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1酰基)(8-(三氟甲基)-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:5.08分钟,MS(ES,m/z)[M+H]+:444。(DMSO-d6,400MHz,ppm):δ7.27(d,J=6.8Hz,1H),7.09(d,J=7.6Hz,1H),6.54-6.51(m,1H),5.89(s,1H),5.84(s,2H),4.97-4.94(m,1H),4.52(s,2H),3.47-3.37(m,2H),3.32-3.28(m,2H),2.97(s,3H),2.48-2.46(m,2H),2.14-2.00(m,2H)。
实施例69和70:(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)((S*)-6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)((R*)-6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
向100mL圆底烧瓶中,加入6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-羧酸(300mg,1.37mmol,1.00equiv)、6-甲基磺酰基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(326mg,1.51mmol,1.10当量)、EDCI(403mg,2.10mmol,1.50当量)、HOBt(284mg,2.10mmol,1.50当量)、N,N-二甲基甲酰胺(10mL)和TEA(692mg,6.84mmol,5.00当量)。所得溶液在室温下搅拌2小时,然后加水(30mL)将反应淬灭。用乙酸乙酯(50mL×2)萃取所得溶液并合并有机层和在真空下浓缩。使用Prep-HPLC在以下条件下对粗产物进行纯化,柱:XSelect CSHPrep C18 OBD柱,5μm,19mm×250mm;流动相A:水(0.05%FA);流动相B:ACN;流速:20mL/min;梯度:10分钟内从10%B到40%B;254nm。将收集的组分冻干,并通过制备-手性-HPLC在以下条件下对其进行分离,柱:Chiralpak IA,2×25cm,5μm;流动相A:Hex--HPLC,流动相B:EtOH--HPLC;流速:20mL/min;梯度:23分钟内从30B到30B;254/220nm。
对映异构体A:得到8.9mg(2%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(S*)-6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:17.86分钟,MS(ES,m/z)[M+H]+:418。(DMSO-d6,300MHz,ppm):δ6.70(s,1H),6.61(s,2H),6.49(s,1H),5.03-4.99(m,2H),4.24(s,2H),3.44-3.40(m,2H),3.25-3.20(m,2H),2.97(s,3H),2.45-2.40(m,2H),2.38-2.30(m,2H),2.05-1.98(m,5H),1.07-1.02(m,3H)。
对映异构体B:得到9.8mg(2%)的(3-氨基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(R*)-6-乙基-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:12.89分钟,MS(ES,m/z)[M+H]+:418。(DMSO-d6,300MHz,ppm):δ6.70(s,1H),6.61(s,2H),6.48(s,1H),5.03-4.99(m,2H),4.24(s,2H),3.44-3.40(m,2H),3.24-3.20(m,2H),2.96(s,3H),2.43-2.38(m,2H),2.38-2.28(m,2H),2.07-1.98(m,5H),1.07-1.02(m,3H)。
实施例71、72和73:(3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮和(S*)-(3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮以及(R*)-(3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:(3-氨基-6-苄基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6-苄基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮
向50mL圆底烧瓶中,加入6-苄基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(190mg,0.83mmol,1.10当量)、8-氯-1,2,3,4-四氢喹啉-4-羧酸(160mg,0.76mmol,1.00当量)、HOBT(150mg,1.11mmol,1.50当量)、EDCI(220mg,1.15mmol,1.50当量)、TEA(230mg,2.27mmol,3.00当量)和N,N-二甲基甲酰胺(3mL)。所得溶液在室温下搅拌4小时,然后加水(40mL)将反应淬灭。用乙酸乙酯(40mL×3)萃取所得溶液并合并有机层,所得混合物用盐水(2×100mL×2)洗涤。混合物经无水硫酸钠干燥,滤掉固体,将得到的混合物在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化,柱:XSelect CSH Prep C18 OBD柱,5μm,19mm×250mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:16分钟内从2%B到30%B;254nm。Rt1:13.8分钟,Rt2:14.88分钟。将收集的组分冻干,得到150mg(47%)的(3-氨基-6-苄基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。MS(ES,m/z)[M+H]+:422;和120mg(38%)的(3-氨基-6-苄基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体,MS(ES,m/z)[M+H]+:422。
步骤2:(3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮
向100mL圆底烧瓶中,加入(3-氨基-6-苄基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮(250mg,0.59mmol,1.00当量)、甲醇(10mL)、钯碳(10%,200mg)和AcOH(0.4mL)。向其中引入氢气,所得溶液在室温下搅拌1.5小时,滤掉固体,将得到的混合物在真空下浓缩。通过使用Prep-HPLC在以下条件下对粗产物进行纯化,柱:XBridge Shield RP18 OBD柱,5μm,19mm×250mm;流动相A:水(10mM NH4HCO3);流动相B:ACN;流速:20mL/min;梯度:3分钟内从5%B到30%B;254nm;Rt:7.63分钟。将收集的组分冻干,得到30mg(15%)的(3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。MS(ES,m/z)[M+H]+:332。
步骤3:(3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮
向100mL圆底烧瓶中,加入(3-氨基-6-苄基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮(120mg,0.28mmol,1.00当量)、甲醇(20mL)、钯碳(10%,120mg)和AcOH(0.2mL)。向其中引入氢气,所得溶液在室温下搅拌40分钟。滤掉固体,将得到的混合物在真空下浓缩。使用Prep-HPLC在以下条件下对粗产物进行进一步纯化,柱:XBridge Prep C18 OBD柱;19×150mm 5um;流动相A:水(10MMOL/L NH4HCO3),流动相B:ACN;流速:20mL/min;梯度:5分钟内从30%B到43.5%B;254/220nm;Rt:4.35分钟。将收集的组分冻干,得到6.8mg(7%)的(3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。MS(ES,m/z)[M+H]+:332。(DMSO-d6,300MHz,ppm):δ7.09(d,J=7.5Hz,1H),6.79(d,J=7.2Hz,1H),6.52-6.39(m,1H),5.71(s,1H),5.63(m,2H),4.98-4.94(m,1H),3.88(s,2H),3.45-3.38(m,2H),2.82-2.79(m,2H),2.25-2.22(m,2H),2.10-1.93(m,2H)。
步骤4:(S*)-(3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮和(R*)-(3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮
通过制备-手性-HPLC在以下条件下分离出(3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮(30mg,0.09mmol,1.00当量),柱:CHIRALPAK AD-H,2.0cm I.D.×25cm L;流动相A:Hex(%DEA)--HPLC,流动相B:IPA--HPLC;流速:20mL/min;梯度:20分钟内30B至30B;220/254nm。
对映异构体A,实施例72:得到14.9mg(50%)的(S*)-(3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:16.51分钟,MS(ES,m/z)[M+H]+:332。(DMSO-d6,300MHz,ppm):δ7.09(d,J=6.9Hz,1H),6.78(d,J=7.2Hz,1H),6.45(s,2H),6.43-6.39(m,1H),5.74(s,1H),5.05-5.02(m,1H),3.71(s,2H),3.60-3.45(m,2H),2.89-2.87(m,2H),2.31-2.27(m,2H),2.18-1.91(m,2H)。
对映异构体B,实施例73:得到11.6mg(39%)的(R*)-(3-氨基-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-氯-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:12.86分钟,MS(ES,m/z)[M+H]+:332。(DMSO-d6,300MHz,ppm):δ7.09(d,J=7.8Hz,1H),6.78(d,J=7.5Hz,1H),6.43(s,2H),6.41-6.38(m,1H),5.73(s,1H),5.05-5.02(m,1H),3.87(s,2H),3.68-3.63(m,2H),2.87-2.84(m,2H),2.29-2.28(m,2H),2.18-1.95(m,2H)。
实施例74和75:(3-氨基-6,7-二氢吡喃并[4,3-c]吡唑-2(4H)-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6,7-二氢吡喃并[4,3-c]吡唑-1(4H)-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:4-羰基恶烷-3-甲腈
向100mL的圆底烧瓶中,加入3-溴恶烷-4-酮(1.5g,8.38mmol,1.00当量)、DMSO(40mL)和NaCN(616g,12.57mmol,1.50当量)。所得溶液在25℃下搅拌过夜,然后加入FeSO4水溶液(150mL)将反应淬灭。用二氯甲烷(200mL×6)萃取所得溶液并合并有机层和在真空下浓缩,得到1.5g(粗品)的4-氧代恶烷-3-腈,为黄色油状物。MS(ES,m/z)[M+H]+:126。
步骤2:2H,4H,6H,7H-吡喃并[4,3-c]吡唑-3-胺
向250mL的圆底烧瓶中,加入4-羰基恶烷-3-甲腈(1.5g,11.99mmol,1.00当量)、乙醇(20mL)和NH2NH2H2O(10mL)。所得溶液在25℃下搅拌过夜,所得混合物在真空下浓缩。将残余物施加到具有二氯甲烷/甲醇(10/1)的硅胶柱上,得到150mg的2H,4H,6H,7H-吡喃并[4,3-c]吡唑-3-胺,为黄色油状物。MS(ES,m/z)[M+H]+:140。
步骤3:(3-氨基-6,7-二氢吡喃并[4,3-c]吡唑-2(4H)-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮和(3-氨基-6,7-二氢吡喃并[4,3-c]吡唑-1(4H)-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮
向100mL圆底烧瓶中,加入6-氟-1,2,3,4-四氢喹啉-4-羧酸(168mg,0.86mmol,1.20当量)、2H,4H,6H,7H-吡喃并[4,3-c]吡唑-3-胺(100mg,0.72mmol,1.00当量)、HOBt(146mg,1.08mmol,1.50当量)、EDCI(207mg,1.08mmol,1.50当量)、N,N-二甲基甲酰胺(8mL)和TEA(218mg,2.15mmol,3.00当量)。所得溶液在25℃下搅拌1小时,反应混合物用DCM(80mL)稀释,用H2O(50mL×3)和盐水(50mL×3)洗涤并用Na2SO4干燥。过滤后,将滤液减压浓缩。使用Prep-HPLC在以下条件下对粗产物进行纯化(分析HPLC-SHIMADZU),柱:XBridgeShield RP18 OBD柱,5μm,19mm×150mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:8分钟内从15%B到40%B;254nm。
组分A:将收集的组分冻干,得到28mg(12%)的(3-氨基-6,7-二氢吡喃并[4,3-c]吡唑-2(4H)-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:7.25分钟,MS(ES,m/z)[M+H]+:317。(400MHz,DMSO-d6,ppm):δ6.81-6.77(m,1H),6.68-6.65(m,1H),6.58(s,2H),6.52-6.49(m,1H),5.80(s,1H),5.00-4.98(m,1H),4.42(s,2H),3.84-3.79(m,2H),3.25-3.15(m,2H),2.62-2.59(m,2H),2.10-1.98(m,2H)。
组分B:将收集的组分冻干,得到28mg(12%)的(3-氨基-6,7-二氢吡喃并[4,3-c]吡唑-1(4H)-基)(6-氟-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:6.19分钟,MS(ES,m/z)[M+H]+:317。(400MHz,DMSO-d6,ppm):δ6.80-6.77(m,1H),6.77-6.75(m,1H),6.69-6.66(m,1H),5.78(s,1H),5.71(s,2H),4.91-4.88(m,1H),4.41(s,2H),3.77-3.75(m,2H),3.33-3.12(m,2H),2.90-2.88(m,2H),2.08-1.92(m,2H)。
实施例76和77:(S*)-(3-氨基-4,5-二氢吡喃并[3,4-c]吡唑-2(7H)-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(R*)-(3-氨基-4,5-二氢吡喃[3,4-c]吡唑-2(7H)-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:2-(3-(苄氧基)丙氧基)乙酸乙酯
向用氮气的惰性气体吹扫并保持氮气的250mL三颈圆底烧瓶中,加入2-溴乙酸乙酯(3.5g,20.96mmol,1.00当量)和四氢呋喃(40mL)。随后在0℃下分批加入氢化钠(1.01g,25.25mmol,1.20当量,60%),将混合物在0℃下搅拌40分钟。0℃下向其中加入3-(苄氧基)丙-1-醇(10.50g,63.17mmol,3.00当量),所得溶液在25℃下搅拌过夜。然后加水(100mL)将反应淬灭,用乙酸乙酯(100mL×3)萃取所得溶液并合并有机层。在真空下除去溶剂,将残余物施加到具有并乙酸乙酯/己烷(1/10)的硅胶柱上。将收集的组分合并和在真空下浓缩。得到3g(57%)的2-(3-(苄氧基)丙氧基)乙酸乙酯,为白色油状物。MS(ES,m/z)[M+H]:253。
步骤2:2-(3-羟基丙氧基)乙酸乙酯
向250mL圆底烧瓶中,加入2-[3-(苄氧基)丙氧基]乙酸乙酯(2.8g、11.10mmol,1.00当量)、Pd(OH)2(2.8g,19.94mmol,1.80当量)和甲醇(15mL)。所得溶液在25℃下搅拌过夜,过滤收集固体。所得混合物在真空下浓缩,得到1.2g(67%)的2-(3-羟基丙氧基)乙酸乙酯,为白色油状物。MS(ES,m/z)[M+H]:163。
步骤3:2-(3-溴丙氧基)乙酸乙酯
向用氮气的惰性气体吹扫并保持的100mL圆底烧瓶中,加入2-(3-羟基丙氧基)乙酸乙酯(1.23g,7.58mmol,1.00当量)、CBr4(3.78g,1.50当量)、PPh3(2.39g,9.11mmol,1.20当量)和四氢呋喃(30mL)。所得溶液在25℃下搅拌过夜。,然后加水(30mL)将反应淬灭。用二氯甲烷(80mL×2)萃取所得溶液并合并有机层,将残余物施加到具有乙酸乙酯/石油醚(1/10)的硅胶柱上。得到1.4g(82%)的2-(3-溴丙氧基)乙酸乙酯,为黄色油状物。MS(ES,m/z)[M+H]:225。
步骤4:2-(3-氰基丙氧基)乙酸乙酯
向250mL圆底烧瓶中,加入2-(3-溴丙氧基)乙酸乙酯(1.4g,6.22mmol,1.00当量)、DMSO(10mL)和NaCN(460mg,9.33mmol,1.50当量)。所得溶液在20℃下搅拌过夜,然后加入FeSO4水溶液(100mL)将反应淬灭。用二氯甲烷(50mL×3)萃取所得溶液并合并有机层,所得混合物用氯化钠(100mL×4)洗涤,将得到的混合物在真空下浓缩。得到1g(94%)的2-(3-氰基丙氧基)乙酸乙酯,为黄色油状物。MS(ES,m/z)[M+H]:172。
步骤5:3-羰基恶烷-4-甲腈
向用氮气的惰性气体吹扫并保持的100mL三颈圆底烧瓶中,加入2-(3-氰基丙氧基)乙酸乙酯(1.2g,7.01mmol,1.00当量)和四氢呋喃(30mL)。然后在0℃下分批加入t-BuOK(1.18g,10.52mmol,1.50当量),所得溶液在25℃下搅拌过夜。然后加水/冰(25mL)将反应淬灭,用盐酸(1mol/L)将溶液的pH值调节至4-5。用二氯甲烷(100mL×5)萃取所得溶液并合并有机层和在真空下浓缩。得到800mg(91%)的3-羰基恶烷-4-甲腈,为红色油状物。MS(ES,m/z)[M+H]:126。
步骤6:2,4,5,7-四氢吡喃并[3,4-c]吡唑-3-胺
向100mL圆底烧瓶中,加入3-羰基恶烷-4-甲腈(750mg,5.99mmol,1.00当量)、乙醇(25mL)和NH2NH2H2O(10mL)。所得溶液在25℃下搅拌过夜,所得混合物在真空下浓缩,将残余物施加到具有二氯甲烷/甲醇(10/1)的硅胶柱上。得到240mg(29%)的2,4,5,7-四氢吡喃并[3,4-c]吡唑-3-胺,为黄色固体。MS(ES,m/z)[M+H]:140。
步骤7:(S*)-(3-氨基-4,5-二氢吡喃并[3,4-c]吡唑-2(7H)-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(R*)-(3-氨基-4,5-二氢吡喃[3,4-c]吡唑-2(7H)-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
向50mL圆底烧瓶中,加入6-氟-8-甲基-1,2,3,4-四氢喹啉-4-羧酸(207mg,0.99mmol,1.20当量)、2H,4H,5H,7H-吡喃并[3,4-c]吡唑-3-胺(150mg,1.08mmol,1.00当量)、HOBT(219mg,1.62mmol,1.50当量)、EDCI(311mg,1.62mmol,1.50当量)、N,N-二甲基甲酰胺(6mL)和TEA(327mg,3.23mmol,3.00当量)。所得溶液在25℃下搅拌3小时,用DCM(80mL)稀释反应混合物,用H2O(50mL×3)和盐水(50mL×3)洗涤并用Na2SO4干燥。过滤后,将滤液减压浓缩。使用Prep-HPLC在以下条件下对粗产物进行纯化(分析HPLC-SHIMADZU),色谱:XSelect CSH Prep C18 OBD柱,5μm,19mm×250mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:7分钟内从25%B到65%B;220nm;Rt:5.38和6.18分钟。通过制备-手性-HPLC在以下条件下分离出该产物,柱,CHIRALPAK IF,2×25cm,5μm;流动相,己醇-和乙醇-(在20分钟内保持20.0%乙醇-);检测器,UV 254/220nm。
对映异构体A:得到16mg(4%)的(S*)-(3-氨基-4,5-二氢吡喃并[3,4-c]吡唑-2(7H)-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt2:6.18分钟,MS(ES,m/z)[M+H]+:331。(400MHz,DMSO-d6,ppm):δ6.75(d,J=2.8Hz,1H),6.73-6.52(m,3H),5.13(s,1H),5.00-4.97(m,1H),4.59-4.51(m,2H),3.80-3.75(m,2H),3.32-3.21(m,2H),2.50-2.41(m,2H),2.11-2.07(m,5H)。
对映异构体B:得到15.7mg(4%)的(R*)-(3-氨基-4,5-二氢吡喃并[3,4-c]吡唑-2(7H)-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。Rt1:5.37分钟,MS(ES,m/z)[M+H]+:331。(400MHz,DMSO-d6,ppm):δ6.75(d,J=2.8Hz,1H),6.73-6.52(m,3H),5.13(s,1H),5.00-4.97(m,1H),4.59-4.51(m,2H),3.80-3.77(m,2H),3.32-3.21(m,2H),2.50-2.41(m,2H),2.10-2.02(m,5H)。
实施例78、79、80和81:(3-氨基-7-甲基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基1,2,3,4-四氢喹啉-4-基)甲酮非对映异构体A和(3-氨基-7-甲基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮非对映异构体B以及(3-氨基-7-甲基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮(非对映体A)和(3-氨基-7-甲基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮(非对映异构体B)
步骤1:2-(3-氰基丙基氨基)丙酸乙酯
向500mL圆底烧瓶中,加入4-溴丁腈(10g,67.57mmol,1.00当量)、2-氨基丙酸乙酯盐酸盐(11.5g,74.87mmol,1.20当量)、甲烷过氧化钾(potassium potassiummethaneperoxoate)(36g,258.60mmol,4.00当量)和ACN(150mL)。所得溶液在70℃下搅拌过夜,冷却至室温后,将固体滤掉。所得混合物在真空下浓缩,将残余物施加到具有乙酸乙酯/石油醚(0-100%,50分钟)的硅胶柱上。得到6g(48%)的2-[(3-氰基丙基)氨基]丙酸乙酯,为黄色油状物。MS(ES,m/z)[M+H]+:185。
步骤2:2-(苄基(3-氰基丙基)氨基)丙酸乙酯
向500mL圆底烧瓶中,加入2-[(3-氰丙基丙基)氨基]丙酸乙酯(6g,32.57mmol,1.00当量)、ACN(200mL)、(溴甲基)苯(8.3g,48.53mmol,1.50当量)和甲烷过氧化钾(13.5g,96.97mmol,3.00当量)。所得溶液在90℃下搅拌过夜,冷却至室温后,将固体滤掉。所得混合物在真空下浓缩,将残余物施加到具有乙酸乙酯/石油醚(0-50%,40分钟)的硅胶柱上。得到8.5g(95%)的2-[苄基(3-氰基丙基)氨基]丙酸乙酯,为黄色油状物。MS(ES,m/z)[M+H]+:275。
步骤3:1-苄基-2-甲基-3-哌啶酮-4-甲腈
向用氮气的惰性气体吹扫并保持的500mL三颈圆底烧瓶中,加入2-[苄基(3-氰基丙基)氨基]丙酸乙酯(8.5g,30.98mmol,1.00当量)和四氢呋喃(200mL),随后在0℃下分批加入t-BuOK(10g,89.12mmol,3.00当量)。所得溶液在室温下搅拌3小时,然后加入NH4Cl水溶液(300mL)将反应淬灭。用盐酸(3mol/L)将溶液的pH值调节至7-8,用二氯甲烷(10%甲醇)(400mL×3)萃取所得溶液并合并有机层和在真空下浓缩。得到6.7g(粗品)的1-苄基-2-甲基-3-哌啶酮-4-甲腈,为黄色固体。MS(ES,m/z)[M+H]+:229。
步骤4:6-苄基-7-甲基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺
向250mL圆底烧瓶中,加入1-苄基-2-甲基-3-哌啶酮-4-甲腈(2.5g,10.95mmol,1.00当量)、NH2NH2H2O(2.5mL)和乙醇(60mL)。所得溶液在室温下搅拌过夜,所得混合物在真空下浓缩,将残余物施加到具有甲醇/二氯甲烷(0-10%,30分钟)的硅胶柱上。得到1.4g(53%)的6-苄基-7-甲基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺,为黄色固体。MS(ES,m/z)[M+H]+:243。
步骤5:7-甲基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺
向250mL圆底烧瓶中,加入6-苄基-7-甲基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(1.4g,5.78mmol,1.00当量)、甲醇(50mL)和钯碳(10%,700mg)。向其中引入氢气,所得溶液在室温下搅拌6小时。过滤收集固体,将得到的混合物在真空下浓缩。得到670mg(76%)的7-甲基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺,为浅黄色固体。MS(ES,m/z)[M+H]+:153。
步骤6:7-甲基-6-(甲基磺酰基)-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺
向100mL三颈圆底烧瓶中,加入7-甲基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺((500mg,3.29mmol,1.00当量)、二恶烷(30mL)和在水(10mL)中的碳酸钾(900mg,6.51mmol,2.00当量)溶液。然后在0℃搅拌下逐滴加入在二恶烷(5mL)中的甲磺酰氯(370mg,3.23mmol,1.00当量)溶液。所得溶液在室温下搅拌过夜,滤掉固体,所得混合物在真空下浓缩。将残余物施加到具有甲醇/二氯甲烷(0-10%,30分钟)的硅胶柱上。得到300mg(40%)的6-甲基磺酰基-7-甲基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺,为灰白色固体。MS(ES,m/z)[M+H]+:231。
步骤7:(3-氨基-7-甲基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮非对映异构体A和(3-氨基-7-甲基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮非对映异构体B以及(3-氨基-7-甲基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮(非对映体A)和(3-氨基-7-甲基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-1-基)-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮(非对映异构体B)
向100mL圆底烧瓶中,加入6-甲基磺酰基-7-甲基-4,5,6,7-四氢-2H-吡唑并[3,4-c]吡啶-3-胺(240mg,1.04mmol,1.00当量)、8-甲基-1,2,3,4-四氢喹啉-4-羧酸(200mg,1.05mmol,1.00当量)、HOBt(210mg,1.55mmol,1.50当量)、EDCI(300mg,1.56mmol,1.50当量)和N,N-二甲基甲酰胺(10mL)。所得溶液在室温下搅拌2小时,然后加水(70mL)将反应淬灭。用乙酸乙酯(70mL×3)萃取所得溶液并合并有机层,所得混合物用盐水(200mL×3)洗涤,混合物经无水硫酸钠干燥,滤掉固体,所得混合物在真空下浓缩。通过制备型TLC(EA:PE=2:1)对残余物进行纯化。使用Prep-HPLC在以下条件下对粗产物进行纯化,柱:XSelectCSH Prep C18 OBD柱,5μm,19 150mm;流动相A:水(0.1%FA);流动相B:ACN;流速:20mL/min;梯度:15分钟内从25%B到30%B;254nm。
组分A:将收集的组分冻干,得到45.3mg(11%)的(3-氨基-7-甲基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮非对映异构体A,为黄色固体。Rt4:16.55分钟,MS(ES,m/z)[M+H]+:404。(DMSO-d6,400MHz,ppm):δ6.82(d,J=7.2Hz,1H),6.67(d,J=7.2Hz,1H),6.59(s,2H),6.36-6.32(m,1H),5.24(s,1H),5.07-5.04(m,1H),4.88-4.83(m,1H),3.86-3.82(m,1H),3.41-3.38(m,1H),3.26-3.21(m,2H),2.96(s,3H),2.41-2.39(m,2H),2.11-2.00(m,5H),1.44(s,3H)。
组分B:将收集的组分冻干,得到37.6mg(9%)的(3-氨基-7-甲基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶-2-基)(8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮非对映异构体B,为黄色固体。Rt3:15.39分钟,MS(ES,m/z)[M+H]+:404。(DMSO-d6,400MHz,ppm):δ6.82(d,J=7.2Hz,1H),6.67(d,J=7.6Hz,1H),6.59(s,2H),6.37-6.33(m,1H),5.23(s,1H),5.02-4.99(m,1H),4.89-4.84(m,1H),3.86-3.82(m,1H),3.26-3.21(m,3H),2.97(s,3H),2.43-2.39(m,2H),2.11-2.03(m,5H),1.44(s,3H)。
组分C:将收集的组分冻干,得到50.7mg(12%)的(3-氨基-7-甲基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶基-1-基)-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮(非对映体A),为黄色固体。Rt2:11.87分钟,MS(ES,m/z)[M+H]+:404。(DMSO-d6,400MHz,ppm):δ6.81(d,J=7.2Hz,1H),6.62(d,J=7.2Hz,1H),6.36-6.33(m,1H),5.77(s,2H),5.31-5.26(m,1H),5.22(s,1H),5.01-4.98(m,1H),3.88-3.83(m,1H),3.42-3.38(m,1H),3.26-3.22(m,2H),2.92(s,3H),2.46-2.41(m,2H),2.08-1.95(m,5H),1.35(s,3H)。
组分D:将收集的组分冻干,得到37.6mg(9%)的(3-氨基-7-甲基-6-(甲基磺酰基)-4,5,6,7-四氢吡唑并[3,4-c]吡啶基-1-基)-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮(非对映体B),为黄色固体。Rt1:10.32分钟,MS(ES,m/z)[M+H]+:404。(DMSO-d6,400MHz,ppm):δ6.82(d,J=6.8Hz,1H),6.64(d,J=7.6Hz,1H),6.37-6.33(m,1H),5.77(s,2H),5.28-5.23(m,1H),5.20(s,1H),4.94-4.91(m,1H),3.88-3.83(m,1H),3.28-3.26(m,3H),2.90(s,3H),2.44-2.40(m,2H),2.09-1.99(m,5H),1.38(s,3H)。
实施例82、83和84:(S*)-(3-氨基-4,5,6,7-四氢吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和(R*)-(3-氨基-4,5,6,7-四氢吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮以及(3-氨基-4,5,6,7-四氢吡唑并[4,3-c]吡啶-1-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
步骤1:3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸叔丁酯
向250mL圆底烧瓶中(1atm)中,加入3-氰基-4-哌啶酮-1-羧酸叔丁酯(5g,22.30mmol,1.00当量)、NH2NH2H2O(11.1g,223mmol,10.00当量)和EtOH(100mL)。所得溶液在25℃下搅拌过夜,将残余物施加具有用氯仿/甲醇(95/5)的硅胶柱上。得到4.9g(93%)的3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸叔丁基酯,为白色固体。MS(ES,m/z)[M+H]+:239。
步骤2:叔丁基(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和叔丁基(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-1-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
向50mL圆底烧瓶中,加入3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-5-羧酸叔丁酯(227.8mg,0.96mmol,1.00当量)、EDCI(275.6mg,1.44mmol,1.00当量)、HOBt(193.8mg,1.43mmol,1.50当量)、6-氟-8-甲基-1,2,3,4-四氢喹啉-4-羧酸酸(200mg,0.96mmol,1.50当量)、TEA(289.9mg,2.87mmol,3.00当量)和DMF(10mL)。所得溶液在25℃下搅拌过夜,然后加水(40mL)将反应淬灭,用乙酸乙酯(50mL×3)萃取所得溶液并合并有机层和在真空下浓缩。通过制备型TLC(DCM:MeOH=10:1)对残余物进行纯化。得到170mg(41%)的叔丁基(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为黄色油状物,MS(ES,m/z)[M+H]+:430;和184mg(45%)的(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-1-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为黄色油状物。MS(ES,m/z)[M+H]+:430。
步骤3:叔丁基(S*)-(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮和叔丁基(R*)-(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
通过制备-手性-HPLC在以下条件下分离出叔丁基-(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮(170mg,0.40mmol,1.00当量),柱:CHIRAL ART Cellulose-SB S-5um,2×25cm,5um;流动相A:Hex--HPLC,流动相B:EtOH--HPLC;流速:20mL/min;梯度:15分钟内从20B到20B;254/220nm;Rt1:8.38min;Rt2:10.99分钟。得到76.5mg(45%)的叔丁基(S*)-(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为黄色油状物,MS(ES,m/z)[M+H]+:430;和77.2mg(45%)的叔丁基(R*)-(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色油状物,MS(ES,m/z)[M+H]+:430。
步骤4:(S*)-(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
向50mL圆底烧瓶中,加入叔丁基(S*)-(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮(76.5mg,0.18mmol,1.00当量)和二氯甲烷(10mL)。随后在室温搅拌下逐滴添加三氟乙酸(1mL)。所得溶液在25℃下搅拌30分钟,所得混合物在真空下浓缩。使用Prep-HPLC在以下条件下对粗产物进行纯化,柱:XBridge Prep C18 OBD柱;19×150mm 5um;流动相A:水(10mM NH4HCO3),流动相B:ACN;流速:20mL/min;梯度:10分钟内从10%B到40%B;254/220nm;Rt:9.53分钟。将收集的组分冻干,得到13.8mg(24%)的(S*)-(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。MS(ES,m/z)[M+H]+:330;(DMSO-d6,400MHz,ppm):δ6.76-6.72(m,1H),6.55-6.51(m,1H),6.42(s,2H),5.12(s,1H),5.04-5.00(m,1H),3.51(s,2H),3.25-3.20(m,2H),2.85-2.86(m,2H),2.46-2.42(m,2H),2.12-1.98(m,5H)。
步骤5:(R*)-(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
向50mL圆底烧瓶中,加入叔丁基(R*)-(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮(77.2mg,0.18mmol,1.00当量)和二氯甲烷(10mL),随后在室温搅拌下逐滴加入三氟乙酸(1mL)。所得溶液在25℃下搅拌30分钟,所得混合物在真空下浓缩。使用Prep-HPLC在以下条件下对粗产物进行纯化,柱:XBridge Shield RP18 OBD柱,5μm,19×150mm;流动相A:水(10mM NH4HCO3);流动相B:ACN;流速:20mL/min;梯度:9分钟内从5%B到50%B;254nm;Rt:8.85分钟。将收集的组分冻干,得到4.8mg(8%)的(R*)-(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-2-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。MS(ES,m/z)[M+H]+:330;(DMSO-d6,400MHz,ppm):δ6.75-6.72(m,1H),6.55-6.52(m,1H),6.44(s,2H),5.13(s,1H),5.03-5.00(m,1H),3.52(s,2H),3.26-3.21(m,2H),2.96-2.90(m,2H),2.46-2.41(m,2H),2.10-1.90(m,5H)。
步骤6:(3-氨基-4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-1-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮
向50mL圆底烧瓶中,加入叔丁基(3-氨基-4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶-1-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮(150mg,0.35mmol,1.00当量)和二氯甲烷(10mL)。随后在室温搅拌下逐滴加入三氟乙酸(1mL)。所得溶液在室温下搅拌30分钟,所得混合物在真空下浓缩。使用Prep-HPLC在以下条件下对粗产物进行纯化,柱:XBridgePrep C18 OBD柱;19×150mm 5um;流动相A:水(10mM NH4HCO3),流动相B:ACN;流速:20mL/min;梯度:7分钟内从25%B到55%B;254/220nm;Rt:6.03分钟。将收集的组分冻干,得到19.2mg(17%)的(3-氨基-4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-1-基)(6-氟-8-甲基-1,2,3,4-四氢喹啉-4-基)甲酮,为白色固体。MS(ES,m/z)[M+H]+:330,(DMSO-d6,300MHz,ppm):δ6.74-6.70(m,1H),6.55-6.51(m,1H),5.61(s,2H),5.09(s,1H),4.96-4.93(m,1H),3.47(s,2H),3.39-3.36(m,1H),3.24-3.18(m,1H),2.83-2.75(m,7H),2.09-1.92(m,5H)。
通过使用类似于上述的方法制备以下实施例:
表1:实施例列表
可以通过类似于与上述的方法制备本申请的以下其他种类。
如本文所用,并如本领域技术人员所理解的,除非进一步明确限制,否则对“化合物”的叙述旨在包括该化合物的盐。在一个具体实施例中,术语“化合物”是指该化合物或制药上可接受的盐。
术语“药学上可接受的盐”是指由制药上可接受的无毒酸或无毒碱(包括无机酸和无机碱以及有机酸和有机碱)所制备的盐。当本发明的化合物为碱性时,盐可以由制药上可接受的无毒酸(包括无机酸和有机酸)制备。适用于本发明化合物的药学上可接受的酸加成盐包括,乙酸、己二酸、海藻酸、抗坏血酸、天冬氨酸、苯磺酸(苯磺酸盐)、苯甲酸、硼酸、丁酸、樟脑酸、樟脑磺酸、碳酸、柠檬酸、乙二磺酸、乙磺酸、乙二胺四乙酸、甲酸、富马酸、葡庚糖酸、葡糖酸、谷氨酸、氢溴酸、盐酸、氢碘酸、羟基萘酸、羟基乙磺酸、乳酸、乳糖酸、月桂基磺酸、马来酸、苹果酸、扁桃酸、甲磺酸、粘酸、萘磺酸、硝酸、油酸、双羟萘酸、泛酸、磷酸、新戊酸、聚半乳糖醛、水杨酸、硬脂酸、琥珀酸、硫酸、单宁酸、酒石酸、戊酸、对甲苯磺酸等。当所述化合物包含酸性侧链时,适用于本申请化合物的药学上可接受的碱加成盐包括但不限于,由铝、钙、锂、镁、钾、钠和锌制成的金属盐,或者由赖氨酸、精氨酸、N,N'-二苄基乙二胺、氯普鲁卡因、胆碱、二乙醇胺、乙二胺、葡甲胺(N-甲基葡糖胺)和普鲁卡因制成的有机盐。药学上可接受的盐还在适当时包括(适当时),无毒的铵阳离子和与具有1至20个碳原子的烷基连接的羧酸根、磺酸根和膦酸根阴离子。
本文还提供了包含上述化合物或其药学上可接受的盐形式,以及药学上可接受的载体或稀释剂的药物组合物。
虽然可将式I或式II的化合物作为原料化学品施用,但是优选将它们作为药物组合物施用。根据另一方面,本申请提供一种药物组合物,其包含式I或式II的化合物或其制药上可接受的盐,以及一种或多种其药学上可接受的载体以及任选地一种或多种其他治疗成分。在与制剂的其他成分相容且对接受者无害的意义上,载体必须是“可接受的”。
制剂包括适合口服,肠胃外(包括皮下,皮内,肌内,静脉内和关节内),直肠和局部(包括皮肤,颊,舌下和眼内)给药的制剂。最合适的途径可能取决于接受者的状况和病症。所述制剂可以方便地以单位剂型存在,并且可以通过制药领域公知的任何方法制备。所有方法都包括使式I或式II化合物或其制药上可接受的盐(“活性成分”)与构成一种或多种辅助成分的载体结合的步骤。通常,通过将活性成分与液体载体或细小的固体载体或两者均匀且紧密地结合,然而如果有必要,将产品成型为所需制剂来制备制剂。
适用于口服给药的本申请制剂可以离散单位存在,例如胶囊、扁囊剂或片剂,每个均包含预定量的活性成分、粉末或颗粒、在水性液体或非水性液体中的溶液或悬浮液,或水包油型液体乳剂或油包水型液体乳剂。活性成分也可以为丸剂、冲剂或糊剂的形式存在。
可通过压制或模制,任选地与一种或多种辅助成分一起制成片剂。可以通过在合适的机器中将自由流动形式的活性成分如粉末或颗粒压缩,任选地与粘合剂、润滑剂、惰性稀释剂、润滑剂、表面活性剂或分散剂混合来制备压制的片剂。模制片剂可以通过在合适的机器中模制用惰性液体稀释剂润湿的粉末状化合物的混合物来制备。片剂可以任选地被包衣或刻痕,并且可以被配制,以提供其中的活性成分的持续,延迟或控制释放。
用于肠胃外给药的制剂包括水性和非水性的无菌注射溶液,其可含有使制剂与预期受体的血液等渗的抗氧化剂、缓冲液、抑菌剂和溶质。肠胃外给药的制剂还包括水性和非水性的无菌悬浮液,其可以包括悬浮剂和增稠剂。制剂可以在多剂量容器的单位剂量中存在,例如密封的安瓿瓶和小瓶,并且可以在冷冻干燥(冻干)条件下储存,仅需要添加无菌液体载体,例如盐水、磷酸盐。在使用前立即使用缓冲液(PBS)等。临时注射溶液和悬浮液可以由前述类型的无菌粉末,颗粒和片剂制备。
抑制凝血因子XIIa的化合物可用于治疗通常受益于抗凝剂的疾病和病症,例如静脉血栓形成。在凝血酶和其他凝血因子存在下选择性抑制凝血因子XIIa的那些化合物还可用于治疗非炎症性疾病和具有炎症成分的疾病。因此,本文提供的化合物可以用于治疗炎症、免疫性疾病、与血管舒张相关的病理或血栓形成。该方法包括,例如,向患者施用治疗有效量的式I或式II的化合物。
在以下试验中对本申请的化合物进行了测试。
因子XIIa(FXIIa)的抑制活性:
在96孔透明底板中,向每个孔添加80μl分析缓冲液。分析缓冲液由0.5×Hank的平衡盐溶液(Invitrogen),25mM HEPES pH 7.4(Invitrogen)缓冲液和0.5×Tris缓冲盐水和Tween-20 0.05%(Santa Cruz Biotechnology)组成。首先将测试化合物溶解在DMSO(Sigma)中,然后将4μl加入含有测定缓冲液的测试孔中。使用自动多通道移液器进行系列稀释可产生约1-100μM的浓度范围。将人FXIIa(酶研究实验室)在测定缓冲液中稀释至最终浓度12.5nM。将80μl的该酶溶液添加至测定孔。酶/化合物的混合物在室温下培养10分钟。将显色底物(Pefachrome XIIa;酶研究实验室)以400μM的最终浓度添加到测定孔中。将测定板以1500g旋转1分钟,然后在SpectraMax M2板读数器(λ=405nm)中在37°下读取。活性被定量为吸光度的变化速率,其对应于底物裂解速率。将IC50值确定为抑制剂浓度,该浓度产生50%无任何抑制剂的对照孔变化率。对于活性<1μM的化合物,以较低的浓度范围(通常为10-1000nM)重复测定。
选择性的相对筛选:
凝血酶。在96孔白色不透明板上,向每个孔添加80μl分析缓冲液。添加测试化合物,并如上所述连续稀释,以产生约1-100μM的浓度范围。将人α-凝血酶(酶研究实验室)在测定缓冲液中稀释至最终浓度为12.5nM。将80μl的该酶溶液添加至测定孔。酶/化合物的混合物在室温下培养10分钟。将荧光底物(Boc-Val-Pro-Arg-7-酰胺基-4-甲基香豆素;Sigma)添加到测定孔中,最终浓度为20μM。将测定板以1500g离心1分钟,然后在SpectraMaxM2板读取器(λex=380nm和λem=460nm)中在37°下读取。将活性定量为荧光的变化速率,其对应于底物裂解的速率。将IC50值确定为抑制剂浓度,该浓度产生50%无任何抑制剂的对照孔变化率。对于活性<1μM的化合物,以较低的浓度范围(通常为10-1000nM)重复测定。
因子Xa。在96孔白色不透明板上,向每个孔添加80μl分析缓冲液。添加测试化合物,并如上所述连续稀释,以产生约1-100μM的浓度范围。将人FXa(酶研究实验室)在测定缓冲液中稀释至最终浓度12.5nM。将80μl的该酶溶液添加至测定孔。酶/化合物混合物在室温下培养10分钟。将荧光底物(Pefafluor FXa;酶研究实验室)以80μM的最终浓度添加到测定孔中。将测定板以1500g离心1分钟,然后在SpectraMax M2板读取器(λex=380nm和λem=460nm)中在37°下读取。将活性定量为荧光的变化速率,其对应于底物裂解的速率。将IC50值确定为抑制剂浓度,该浓度产生50%无任何抑制剂的对照孔变化率。
因子XIa。在96孔透明底板中,向每个孔添加80μl分析缓冲液。添加测试化合物,并如上所述连续稀释,以产生约1-100μM的浓度范围。将人FXIa(酶研究实验室)在测定缓冲液中稀释至最终浓度12.5nM。将80μl的该酶溶液添加至测定孔。酶/化合物混合物在室温下培养10分钟。将显色底物(Pefachrome FXIa 3371;酶研究实验室)添加到测定孔中,最终浓度为100μM。将测定板以1500g旋转1分钟,然后在SpectraMax M2板读数器(λ=405)中在37°下读取。活性被定量为吸光度的变化速率,其对应于底物裂解的速率。将IC50值确定为抑制剂浓度,该浓度产生50%无任何抑制剂的对照孔变化率。
血浆激肽释放酶。在96孔白色不透明板上,向每个孔添加80μl分析缓冲液添。添加测试化合物,并如上所述连续稀释,以产生约1-100μM的浓度范围。将人血浆激肽释放酶(酶研究实验室)在测定缓冲液中稀释至最终浓度12.5nM。将80μl的该酶溶液添加至测定孔。酶/化合物混合物在室温下培养10分钟。把荧光底物(Z-Phe-Arg 7-氨基-4-甲基香豆素;Sigma)添加到测定孔中,最终浓度为50μM。将测定板以1500g离心1分钟,然后在SpectraMaxM2板读取器(λex=380nm和λem=460nm)中在37°下读取。将活性定量为荧光的变化速率,其对应于底物裂解的速率。将IC50值确定为抑制剂浓度,该浓度产生50%无任何抑制剂的对照孔变化率。
上述屏幕中某些实施例的测试结果如表2所示,其中IC50以μM表示:
表2
为了确认体内疗效,在类风湿性关节炎模型中研究了实施例35。DBA/1小鼠中的胶原诱导的关节炎(CIA)是类风湿关节炎最常用的动物模型之一。胶原诱导关节炎在胶原诱导的关节炎中发生的关节炎症类似于类风湿关节炎患者的炎症。减轻人的类风湿关节炎的治疗剂(例如非甾类抗炎药,皮质类固醇,甲氨蝶呤等)在胶原诱导的关节炎中也是有效的,并且在小鼠胶原诱导的关节炎模型中的功效对于类风湿关节炎的功效具有极好的预测价值。通过用在弗氏完全佐剂中乳化的II型胶原蛋白免疫,然后用在弗氏不完全佐剂中乳化的II型胶原蛋白加强免疫来诱导胶原诱导的关节炎。免疫接种三至四个星期后,老鼠的爪子发炎。免疫时开始治疗,持续6周。将小鼠以平衡的方式分配给各组,以在免疫时达到相似的体重。胶原诱导的关节炎的评分是盲目的,评分人不清楚这两种治疗,也不知道每种动物的之前分数。动物的得分是所有四个爪子得分的总和,范围为0-16,其中每个爪子的得分如下:0表示正常爪子;1表示一只脚趾发炎肿胀;2表示一个以上脚趾(但不是整个爪子)发炎和肿胀,或整个爪子轻度肿胀;3表示整个爪子发红肿胀;4表示严重发炎,肿胀或僵硬的的爪子。
与安慰剂相比,实施例35的化合物显著改善了疾病表型:
Claims (35)
1.一种如下式I或式II所示的化合物:
其中
R1是任选被取代的双环系统;
R2选自氢、卤素、羟基、氨基、氰基、(C1-C4)烷基、(C1-C4)烷氧基、(C1-C4)烷基氨基、二(C1-C4)烷基氨基、(C1-C4)酰胺基、(C1-C4)氟烷基、(C1-C4)氟烷氧基和(C1-C6)氧杂烷基;
X1和X2中的一个选自-O-和-N(QR5)-,另一个选自-CR3R4-;
Q选自直接键、-CH2-、-C(=O)-、-C(=O)O-、-C(=O)NR6-、-SO2-和-SO2NR6-;
R3、R4、R6和R7独立地选自氢和(C1-C6)烷基;
R5选自氢、(C1-C6)烷基、羟基(C2-C6)烷基、三至七元碳环和三至七元杂环。
2.根据权利要求1的化合物,其中R1是6:6或6:5的双环,任选地被选自以下的一个至三个取代基取代:卤素、羟基、氨基、氰基、氧代、(C1-C6)脂族烃基、(C1-C4)烷氧基、(C1-C4)烷基氨基、二(C1-C4)烷基氨基、(C1-C4)酰基氨基、(C1-C4)烷基磺酰基、[(C1-C4)烷基磺酰基]氨基、(C1-C4)氟烷基、(C1-C4)氟烷氧基、(C1-C6)氧杂烷基、芳基和杂芳基。
3.根据权利要求2的化合物,其中所述任选被取代的双环系统选自,任选取代的吲哚、异吲哚、羟吲哚、四氢吲哚、四氢化萘、二氢吲哚、异吲哚啉、四氢喹啉、四氢异喹啉、3,4-二氢-1H-异苯并吡喃、3,4-二氢-2H-苯并吡喃、苯并呋喃、二氢苯并呋喃、四氢苯并呋喃、苯并噻吩、四氢苯并噻吩、吲唑、四氢吲唑、2,3-二氢-1H-茚、萘、四氢化萘、萘啶、四氢萘啶和异苯并二氢吡喃。
4.根据权利要求2的化合物,其中R1是含氮双环。
5.A根据权利要求4的化合物,其中R1是任选被取代的四氢喹啉、吲哚或四氢吲哚。
6.根据权利要求3的化合物,其中R1任选地被下述的一个或多个取代基取代:卤素、(C1-C6)脂族烃基、(C1-C4)氟烷基、(C1-C4)烷氧基、(C1-C4)酰胺基、(C1-C4)烷基磺酰基、苯基和吡啶基。
7.根据权利要求6的化合物,其中R1任选地被下述的一个或两个取代基取代:氟、氯、溴、甲基、乙基、丙基、三氟甲基、甲氧基、甲磺酰基、乙酰胺基、苯基和吡啶基。
10.根据权利要求9的化合物,其中标有星号的碳在(R)绝对构型中>90%e.e.。
11.根据权利要求9的化合物,其中标有星号的碳在(S)绝对构型中>90%e.e.。
12.根据权利要求6的化合物,其中R1是任选被取代的四氢-1,8-萘啶。
13.根据权利要求1的化合物,其中X1是-CR3R4-,和X2是-O-。
14.根据权利要求1的化合物,其中X1是-O-,和X2是-CR3R4-。
15.根据权利要求1的化合物,其中X1是-CR3R4-,和X2是-N(QR5)-。
16.根据权利要求1的化合物,其中X1是-N(QR5)-,和X2是-CR3R4-。
17.根据权利要求1的化合物,其中R2和R7独立地选自氢和甲基。
18.根据权利要求17的化合物,其中R2和R7都是氢。
19.根据权利要求17的化合物,其中R2是氢,和R7是甲基。
20.根据权利要求13-19任一项的化合物,其中R3和R4均为氢。
21.根据权利要求1或15-19任一项的化合物,其中Q选自直接键、-CH2-、-C(=O)-、-C(=O)O-、-C(=O)NR6-、-SO2-和-SO2NR6-;和R6是氢或甲基。
22.根据权利要求21的化合物,其中R5选自H、(C1-C4)烷基、(C3-C6)环烷基、羟基(C2-C6)烷基、氟甲基、二氟甲基、苯基、吡啶基、氧杂环丁基、四氢呋喃基和四氢吡喃基。
25.根据权利要求24的化合物,其中R3和R4均为氢;Q选自直接键、-CH2-、-C(=O)-、-C(=O)O-、-C(=O)NR6-、-SO2-和-SO2NR6-;R6和R7是氢或甲基,且R5选自H、(C1-C4)烷基、(C3-C6)环烷基、氟甲基、二氟甲基、苯基、吡啶基、氧杂环丁基、四氢呋喃基和四氢吡喃基。
26.一种用于抑制受试者的因子XIIa的方法,包括向所述受试者施用抑制量的根据权利要求1至19任一项所述的化合物。
27.一种用于抑制受试者的因子XIIa的方法,包括向所述受试者施用抑制量的根据权利要求26所述的化合物。
28.一种在凝血酶和激肽释放酶存在下选择性抑制因子XIIa的方法,包括使抑制量的根据权利要求1-19任一项的化合物与因子XIIa接触。
29.根据权利要求27的体内方法。
30.根据权利要求28的体外方法。
31.一种用于治疗患者的炎症的方法,包括向所述患者施用治疗有效量的根据权利要求1至19任一项所述的化合物。
32.一种用于治疗患者的免疫失调的方法,包括向所述患者施用治疗有效量的根据权利要求1至19任一项所述的化合物。
33.一种治疗患者的血管扩张的方法,包括向所述患者施用治疗有效量的根据权利要求1至19任一项所述的化合物。
34.一种治疗患者的血栓形成的方法,包括向所述患者施用治疗有效量的根据权利要求1至19任一项所述的化合物。
35.一种用于治疗患者的类风湿性关节炎的方法,包括向所述患者施用治疗有效量的根据权利要求1至19任一项所述的化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762592003P | 2017-11-29 | 2017-11-29 | |
US62/592,003 | 2017-11-29 | ||
PCT/US2018/062702 WO2019108565A1 (en) | 2017-11-29 | 2018-11-28 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111670034A true CN111670034A (zh) | 2020-09-15 |
Family
ID=66664238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880087852.5A Pending CN111670034A (zh) | 2017-11-29 | 2018-11-28 | 用于治疗自身免疫性疾病的吡喃并吡唑类和吡唑并吡啶类免疫调节剂 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11312723B2 (zh) |
EP (1) | EP3716972A4 (zh) |
JP (1) | JP2021504490A (zh) |
KR (1) | KR20200106494A (zh) |
CN (1) | CN111670034A (zh) |
AU (1) | AU2018375308A1 (zh) |
CA (1) | CA3083938A1 (zh) |
WO (1) | WO2019108565A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4017850A1 (en) | 2019-08-21 | 2022-06-29 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
EP4017587A1 (en) | 2019-08-21 | 2022-06-29 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
WO2021032934A1 (en) | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
AU2019462669A1 (en) | 2019-08-21 | 2022-02-24 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
TW202237578A (zh) | 2020-12-01 | 2022-10-01 | 英商卡爾維斯塔製藥有限公司 | 酶抑制劑 |
AU2022222458A1 (en) | 2021-02-19 | 2023-08-24 | Kalvista Pharmaceuticals Limited | Factor xiia inhibitors |
WO2024038282A1 (en) | 2022-08-18 | 2024-02-22 | Kalvista Pharmaceuticals Limited | 2-aza- and 2-oxabicyclo[2.1.1]hexane derivatives as factor xiia enzyme inhibitors |
WO2024084217A1 (en) | 2022-10-19 | 2024-04-25 | Kalvista Pharmaceuticals Limited | 3a,4,5,6-tetrahydro-1 h-pyrazolo[3,4-c]pyridin-7(7ah)-one derivatives as factor xiia inhibitors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070265256A1 (en) * | 2006-02-21 | 2007-11-15 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
US8835444B2 (en) * | 2010-02-02 | 2014-09-16 | Novartis Ag | Cyclohexyl amide derivatives as CRF receptor antagonists |
WO2017123518A1 (en) * | 2016-01-11 | 2017-07-20 | The Rockefeller University | Aminotriazole immunomodulators for treating autoimmune diseases |
US20170247375A1 (en) * | 2014-09-08 | 2017-08-31 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Un | Pyrazolopyridine derivatives and their use in therapy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007079695A (ja) * | 2005-09-12 | 2007-03-29 | Toshiba Corp | 紙葉類処理装置及びこれに用いられるヘッダカード |
JP2017529382A (ja) * | 2014-09-29 | 2017-10-05 | アギオス ファーマシューティカルス,インコーポレーテッド | 治療活性を有する化合物及びその使用方法 |
CA3025810A1 (en) * | 2016-05-23 | 2017-11-30 | Manish P. PONDA | Aminoacylindazole immunomodulators for treatment of autoimmune diseases |
-
2018
- 2018-11-28 WO PCT/US2018/062702 patent/WO2019108565A1/en unknown
- 2018-11-28 JP JP2020548864A patent/JP2021504490A/ja active Pending
- 2018-11-28 US US16/767,936 patent/US11312723B2/en active Active
- 2018-11-28 KR KR1020207018531A patent/KR20200106494A/ko not_active Application Discontinuation
- 2018-11-28 AU AU2018375308A patent/AU2018375308A1/en not_active Abandoned
- 2018-11-28 EP EP18883794.2A patent/EP3716972A4/en not_active Withdrawn
- 2018-11-28 CA CA3083938A patent/CA3083938A1/en active Pending
- 2018-11-28 CN CN201880087852.5A patent/CN111670034A/zh active Pending
-
2022
- 2022-03-21 US US17/655,630 patent/US20220213114A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070265256A1 (en) * | 2006-02-21 | 2007-11-15 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
US8835444B2 (en) * | 2010-02-02 | 2014-09-16 | Novartis Ag | Cyclohexyl amide derivatives as CRF receptor antagonists |
US20170247375A1 (en) * | 2014-09-08 | 2017-08-31 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Un | Pyrazolopyridine derivatives and their use in therapy |
WO2017123518A1 (en) * | 2016-01-11 | 2017-07-20 | The Rockefeller University | Aminotriazole immunomodulators for treating autoimmune diseases |
Also Published As
Publication number | Publication date |
---|---|
JP2021504490A (ja) | 2021-02-15 |
EP3716972A4 (en) | 2021-08-25 |
AU2018375308A1 (en) | 2020-06-25 |
US11312723B2 (en) | 2022-04-26 |
KR20200106494A (ko) | 2020-09-14 |
CA3083938A1 (en) | 2019-06-06 |
WO2019108565A1 (en) | 2019-06-06 |
US20220213114A1 (en) | 2022-07-07 |
US20200369677A1 (en) | 2020-11-26 |
EP3716972A1 (en) | 2020-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111670034A (zh) | 用于治疗自身免疫性疾病的吡喃并吡唑类和吡唑并吡啶类免疫调节剂 | |
CN109475530B (zh) | 用于治疗自身免疫性疾病的氨酰基吲唑免疫调节剂 | |
WO2021219072A1 (zh) | 作为kras抑制剂的杂环化合物的制备及其应用方法 | |
CN110770233B (zh) | 稠合双环类化合物及其在药物中的应用 | |
CN109641882B (zh) | 作为nik抑制剂的杂芳族衍生物 | |
JP6342069B2 (ja) | アザビシクロ誘導体、その製造方法および医薬品における使用 | |
CN114787161A (zh) | 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用 | |
CN117677624A (zh) | 新型吡啶并嘧啶衍生物 | |
CN110041253B (zh) | 吡啶类n-氧化衍生物及其制备方法和应用 | |
CN115515949A (zh) | 新型氨基嘧啶类egfr抑制剂 | |
CN115433163A (zh) | Nlrp3炎症小体抑制剂及其应用 | |
CA2869239A1 (en) | Pyranopyridone inhibitors of tankyrase | |
CN112469722A (zh) | 作为a2a受体拮抗剂的吡唑并三唑并嘧啶衍生物 | |
TWI787857B (zh) | 吡唑并[1,5-a]吡啶類化合物及其製備方法和應用 | |
CN110418790B (zh) | 作为p53-MDM2抑制剂的咪唑并吡咯酮化合物 | |
WO2022107755A1 (ja) | 新規アクリジニウム塩およびその製造方法 | |
WO2024091506A2 (en) | Novel ergolines and methods of treating mood disorders | |
CN110461849A (zh) | 一种csf1r抑制剂及其制备方法和应用 | |
KR20190071718A (ko) | 돌연변이체 이소시트레이트 탈수소효소 억제제 및 그 조성물 및 그 제조방법 | |
WO2023143352A1 (zh) | 一种含氮杂环化合物、其制备方法及应用 | |
WO2021227904A1 (zh) | 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途 | |
CN115960094A (zh) | 一类芳香环取代的甲胺衍生物的制备及其用途 | |
WO2022226408A1 (en) | Novel ergolines and methods of treating mood disorders | |
CN114644631A (zh) | Kras g12c蛋白突变抑制剂、其制备方法、药物组合物及其应用 | |
WO2021197467A1 (zh) | 多靶点的抗肿瘤化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200915 |